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ABSTRACT 
 
This dissertation consists of three papers studying existing practices in measuring 
quality of care for Medicare beneficiaries that warrant further examination. Quality of 
diabetes care is currently reported at the practice or plan level as a composite, summarizing 
multiple binary measures in the diabetes measure set. Medicare’s Accountable Care 
Organization demonstration uses an all-or-none approach deeming only diabetics who 
receive all measures in the diabetes care measure set to have met the quality threshold. This 
approach while simple might not be as meaningful as a graduated approach. Other 
approaches to composite quality measurement, like Medicare’s value based payment 
system for physicians, add up binary measures in the diabetes care measure set, weighting 
them equally.  But all measures in the set might not be equally important for quality, making 
the case for weighting measures accordingly.  Finally, Medicare’s Physician Quality 
Reporting System (PQRS) offers incentive payments to physicians for reporting quality for 
their patients.  In the absence of incentives for outcomes, the impact of reporting on 
outcomes is questionable. 
The dissertation employs Medicare administrative claims to answer the above 
questions. Paper 1 compares prediction of subsequent outcomes for Medicare beneficiaries 
using all-or-none approach against a graduated approach to quality measurement. Paper 2 
compares measure weights for diabetes care processes obtained using three alternate 
approaches to weighting composites, to study whether equal weighting is justified in 
practice.  Paper 3 studies whether PQRS quality reporting for diabetics is linked to receipt of 
more recommended diabetes care processes and better outcomes.  
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The all-or-none approach all-or-none approach was found to discard meaningful 
important quality information, have poor discrimination and predictive validity. It was 
unsuited for the Medicare population as most diabetics did not receive all recommended 
care. Also, irrespective of how the quality construct was viewed, current practices of 
treating all process measures as equally important for ambulatory diabetes care were 
specious. Finally, PQRS reporting was associated with receipt of more recommended 
diabetes care processes. Reporting was also associated with greater guideline 
recommended pharmacotherapy and fewer avoidable hospitalization outcomes- through 
these processes. This dissertation ultimately emphasizes the need to better understand 
quality mechanisms to measure it appropriately for quality improvement. 
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CHAPTER 1: INTRODUCTION 
NATURE OF RESEARCH AND SIGNIFICANCE 
The original research for this dissertation was motivated by current practices in 
measurement of quality of care for Medicare beneficiaries that warrant further 
examination.  This dissertation uses diabetes care as an example to study issues 
surrounding quality measurement that are applicable to care for other chronic conditions as 
well. 
Diabetes is one of the most prevalent chronic conditions in the United States. 
Twenty five percent of  Medicare beneficiaries in 2011 suffered from diabetes [1]. The 
disease and its long-term complications- viz. cardiovascular disease, renal failure, 
cerebrovascular disease, lower-extremity amputations and blindness, place tremendous 
burden on the Medicare population,  accounting for 32 percent of Medicare spending [2].  
Given its prevalence, economic burden, and consensus around care elements, diabetes care 
has been at the forefront of quality measurement efforts for almost two decades. Apart from 
long being incorporated as measures of Medicare plan quality through Healthcare 
Effectiveness Data and Information set (HEDIS), diabetes care quality measures have more 
recently been adopted by the Centers for Medicare and Medicaid Services (CMS) for use at 
the physician and group practice levels with programs such as Medicare’s Physician Quality 
Reporting System (PQRS) and Accountable Care Organization (ACO) demonstrations [3-5]. 
Quality of diabetes care is reported currently at the plan, physician or ACO level as a 
summary composite that combines criterion measures for diabetes care by weighting them 
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equally. The Medicare ACO demonstration uses an all-or-none rule, deeming only diabetics 
who receive all measures in the diabetes care measure set to have received quality diabetes 
care[5].  This approach is questionable if diabetics who get fewer measures have the same 
outcomes as those who get all, or if diabetics who get some measures do better than those 
who get none. Medicare’s value-based payment system for physicians to be implemented in 
2015, considers each of the four process measures in its diabetes composite to be equally 
important for quality[6]. However all process measures in the composite may not be equally 
important for diabetes care. Finally, with more thrust placed on physician reporting of 
diabetes care quality measures through payments and penalties [3], it is worthy to examine 
whether quality reporting for diabetics is linked to better outcomes and more conscientious 
ambulatory care. 
SPECIFIC AIMS 
 This dissertation makes important contributions to measurement of quality of 
diabetes care for Medicare beneficiaries. It consists of three separately publishable 
manuscripts. The first paper contrasts the all-or-none approach with a graduated approach 
to measuring quality of diabetes care for Medicare beneficiaries, to examine the predictive 
validity of the former with respect to hospitalization outcomes. The second paper compares 
measure weights for diabetes care processes obtained from three alternate approaches for 
developing weighted composites for diabetes care quality, to study whether equal 
weighting of these process measures is justified in practice.  In the third paper, we study 
whether PQRS quality reporting for diabetics is linked to receipt of more recommended 
diabetes care processes, better guideline recommended pharmacotherapy & hospitalization 
outcomes, and more conscientious ambulatory care. 
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CHAPTER 2: BACKGROUND 
In this chapter, background and literature on diabetes and standards of care for 
diabetes are first reviewed. Thereafter the chapter reviews background and literature on 
quality measurement both in the general context and in the context of diabetes care. The 
review helps develop the methodology and conceptual framework for the research papers 
presented three subsequent chapters. 
DIABETES 
CLASSIFICATION, PREVALENCE AND BURDEN 
 Diabetes is a group of chronic clinical conditions characterized by hyperglycemia. 
The classification of diabetes includes four clinical classes: 1) type 1 diabetes 2) type 2 
diabetes 3) gestational diabetes mellitus 4) other specific types of diabetes due to other 
causes, e.g. genetic, drug or chemical [7].  This focus of this dissertation is type 1 and type 2 
diabetes. 
According to the CDC , the total number of individuals reported to have diabetes in 
the United States has more than tripled from 5.8 million in 1980 to 18.8 million in 2010 [8]. 
The disease is prevalent in the elderly Medicare population. In 2011, the prevalence of 
diabetes in the Medicare population was 25% [1]. Diabetes prevalence varies with age, 
gender and race/ethnicity. The prevalence of diabetes increases with age (highest in age of 
60 years and above) and more likely to occur in men. Diabetes is at least 2 to 4 times 
prevalent among non-Hispanic Black, and Hispanic/Latino Americans than non-Hispanic 
whites [8]. 
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Diabetes poses an immense economic burden on the healthcare system. The total 
annual cost of diabetes was estimated to be $174 billion in 2007. The direct medical 
expenditures accounted for $116 billion out of which $29.3 billion was spent for diabetes 
care, $31.1 billion for chronic diabetes-related complications, and $55.7 billion for an excess 
prevalence of general medical conditions. Indirect costs associated with diabetes totaled 
$58 billion, mainly resulting from the lost workdays, restricted activity days, mortality, and 
permanent disability. Individuals age 65 or older bore the majority of the estimated costs at 
$60.1 billion [8]. According to CMS, 32% of Medicare spending can be attributed 
beneficiaries with diabetes [2]. 
COMORBIDITIES AND COMPLICATIONS OF DIABETES 
Hypertension is the most common comorbidity associated with diabetes, with the 
two conditions being mutual reinforces. More than 60-70% of people with diabetes have 
hypertension. The prevalence of hypertension is three times higher in diabetics than non-
diabetics [7, 8]. Hypertension is a risk factor for complications of diabetes, and control of 
hypertension is hence an integral part of managing diabetes [7]. 
The complications of hyperglycemia in diabetes can be classified into three types: (1) short-
term complications (2) microvascular complications (3) macrovascular complications.  
Short-term complications 
Hypoglycemia, Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state 
(HHS) and uncontrolled hypertension are the four acute metabolic complications of 
diabetes resulting in ER visits and hospitalizations related to diabetes. These complications 
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can occur in both type 1 and type 2 diabetes, but are more likely to occur in diabetics taking 
insulin.  
Micro and macrovascular complications of diabetes are a result of disease 
progression over a much longer time frame (>5-10 years) [9]. 
Microvascular complications:  
Diabetic Retinopathy: Diabetic retinopathy is the most common microvascular 
complication of diabetes and is responsible for approximately 100,000 new cases of 
blindness annually in the United States [10]. The risk of developing retinopathy and other 
microvascular complications of diabetes depends on both severity & duration of 
hyperglycemia, as well as hypertension, as shown in the U.K Prospective Diabetes Study 
(UKPDS) [7].  Retinopathy is estimated to take at least 5 years to develop after the onset of 
diabetes [11]. 
Diabetic Nephropathy: Diabetic nephropathy is the leading cause of chronic kidney 
disease (CKD) and end-stage renal disease (ESRD, i.e. the fifth and final stage of CKD) in the 
United States [11]. Nephropathy is characterized by macroalbuminuria, i.e. proteinuria > 
300mg in 24 hours; and is preceded by microalbuminuira. Like other microvascular 
complications of diabetes, there are strong associations between glycemic control and the 
risk of developing diabetic nephropathy[8].  
Diabetic Neuropathy: Diabetic neuropathy is characterized by presence of 
symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the 
exclusion of other causes [7]. Amputation and foot ulceration resulting from diabetic 
neuropathy and/or peripheral artery disease are common and major causes for morbidity 
and disability in people with diabetes [8] 
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Macrovascular Complications:  
Cardiovascular Disease: Diabetes increases the risk of cardiovascular disease 
(CVD) in individuals. [12, 13]. CVD also accounts for the greatest component of health care 
expenditures in people with diabetes [14]. Microvascular manifestations of diabetes are 
additional risk factors for coronary events [15]. 
Stroke: Diabetes is also an important independent predictor of stroke and 
cerebrovascular disease. The risk of stroke can be as high as 150-400% in people with type 
2 diabetes compared to non-diabetics [9]. Stroke is the leading cause of disability and the 
third leading cause of death among persons with diabetes [16].  
Peripheral Vascular Disease: Peripheral artery disease (PAD) along with 
neuropathy is a major risk factor for lower extremity amputations in diabetics[11]. PAD is 
also a marker for CVD. 30% of diabetics with PAD have lower extremity amputations and 
20% die within 6 months of having the disease[7]. 
STANDARDS OF CARE FOR DIABETES  
The first evidence-based standards of care for persons with diabetes were published 
by the American Diabetes Association (ADA) in 1988. Since, ADA has regularly revised and 
published guidelines for the care of diabetics [17]. The guidelines recommend the following 
to providers treating diabetics: 
  Glycemic Control and Assessment with HbA1C Testing: The assessment of 
glycemic control is to be continually done by the provider by measurement of hemoglobin 
A1C (HbA1C or A1C). ADA recommends that HbA1C testing be done at least twice a year in 
patients who meet treatment goals and quarterly in patients whose therapy has changed or 
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are not meeting treatment goals [17]. HbA1C levels >9% reflect poor glycemic control and 
HbA1C levels  at or below 7% reflect good glycemic control, and the ADA recommends the 
latter goal in diabetics <65 years of age. ADA however recognizes that less stringent A1C 
goals may be appropriate for patients with a history of severe hypoglycemia, limited life 
expectancy, advanced microvascular or macrovascular conditions, extensive comorbid 
conditions etc.  Epidemiological studies and meta-analyses have shown a direct relationship 
between A1C and CVD, but the potential of intensive glycemic control to reduce CVD is less 
clearly defined [17]. Clinical guidelines in the last decade moved the good glycemic control 
threshold to <8%, due to findings from clinical trials that have shown increased risk of 
mortality among diabetics with aggressive glycemic control. More recent clinical guidelines 
recommend individualizing ‘good’  HbA1c goals for patients [17]. Pharmacotherapy with 
insulin or oral antidiabetic (OAD) medications should be used to achieve the goals of 
glycemic control [17].  
Control and Measurement of Hypertension: ADA recommends that blood 
pressure be measured at every routine diabetes visit and that patients be treated to achieve 
systolic blood pressure <130 mmHg and  diastolic pressure <80 mmHg. Pharmacotherapy 
using Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers 
(ARBs) are recommended to control blood pressure in patients who have systolic pressure 
≥140 mmHg or diastolic pressure ≥90 mmHg [17].β blockers, diuretics and calcium channel 
blockers may also be used in addition to achieve blood pressure targets or where ACE 
inhibitors and ARBs are contraindicated. Results from clinical trials have shown that 
lowering blood pressure to the recommended goals in individuals with diabetes was 
associated with reduction of CHD events, stroke and nephropathy[17]. 
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Control and Measurement of Dyslipidemia: ADA recommends that lipid profile 
for adults with diabetes be measured at least annually[17]. The goal of lipid management is 
to keep levels of LDL cholesterol <100 mg/dl in diabetics without overt CVD, or <70mg/dl 
in diabetics with overt CVD on pharmacotherapy. Diabetics with overt CVD and those over 
the age of 40 with one or more CVD risk factors are recommended statin therapy. In other 
diabetics statin therapy may be considered. Multiple trials have demonstrated the effect of 
statin therapy on CVD outcomes in subjects with coronary heart disease. Sub analyses of 
diabetic subgroups in these trials, as well as clinical trials with diabetic subjects, have 
shown significant primary and secondary prevention of CVD events in diabetic population 
with statin therapy[17].  
Nephropathy screening and treatment: Apart from optimizing glucose control 
and blood pressure control, ADA recommends annual screening for microalbuminuria to 
prevent nephropathy. An annual test to assess urine albumin excretion is advised in all type 
2 diabetes patients starting at diagnosis and in all type 1 diabetes patients with diabetes 
duration of 5 years or more[17]. Annual measurement of serum creatinine in the urine is 
also recommended in diabetics to stage the level of chronic kidney disease. Diabetics with 
micro- or macroalbuminuria are to be treated with ACE inhibitors or ARBs[17]. 
Retinopathy screening and treatment: Annual dilated eye examination by an 
ophthalmologist or optometrist is recommended for preventing diabetic retinopathy, along 
with control of  glycemia and blood pressure [17]. Patients with any level of macular edema, 
severe NPDR or PDR should be referred to an ophthalmologist for laser photocoagulation 
therapy[17]. 
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Prevention of cardiovascular disease using antiplatelet agents:  Aspirin therapy 
(75-162 mg/day) is recommended as a primary prevention strategy in those with type 1 or 
type 2 diabetes with cardiovascular risk factors. Aspirin therapy is also recommended as a 
secondary prevention strategy in diabetics with CVD[17].  One large meta-analysis and 
several clinical trials have shown the efficacy of aspirin therapy as a preventive measure for 
cardiovascular and cerebrovascular events, including AMI and stoke[17]. 
Smoking Cessation: Studies on diabetics have found a heightened risk of CVD and 
premature deaths among smokers. Hence ADA recommends that smoking cessation 
counseling and treatment be included as a routine component of diabetes care[17]. The 
smoking status of diabetics should be assessed and they should be advised to stop smoking. 
A large number of randomized trials have demonstrated the efficacy of smoking cessation 
counseling on altering smoking behavior and reducing tobacco use[17]. 
Neuropathy screening and treatment: ADA recommends that all diabetics should 
be screened for distal symmetric polyneuropathy (DPN) at diagnosis and annually 
thereafter, using simple tests. Patients with DPN should aim for glycemic control and may 
benefit from pharmacological treatment for their symptoms [17]. 
Foot Care: All patients with diabetes are required to have a comprehensive annual 
foot examination to identify risk factors for foot ulcers and amputations. The risk of ulcers 
and amputations is higher for diabetics with previous amputation, past foot ulcer history, 
peripheral neuropathy, PAD, foot deformity, retinopathy, nephropathy, poor glycemic 
control and cigarette smoking. Patients should also be educated on appropriate foot care 
and its implications[17]. 
10 
 
Diabetes Education Programs: Diabetes education programs recommended by 
ADA include Medical Nutrition Therapy (MNT) and Diabetes Self-management Education 
(DSME).  ADA recommends that individuals with diabetes receive individualized MNT 
provided by a dietician, as needed, to achieve treatment goals. ADA also recommends 
diabetics receive DSME according to national standards upon diagnosis and as needed 
thereafter. DSME helps diabetics undertake effective self-care when they are first 
diagnosed, while follow-up DSME helps them maintain effective self-management as the 
disease presents new challenges and treatments[17].  
Other Preventive Care: ADA recommends annual influenza vaccination for all 
diabetics 6 months of age or older, and a lifetime pneumococcal vaccine for those 2 years of 
age or older. A one-time revaccination of the pneumococcal vaccine is recommended for 
elderly diabetics if they were immunized previously when they were less than 65 years and 
the vaccine was administered 5 or more years ago[17].  
QUALITY MEASUREMENT 
According to Institute of Medicine (IOM), healthcare should aim to be safe, effective, 
patient-centered, timely, efficient and equitable[18]. Keeping with these six aims, health 
quality can be measured at four different hierarchical levels: (1) patients, (2) physician 
microsystems, (3) organizations that house physician microsystems, or (4) the 
macrosystem in which organizations are nested [18].  While the level of the patient remains 
the fundamental level of quality measurement, quality at each level is measured as 
structures, processes or outcomes, as proposed by Donabedian [19]. The IOM’s well 
accepted definition of quality of care - “the degree to which health services for individuals 
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or populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge” [20], recognizes that quality at the patient level can be 
measured either as desired health outcomes or as adherence to processes proven by 
scientific evidence [21].  
PROCESS VERSUS OUTCOME MEASURES IN QUALITY MEASUREMENT  
Outcomes are the ‘bottom-line’ of quality of care. Patients and providers both care 
about outcomes of care. Process measures have little value unless they are linked to 
outcomes; however that link is often difficult to demonstrate. Clinicians tend not to prefer 
outcome measures as differences in outcomes are influenced by factors other than the 
quality of care such as differences in patient type, differences in measurement and random 
variation[22]. Comparison of outcome measures hence requires exhaustive risk adjustment. 
While intermediate outcomes may be obtained from shorter periods of observation (1-2 
years), terminal outcome measures are rarer and require longer periods of observation (5-
10 years) and concomitantly larger patient samples. Intermediate and terminal outcome 
measures are also not easily obtained from administrative data [22]. 
Process measures have been increasingly used in quality measurement due to their 
advantages over outcome measures. Process measures have the advantage of being 
actionable, i.e. they identify what is being done well and what needs improvement. While 
differences in outcomes can be attributed to factors other than differences quality of care, 
process measures are more sensitive to quality of care. Process measures are easy to 
measure using administrative data, they have face validity and can be easily interpreted by 
clinicians - as most of them directly measure quality, and they do not require exhaustive 
risk adjustment as long as the eligible population is clearly defined [22]. However, in order 
12 
 
to be valid, process measures need to be strongly linked to outcomes Apart from clear 
definition of the eligible population, process measures need to be constantly reviewed and 
updated according to advances in treatment. Feasible process measures measure only 
specific aspects of quality of care for a disease. The comprehensive measurement of quality 
of care for a disease requires multiple process measures that measure all aspects of care for 
that disease [22].  
QUALITY COMPOSITES  
As multiple process measures are considered for measuring quality of care for a 
disease in value based purchasing initiatives, it becomes challenging to ascertain the value 
of specific process and compare providers or plans accordingly. In such cases, measures of 
quality from different domains of care for the disease can be combined into one summary 
composite quality measure. Composite process measures offer four advantages over 
unaggregated measures [23]. Firstly, they provide an overall summary of quality of care, 
facilitating easy comparison of quality at the patient, provider or plan level. E.g. NCQA has 
used a single composite measure of diabetes care to compare plans by combining  rates of 4 
process measures viz. HbA1c testing, LDL-C testing,  eye exam and medical attention to 
nephropathy at the plan level [24].  Standardized composite measures allow the ranking of 
providers and plans by overall quality score. Composite measures, based on the method of 
their weighting, may provide a ‘fairer’ method of comparing clinical performance as there 
would be many ways for providers or plans to get a good overall composite score. Finally, 
composite quality measures have higher reliability than unaggregated measures, and hence 
allow for comparison of smaller sample sizes of patients, providers or plans. Composite 
measures also have their disadvantages [23]. They are harder to interpret and are less 
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actionable for quality improvement than unaggregated measures. Composite measures are 
more difficult to validate than individual measures. There is a lot of debate on what 
individual process measures should be included in a composite and how they should be 
combined to create the composite.  
There are three steps commonly used to create quality composites from individual 
measures [23]. The first step is the sampling of individual measures of quality of care from 
the domain of observables. The measures chosen should have a direct hypothesized 
relationship to the construct, based either on clinical evidence or sound conceptual 
reasoning. The second step is ensuring that the individual measures are transformed to 
metrics that allow them to be combined to a composite. Items with different metrics can be 
combined by using standardized z-scores or standardization using scoring range. Finally, 
individual items included in the composite should be alterable to provider attempts to 
improve quality. Measures that are independent of the quality of care provided and depend 
solely on patient or regional characteristics should not be included in the composite[23].  
The individual items can be combined in a variety of ways to create the composite as 
shown in Table 2.1 below [23].  All these methods weight the individual measures equally. 
Reeves et al (2007) compared 5 different composite scoring methods- ‘All-or-none’, ‘70% 
Standard’, ‘Overall Percentage’, ‘Indicator Average’ and ‘Patient Average’, to rank primary 
care physician practices using two patient data sets, the first with acute, preventive and 
chronic measures, and the second with only chronic measures. They found that the different 
scoring methods produced different physician practice rankings and a third of the practices 
moved between the top and bottom quartiles depending on the scoring method used[25].  
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The variation in scores was lesser in the data set with chronic measures.  Criterion 
based scoring methods like ‘All-or-none’ & ‘70% Standard’ dichotomized composite quality. 
The case for these scoring methods was strongest only when all individual quality 
indicators were equally important clinically, which is not the case in practice[25]. ‘Overall 
Percentage’ and ‘Patient average’ are best used for homogenous populations as common 
indicators swamp them more than less common ones. ‘Indicator average’ which provides an 
average measure of quality across processes of care is best for heterogeneous populations 
and measures. ‘Patient averages’ which give composite quality scores for patients as well as 
the entire sample provide analytic advantage over other composites[25]. However these 
methods simply combine individual measures into composites, without weighting them 
based on their relative importance. The next section discusses the theory and methods for 
creating weighted composites. 
 
 
Table 2.1: Alternative Scoring Methods to Create Composites by Equal 
Weighting of Measures [25]. 
Scoring Method used 
to Create Composite 
Description of Scoring Method  Example 
(Combination of 
Individual Item 
Scores= Composite 
Score) 
i) Linear 
Scoring 
The composite is a linear combination of the 
individual items. Linear scores reported as 
overall percentages providing a measure of 
average quality across opportunities of 
care. 
CMS Hospital Compare 
1, 1, 1=3 
1,0,1 = 2 
0,0, 1= 1 
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Scoring Method used 
to Create Composite 
Description of Scoring Method  Example 
(Combination of 
Individual Item 
Scores= Composite 
Score) 
ii) All-or-
None or 
Multiplica
tive 
Scoring 
 The composite has a ‘successful’ score only 
when all individual items have successful 
scores.  
Medicare ACO 
Demonstration 
1,1,1=1 
1,0,1=0 
0,0,1=0 
 
iii) Opportuni
ty Scores 
Indicator Averages or Patient Averages. 
Indicator averages created by dividing the 
number of eligible patients who receive 
recommended care for each measure by the 
number of eligible patients. Opportunity 
scores for individual measures are then 
averaged to create the indicator average 
composite, which provides a measure of 
average quality across processes of care. 
Opportunity scores can also be created as 
patient averages, i.e. the care opportunities 
that were met for each patient, providing a 
measure of average quality of care 
provided to a sample of patients.  
Medicare’s Physician 
Value-based  Payment  
System & HEDIS 
Comprehensive 
Diabetes Care 
composite (reported at 
the plan level) 
300/1000, 400/1000, 
500/1000= 0.4 
  
APPROACHES TO CREATING WEIGHTED QUALITY COMPOSITES 
Most scoring methods for combining individual measures into composites are ad 
hoc, as they pay little or almost no theoretical attention to what is being measured. The 
methods used to create weighted composite scores should be based on theory. Health care 
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quality can be viewed as an ‘unobserved’ construct or a latent variable. The only variables 
that we observe, i.e. process or outcome measures, are either ‘reflective’ or ‘formative’ of 
this construct (Figure 2.1) [26].  
Figure 2.1: Reflective and Formative Measurement Models [27] 
 
 
 
A construct exists independent of its reflective measures. The observed measures 
are merely manifestations or effects of a reflective construct.  The direction of causation 
here is from the unobserved construct (or latent variable), healthcare quality, to its 
measures -processes and outcomes. If observed measures of healthcare quality are indeed 
effect measures, we would expect all process and outcome measures to be positively 
intercorrelated as they share a common latent cause. Any variation in quality of care should 
cause variation in all of the observed process and outcome measures. In a reflective model, 
health care quality, η, is viewed as a common cause shared by all observed effect measures 
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xi of the construct, where each measure is a linear function of the construct plus 
measurement error [27]. 
 
where, xi  is the ith measure of the latent variable η, εi is the measurement error for the ith 
indicator, and λi is a coefficient (loading) capturing the effect of η on xi. Measurement errors 
are assumed to be independent (i.e., cov(εi, εj)=0, for i≠j) and unrelated to the latent variable 
(i.e., cov(η, εi)=0, for all i).  
 
A construct is defined by its formative measures. In this case, observed measures – 
process and outcomes would be viewed as causes of the formative construct- healthcare 
quality. Formative measures may be correlated with one another however they need not be. 
Each formative measure, process or outcome, captures a specific aspect of the domain of 
healthcare quality, and omitting a measure alters the nature of the construct. According to 
the formative model, health care quality, η, would be: 
 
where, γi is a coefficient capturing the effect of measure xi on the latent variable η, and ζ is a 
disturbance term. The disturbance term, specified at the construct level, comprises all 
remaining causes of the construct which are not represented by the measures and are not 
correlated to the latter; thus following the assumption that cov(xi,ζ)=0 [27]. 
Consider the case of the construct “quality culture in a health plan”. The health 
plan’s quality culture could be viewed as a reflective construct that manifests in the form of 
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the plan’s process measure scores and health outcomes for plan members. Else the quality 
culture in plan can be viewed as a formative construct caused by the plan’s adherence to 
process measures and performance on health outcomes for its members [28]. 
   The method of developing a composite measure of healthcare quality would depend 
on whether the observed measures were viewed as reflective (effects) or formative (causes) 
of the latent construct. Reflective measurement models, employed extensively in 
psychology and social sciences, use methods like factor analysis and latent variable 
modeling that identify the underlying construct based on correlations between the 
observed measures and scale them into a composite measure. Since reflective indicators 
are expected to have a high correlation, the reliability of composite measures can be 
assessed empirically with measures such as factor loadings, communalities, and Cronbach's 
alpha. In formative measurement models, the individual measures would be weighted to 
create a composite index of healthcare quality, based on the relative importance of the 
measures for quality. The weights can be obtained either empirically or using expert 
opinion. 
According to Wilcox et al (2008), constructs by themselves are neither reflective nor 
formative; however researchers may choose to view them as either, based on the items that 
are used to measure the construct and their relation to the construct, to each other, as well 
as to the construct’s antecedents and consequences [29].  
A review of the literature, summarized in Table 2.2 below shows that researchers 
have viewed constructs like health plan quality as reflective constructs and hospital quality 
as formative constructs. The formative view of quality in hospitals has been motivated by 
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the different domains of quality that hospital process measures capture, as well as the poor 
correlation among hospital process measures.  
Table 2.2 Approaches Chosen for Weighting Quality Composites in Health 
Services Research Studies 
 
Author 
(Year) 
Composite Construct 
(Reflective/Formative) 
and method of 
estimation 
Observed 
Measures 
Reason for 
Reflective/Formative 
Model Choice 
Shwartz et al 
(2008)[30] 
Hospital Quality 
Composite (Reflective) 
using weights from a 
Bayesian latent variable 
model for hospital level 
process measures based 
on the correlation 
between measures 
Hospital level 
process 
measures for 
AMI, CHF and 
Pneumonia from 
the hospital 
compare 
database 
 Correlation between 
process measures 
Staiger et al 
(2009)[31] 
Composite measure of 
Surgical Performance 
in Hospitals 
(Formative) using 
hospital level surgical 
performance measures. 
Weights for these 
measures were 
empirically derived 
based on how they 
predicted hospital level 
surgical mortality 
Hospital level 
performance 
measures for 
Aortic Valve 
Replacement and 
related surgeries 
 Surgical performance 
measures at the 
hospital level 
predicted mortality 
 Surgical 
performance 
measures captured 
different dimensions 
of hospital surgical 
performance 
 
Glickman et al Composite measure of Hospital level  Process measures 
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Author 
(Year) 
Composite Construct 
(Reflective/Formative) 
and method of 
estimation 
Observed 
Measures 
Reason for 
Reflective/Formative 
Model Choice 
(2009)[32] Process-measure 
Adherence in 
Hospitals (Formative) 
created using weights 
from principal 
component analysis of 
CMS hospital level 
process measures 
process 
measures for 
AMI and CHF and 
Pneumonia from 
the hospital 
compare 
database 
are a reflection of 
how hospitals 
operate and provide 
care. Process 
measures that 
capture different 
dimensions of 
hospital quality load 
on different factors. 
 
Caldis (2007) 
[33], 
Leid et al 
(2002)[34] 
 
A scale for Health Plan 
Quality (Reflective) 
from  factor analysis of 
HEDIS measures 
Plan rates for 31 
[33] and 17 [34] 
HEDIS process 
and outcome 
measures  
 HEDIS measures are 
an effect of plan 
quality of care 
 High correlation 
between certain 
HEDIS measures at 
the plan level 
Zaslavsky et 
al (2002)[35] 
 
 
 
 
 
 
Four composite scores 
summarizing Health 
Plan Quality 
(Reflective) from factor 
analysis of HEDIS 
measures and CAHPS 
survey results 
Plan rates for 8 
HEDIS and 12 
CAHPS quality of 
care measures 
 HEDIS and CAHPS 
measures are 
reflective of plan 
quality of care 
 High correlation 
between certain 
HEDIS & CAHPS 
measures at the plan 
level 
21 
 
  
In the reflective measurement model the underlying construct is identified using 
factor analysis, based on the observed correlation between measures. Factor scores can 
then be used to weight individual measures. In the formative measurement model, 
individual measures can be weighted empirically or using expert opinion. The empirical 
weighting of measures using formative measurement models is methodologically 
challenging, especially if there is multicollinearity between observed measures. The 
problem with empirical formative model identification using structural equation modeling 
is well documented and has resulted in their criticism[27]. Weights for measures in 
formative measurement models can be otherwise assigned using an expert panel, i.e. a 
panel of physicians can be asked to weight individual process measures based on their 
relative importance.  However, if we assume the observed measures to be independent, 
then the measures can be empirically weighted based on their association with subsequent 
patient outcomes. In Chapter 4 we employ factor weighting, physician weighting and 
outcomes-based empirical weighting to weight diabetes care measures for creating quality 
of diabetes care composites. 
QUALITY MEASUREMENT FOR DIABETES CARE 
Diabetes care has been at the center of quality measurement initiatives, since the 
first national effort to develop a set of performance measures for the disease was convened 
by the CMS, the National Committee on Quality Assurance (NCQA), and the ADA in 1995. 
The Diabetes Quality Improvement Program (DQIP) developed a set of eight binary process 
and intermediate outcome measures that were based on either evidence from clinical trials 
or consensus[36] . As these measures could be readily obtained from healthcare claims or 
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medical records, and their periodic measurement was appropriate for all patients with the 
exception of the very elderly- they were adopted by NCQA as HEDIS measures and widely 
used to assess diabetes care performance of Medicare, Medicaid and commercial health 
plans [4]. The last fifteen years have seen an increase in the rates of these recommended 
diabetes care measures among diabetics in the US. Even as the performance of these 
measures has improved, there has been a concurrent reduction in rates of adverse 
outcomes such as renal failure and LEA in the diabetic population [37-39].  
REVIEW OF LITERATURE ON QUALITY OF DIABETES CARE AND PATIENT OUTCOMES 
 
Studies investigating the effect of quality of diabetes care on diabetic outcomes have 
usually examined the effect of process measures on intermediate outcomes (e.g. HbA1c 
testing on HbA1c level), process measures on terminal outcomes (e.g. HbA1c testing on 
micro or macro vascular complications), or intermediate outcomes on terminal outcomes 
(e.g. HbA1c level on incidence of cardiovascular disease) [40]. A systematic review of 
twenty four such studies showed that (i) improvements in processes of care like HbA1c and 
blood pressure measurement did not really result in improvement in intermediate 
outcomes, viz. better control of HbA1c and blood pressure; (ii) more processes of care, e.g. 
more HbA1c tests, were associated with poorer terminal outcomes like hospitalizations for 
metabolic events due to confounding with severity of diabetes; (iii) studies that 
demonstrated an association between better intermediate outcomes and better terminal 
outcomes did not adequately risk-adjust for patient factors that were  associated with poor 
intermediate and terminal outcomes [40]. The terminal outcomes chosen in these twenty 
four studies were health status;  hospitalizations for metabolic, micro vascular, and macro 
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vascular complications, cardiovascular events, heart and kidney disease, and  amputations 
;and death[40]. Attributing outcomes such as micro or macro vascular complications that 
are the consequence of multiple years of diabetes progression (>5-10 years) to quality of 
diabetes care in a short time frame (0-2 years) is dubious [9]. None of these studies 
adequately adjusted for duration of diabetes, which is more important than merely 
adjusting for age. Finally, none of these studies looked at the effect of ambulatory diabetes 
care measures on subsequent hospitalizations for a set of ambulatory care sensitive 
conditions associated with diabetes (diabetes ACSCs), viz. uncontrolled diabetes, 
complications of diabetes, hypoglycemia and hypertension [40, 41].  
In this dissertation, we address the limitations of previous studies by studying the 
effect of ambulatory diabetes care measures on hospitalizations for diabetes ACSCs. To 
study if diabetes care measures also have an effect on overall ambulatory care, we examine 
the effect of these measures on subsequent hospitalizations for all ACSCs[41]. 
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CHAPTER 3: QUALITY OF AMBULATORY DIABETES CARE FOR 
MEDICARE BENEFICIARIES: A CRITIQUE OF THE “ALL-OR-
NONE” APPROACH TO QUALITY MEASUREMENT 
 
Objective: To examine the predictive validity of the all-or-none approach for measuring the 
quality of ambulatory diabetes care for fee-for-service Medicare beneficiaries, we studied 
whether beneficiaries who receive ‘all ‘ and ‘not-all ‘ scores for a set of four claims computable 
diabetes process measures, viz. annual HbA1c testing, annual LDL cholesterol testing, annual 
dilated eye examination and, annual testing for diabetic nephropathy, differed in their 
likelihood of hospitalizations related to ambulatory diabetes care and ambulatory care in the 
subsequent year. 
Data and Methods: A retrospective cohort study design following a 5 percent nationally 
representative sample of 194,345 fee-for-service Medicare beneficiaries with diabetes aged 18-
75 years in 2006, who were alive at the end of 2007. We used multivariate logistic regression 
to examine the association between number of diabetes process measures in 2006 and 
likelihood of hospitalizations for ambulatory care sensitive conditions associated with diabetes 
(diabetes ACSCs) and all ambulatory care sensitive conditions (ACSCs) in 2007. For 
beneficiaries who received one, two or three of the four diabetes process measures we 
employed stratified multivariate logistic regressions to examine the association between type 
of diabetes process measures in the prior year and likelihood of hospitalization for diabetes 
ACSCs and all ACSCs in the subsequent year. 
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Results: There was no difference in the likelihood of diabetes ACSCs or all ACSCs between 
beneficiaries who received three and four process measures, even though the all-or-none 
approach views them to be diametrically different with respect to quality. Beneficiaries who 
received one, two or three process measures had a significantly lower risk of hospitalizations 
for diabetes ACSCs and ACSCs compared to beneficiaries who received no process measures - 
even though the all-or-none approach views these beneficiaries to have received the same 
quality of diabetes care. Beneficiaries who did not receive either HbA1c testing or LDLC testing 
had a significantly higher likelihood of either hospitalization compared to other beneficiaries 
who received at least two process measures.  
Conclusion:  The all-or-none approach to quality measurement has poor predictive validity, 
discards important quality information and has poor discrimination. It is not suited for the 
Medicare population, nor is it ideal for diseases where multiple measures vary in their relative 
importance. 
INTRODUCTION 
More than twenty-five percent of Medicare beneficiaries suffer from diabetes.  
Annual healthcare expenditures for these beneficiaries are two and half times greater than 
those without the disease [14]. Given its prevalence, economic burden, and consensus 
around care elements, diabetes care has been at the forefront of quality measurement 
efforts for almost two decades- since the first set of quality measures for the disease was 
developed by the National Committee on Quality Assurance (NCQA) to measure health plan 
performance in 1995 [36].   
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Over the years, these quality measures for diabetes have been used in a binary 
format for process (done/not) and intermediate outcome measures (above/below 
threshold value)1[4]. These criterion measures are often combined together by addition, to 
obtain a composite measure that provides a summary of the quality of ambulatory diabetes 
care provided by physicians or health plans.  Recently, there has been movement towards 
adopting an all-or-none approach (second level of binary), where binary process and/or 
intermediate outcome measures are combined into a single 0-1 composite score by 
multiplication. In this approach, credit is given only when all discrete elements of care are 
provided, in contrast to the traditional approach that gives partial credit when at least some 
of the elements of care are provided [42].  Developed first by Health Partners, the all-or-
none approach is used by Minnesota Community Measurement for measuring quality of 
diabetes care2 provided by 300 medical clinics in the state[43].  The Center for Medicare 
and Medicaid Services’ Accountable Care Organization (ACO) demonstration has also 
adopted the all-or-none approach to measure quality of care provided by group practices 
for diabetes and coronary artery disease[5].  
The all-or-none approach has some advantages in that it is easy to implement as it 
treats all elements of care as equally important, and  allows more opportunity for quality 
                                                             
1
 Process measures include annual Hemoglobin A1c (HbA1c) testing, annual low density lipoprotein 
cholesterol (LDLC) testing, annual dilated eye exam, and medical attention for nephropathy.  Intermediate 
outcome measures include blood pressure control (<140/90 mmHg), HbA1c control (<9%), LDLC control 
(<130 mg/dL) 
2
 Minnesota Community Measurement’s D5 measure for diabetes gives a clinic credit only when it meets 
all five treatment goals for the diabetic patient, viz. blood pressure less than 140/90 mmHg, LDL 
Cholesterol less than 100mg/dl, HbA1c of less than 8%, tobacco cessation and daily use of Aspirin.    
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improvement by setting the bar high [42].  However, the approach falls short if it combines 
criterion measures where some measures in the set are more important than others, say 
with respect to quality of care measured as patient outcomes [4]. In the case of ambulatory 
diabetes care, some process measures could be more important than others in preventing 
subsequent patient outcomes such as hospitalizations for ambulatory care sensitive 
conditions associated with diabetes. The all-or-none approach also has lesser 
discrimination than the equally simple additive approach.  It ignores the different levels of 
quality that truly exists among beneficiaries who do not get all measures[4]. This problem is 
especially amplified in the older Medicare population where the majority of beneficiaries do 
not receive all recommended ambulatory diabetes care measures.  
This paper tests the predictive validity of the all-or-none approach for measuring 
the quality of ambulatory diabetes care for fee-for-service Medicare beneficiaries. We  
compare the likelihood of ambulatory diabetes care-related outcomes in the subsequent 
year for beneficiaries who receive ‘all ‘ and ‘not-all ‘ scores for a set of four claims-
computable diabetes process measures: (i) annual HbA1c testing, (ii) annual LDL 
cholesterol testing, (iii) annual dilated eye examination and, (iv) annual testing for diabetic 
nephropathy. We specifically compare the likelihood of hospitalizations for ambulatory care 
sensitive conditions associated with diabetes (diabetes ACSCs) and  for all  ambulatory care 
sensitive conditions (all ACSCs) in the subsequent year among Medicare beneficiaries (aged 
75 or younger) who receive none, one, two, three or all of the ambulatory diabetes care 
measures in the prior year. Better ambulatory care has been shown to lower the rate of  
ACSCs [45-47].  We also examine whether some of the ambulatory diabetes care process 
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measures are more important than others in predicting the risk of avoidable 
hospitalizations in the subsequent year. 
METHODS 
DATA  
This study employed data from the 2006 and 2007 Chronic Condition Data 
Warehouse (CCW) 5% Medicare files. Specifically, we used beneficiary summary, inpatient, 
outpatient, and carrier claims (physician and durable medical equipment) for a 5 percent 
random sample of Medicare beneficiaries. We also used Small Area income and education 
data sets from the Census Bureau. Our study sample consisted of Medicare fee-for service 
beneficiaries with diabetes, who were alive at the end of 2007. Beneficiaries were 
continuously enrolled in Part A (coverage for hospital care) and Part B (coverage for 
physician care), with no months of managed care enrollment for either year. We identified 
beneficiaries with diabetes using the chronic condition flag for the disease [48]. We applied 
additional restrictions so that our sample met the HEDIS denominator definitions for 
quality : we excluded beneficiaries older than 75 years in 2006 and, those with HIV, active 
cancer treatment, organ transplant and end-stage-renal disease (see Appendix 1 for 
exclusion codes) [44]. The final study cohort consisted of 194,345 beneficiaries 
MEASURES 
We used CPT codes to identify beneficiaries who received the following diabetes 
process measures in 2006 from their carrier and outpatient claims: (i) annual HbA1c testing 
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(ii) annual LDLC testing (iii) annual dilated eye exams 3  , and (iv) testing for 
nephropathy4.The definitions of these measures and the codes used to identify them from 
claims are summarized in Appendix 2. The four diabetes process measures are claims 
computable HEDIS diabetes measures that have long been used to measure quality of 
diabetes care in health plans, and more recently for physicians. 
OUTCOMES OF INTEREST 
We chose two avoidable hospitalization outcomes in the subsequent beneficiary year that 
should be closely tied to quality of ambulatory care for diabetes: 
(i) Hospitalizations for ambulatory care sensitive conditions associated with 
diabetes (diabetes ACSCs): These were hospitalizations for complications of diabetes, 
uncontrolled diabetes, hypoglycemia, and hypertension [41]. 
 (b) Hospitalization for all ambulatory care sensitive conditions (ACSCs): These are a 
larger set of hospitalizations, defined by the Agency for Healthcare Research and Quality, 
that can be avoided by better ambulatory care (all ACSCs)  [41]. 
We identified hospitalizations for diabetes ACSCs and all ACSCs in 2007 from 
inpatient hospital claims (see Appendix 3 for the list of conditions and diagnosis codes for 
diabetes ACSCs and all ACSCs).  
 
                                                             
3
 The HEDIS measure set counts any E&M visit to an Ophthalmologist or Optometrist as an eye exam. We 
use a more conservative definition of the process measure to include only dilated retinal exams. 
4
 The HEDIS measure set defines attention for nephropathy as documentation of nephropathy or testing 
for nephropathy. We define the process measure to include only testing for nephropathy. 
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STATISTICS 
We obtained descriptive statistics for outcomes, demographics, diabetes severity 
and comorbidities for beneficiary groups receiving four, three, two, one and none of the 
diabetes process measures. We compared differences in group means using one-way ANOVA 
or Kruskal-Wallis Rank Test for interval variables and Chi-square for categorical variables. We 
employed multivariate logistic regression to model the association between the number of 
diabetes process measures in the prior year and diabetes ACSC & all ACSC hospitalization in 
the subsequent year. For beneficiaries who received one, two or three of the four process 
measures in the prior year, we modeled the association between the type of process measure 
set and diabetes ACSC & all ACSC hospitalization in the subsequent year using stratified 
multivariate logistic regresssion models. This allowed us to compare whether some diabetes 
process measures were more important than others in predicting of hospitalizations in the 
subsequent year. We ran separate analysis for the two hospitalization outcomes. 
In the models, we controlled for beneficiary’s (i) demographic characteristics: age 
(<60 years, 60-64 years, 65-69 years, and 70-75 years) , sex, race (White, Black, Hispanic, 
Asian and Other) , Medicare-Medicaid dual eligible status,  rural-urban status, median zip 
code income and median zip code education (ii) diabetes severity in 2006: Type I 
diabetes, insulin pump use (from part B and DME claims),  self-monitoring of blood glucose 
(from durable medical equipment claims)  and years of diabetes duration from CCW records 
(iii) comorbidity in 2006: using 70  hierarchical condition categories (HCCs) computed  
using the CMS HCC model on beneficiary’s claims for 2006 and (iv) outcomes in 2006:  we 
also controlled for whether the beneficiary was hospitalized for micro/macro vascular 
hospitalizations or ASC hospitalizations in 2006.  
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We performed sensitivity analysis where we controlled for observed confounding, 
using propensity score inverse probability treatment weighting-for the propensity to 
receive the diabetes process measures (modeled as 0-4)5.  Results of the propensity score 
inverse probability weighting did not differ from that obtained with simple logistic 
regression results and are not reported here. 
All standard errors were robust in multivariate analyses. P values were 2-sided with 
a level of significance of ≤.05. We used SAS version 9.1 [49] and STATA 12 [50] for all 
analyses.  
RESULTS 
Table 3.1 shows the descriptive statistics for our beneficiary cohort, stratified into 
subsamples based on the number of ambulatory diabetes care process measures they 
received in 2006. Seven percent of the beneficiaries received none of the diabetes care 
process measures. Only 22 percent of the beneficiaries received all four process measures. 
The all-or-none approach would deem the remaining 88 percent of the beneficiaries as not 
having received ambulatory diabetes care of creditable quality, even though 37 percent and 
24 percent received three and two process measures respectively. Beneficiaries who 
                                                             
5 Weighting with inverse probability treatment weights of propensity scores is an efficient approach that 
uses all available data and does not require any arbitrary decisions with regards to stratification into 
groups or matching. We applied inverse probably treatments weights of the propensity score in the 
following steps. We first employed multinomial logistic regression to obtain the probability of receiving 0-4 
process measures for each beneficiary. We then estimated the probability of having a hospitalization 
outcome in the subsequent year based on receipt of number of process measures by the beneficiary, 
beneficiary covariates and the beneficiary’s inverse probability propensity score treatment weight. We 
carried out separate analyses for the two hospitalization outcomes.  
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received two or three process measures were more likely to have HbA1c testing and Lipid 
Testing, and least likely to have dilated eye examinations. 10 percent of the beneficiaries 
who received only one process measure were more likely to receive HbA1c (29%) and least 
likely to receive nephropathy testing (20%).  
Beneficiaries receiving fewer than four diabetes process measures were more likely 
to be- disabled (<65 years), male, non-white, dual eligible, and reside in rural areas, or in zip 
codes with lower median income and education. Beneficiaries receiving all the process 
measures were more likely to have Type 1 diabetes, used insulin pump, suffered from the 
disease for a longer-duration, and less likely to have multiple comorbidities- as evinced 
from their average HCC scores. These beneficiaries were also more likely monitor their own 
blood glucose level (measured from their durable medical equipment claims for the year), 
receive influenza vaccination, cancer screening, attend diabetes education programs, see an 
endocrinologist, and have more evaluation and management visits for their disease during 
the measure year, than beneficiaries who received fewer than four process measures. 
Finally, the rates of diabetes ACSCs and all ACSCs, in both the measure year and subsequent 
year, were lower for beneficiaries who received all four of the diabetes process measures.  
Table 3.2 shows results from the multivariate logit models predicting the likelihood 
of hospitalizations for diabetes ACSCs and all ACSCs in the subsequent year, based on the 
number of diabetes process measures in the prior year.  Beneficiaries receiving all four 
measures had significantly lower risk6 [51]of hospitalizations for the two outcomes than 
                                                             
6
 Given the low incidence of both the outcomes of interest in the subsequent year (<<10 percent), we can 
assume that the odds ratio approximate relative risk (Zhang & Yu 1998). 
33 
 
those receiving none, one or two measures. Beneficiaries receiving none of the diabetes 
process measures had a 119 percent higher risk of diabetes ACSC and 62 percent higher risk 
of all ACSC hospitalizations compared to those who received all four process measures. The 
relative risk of hospitalization for beneficiaries receiving one or two process measures, 
compared to those who received all, was lower, ranging from 20-40 percent. But there was 
no significant difference in the likelihood of having hospitalizations for either diabetes ACSCs 
or all ACSCS in the subsequent year between beneficiaries receiving three diabetes process 
measures and those receiving four diabetes measures. Beneficiaries receiving one, two, and 
three out of the four process measures had significantly lower risk of hospitalization for 
diabetes ACSC, (25 percent, 39 percent, and 45 percent, respectively), compared to 
beneficiaries receiving none of the process measures. The risk of all ACSC hospitalizations 
was also significantly lower for beneficiaries who received one (8%), two (24%) or three 
(31%) of the four process measures compared to those who received none.  
Table 3.3 shows results from the multivariate logit models predicting the 
probability of hospitalization for diabetes ACSCs and all ACSCs in the subsequent year, 
based on the type of process measure beneficiaries received- for the sample of beneficiaries 
stratified into subgroups that received one, two or three process measures. Among 
beneficiaries who received two process measure, receiving neither LDLC nor HbA1c testing 
was associated with significantly higher relative risk of hospitalizations for diabetes ACSCs 
(44% higher than LDLC and HbA1c testing) and all ACSCS (35% higher than LDLC and 
HbA1c testing). There was no difference in the likelihood of hospitalization for diabetes 
ACSCs or ACSCs by type of measure set among beneficiaries who received one or three 
measures. 
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DISCUSSION 
We examined the limitations and predictive validity of the all-or-none approach in 
measuring the quality of ambulatory diabetes care for the Medicare beneficiaries. Only 22 
percent of beneficiaries in our study received all four of the recommended process 
measures during the year, echoing findings from prior studies that have shown low rates of 
recommended diabetes care measures for Medicare beneficiaries [52]. This is the biggest 
limitation of using the all-or-none approach for quality measurement for Medicare 
beneficiaries- where majority of the beneficiaries would be classified as failures rather than 
partial successes in reaching the quality bar. This problem would only be compounded with 
the addition of more criterion measures capturing different elements of care for the disease.  
Hence, there must be parsimony in selecting criterion measures for a disease while using 
the all-or-none approach.  
The all-or-none approach to quality measurement does not distinguish between the 
37 percent of beneficiaries in our study who received three of the four measures- and the 
10 percent who received none, even though these two groups had very different subsequent 
ambulatory care related outcomes. We compared outcomes in the subsequent year- 
hospitalizations for diabetes ACSCs and all ACSCs, by the number of process measures 
beneficiaries received in the prior year, and found no difference in likelihood of 
hospitalizations for either outcome between beneficiaries receiving all four process 
measures and those receiving three of the four process measures- even though the all-or -
none approach regards the former group to have met quality benchmark and the latter to 
have failed to meet the quality benchmark for the ambulatory diabetes care. The 
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discrimination works at the bottom as well; any is better than none. Beneficiaries who 
received one, two or three of the four process measures had much lower probability of 
hospitalizations for either outcome, compared to those who received none of the four 
process measures. The all-or-none approach to quality measurement lumps those who 
receive a subset of criterion quality measures together, and does not distinguish the 
incremental levels of quality among these beneficiaries. 
The all-or-none approach assumes that anything less than good care is not 
acceptable. Like other approaches that do not involve measure weighting, it also assumes 
that that all components of care are “good care” and equally important for patient outcomes 
and experience. But all components of care are seldom equal when it comes to outcomes. 
Our comparison of the likelihood of diabetes ACSC and all ACSC hospitalizations among 
beneficiaries who received two measures showed that those who did not receive either LDL 
cholesterol or HbA1c testing in the prior year had poorer outcomes in the subsequent year.  
The choice of avoidable hospitalizations as the outcome of interest in our study, preferential 
biased it towards LDL cholesterol testing and HbA1c testing, rather than eye examinations. 
This is a limitation of Medicare claims data- in that the only observed outcomes attributable 
to ambulatory diabetes care are avoidable hospitalizations. 
A few other limitations of this study must be acknowledged. The quality measures 
we studied- were claims computable process measures and not intermediate outcome 
measures like HbA1c control.   The outcomes of interest we used in our study were limited 
by what could be readily measured from Medicare claims. Finally, our study controlled only 
for observed confounding using propensity scores. We did not control for bias due to 
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unobserved confounders like prescription drug use by beneficiaries- which is more often 
than not balanced in such large Medicare beneficiary samples.  The low prevalence of 
hospitalization outcomes allowed us to infer odds ratios as relative risks. These limitations 
however do not impact the overall conclusions of our study. 
CONCLUSION 
In summary, even as the all-or-none approach to quality measurement is 
increasingly adopted because of its simplicity, ease of calculation and interpretation; it may 
neither be ideally suited for the Medicare population nor for measurement of quality of care 
for chronic conditions- where there are multiple care components with varying importance. 
This approach has poor predictive validity, discards meaningful & important quality 
information and has poor discrimination.  The science of quality measurement would be 
better served with greater investment in the measurement and reporting of patient 
outcomes, to be used as the yardstick for developing weighted composites, which are truer 
measures quality of care.  
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Table 3.1: Comparison of Descriptive Statistics by Subsample based on Number of 
Diabetes Quality Process Measures in Prior Year 
  
ALL NONE 
4 MEASURES 3 MEASURES  2 MEASURES 1 MEASURE 0 MEASURES 
Number of 
Beneficiaries 42,015 72,020 46,969 20,279 13,062 
% of Total Sample 21.6% 37.1%* 24.2%* 10.4%* 6.7%* 
Variable Mean (SD) or Percent 
Outcome in Subsequent Year  
Hospitalizations for 
Diabetes ACSCs 
1.4%* 1.6%* 2.0%* 2.5%* 2.2%* 
Hospitalizations for 
All ACSCs 
6.9%* 8.0%* 10.2%* 12.6%* 11.2%* 
Demographic Characteristics  
Age: < 60 years 11.8%* 16.8%* 20.2%* 24.1%* 30.1%* 
Age: 60-64  Years 37.3%* 33.3%* 31.3%* 29.7%* 25.0%* 
Age: 65-69 years 7.2%* 8.7%* 9.3%* 10.3%* 10.7%* 
Age: 70-75 Years 43.6%* 41.1%* 39.2%* 35.8%* 34.2%* 
Sex: Female 59.6%* 55.9%* 53.6%* 50.1%* 41.1%* 
Race: White 81.6%* 79.8%* 79.4%* 75.0%* 70.6%* 
Race: Black 12.3%* 14.2%* 15.1%* 18.4%* 20.3%* 
Race: Other 6.1%* 6.0%* 5.5%* 6.5%* 9.1%* 
Rural 17.9%* 18.6%* 19.4%* 19.1%* 18.7%* 
Dual Eligible 23.1%* 26.8%* 29.7%* 32.3%* 29.1%* 
Disabled 16.8%* 23.0%* 26.9%* 31.7%* 38.7%* 
Median Zip Code 
Income (In $10,000) 
4.30*(1.59) 4.15* (1.51) 4.04* (1.45) 3.96* (1.41) 3.95* (1.43) 
Median Zip Code 13.34*(1.12) 13.24* (1.10) 13.16* (1.08) 13.13 13.09 *(1.09) 
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ALL NONE 
4 MEASURES 3 MEASURES  2 MEASURES 1 MEASURE 0 MEASURES 
Number of 
Beneficiaries 42,015 72,020 46,969 20,279 13,062 
% of Total Sample 21.6% 37.1%* 24.2%* 10.4%* 6.7%* 
Education (In Years) *(1.07) 
Diabetes  
Diabetes Type 1 22.0%* 19.7%* 17.7%* 14.8%* 10.1%* 
Insulin Pump 5.4%* 5.0%* 4.6%* 4.7%* 4.1%* 
Self-Monitoring of 
Blood Glucose 
56.2%* 50.2%* 43.0%* 32.4%* 24.4%* 
Diabetes Duration in  
Years 
4.22*(2.4) 4.01* (2.4) 3.77 *(2.4) 3.56*(2.4) 3.45*(2.4) 
HCC Score 1.29* (0.90) 1.38* (1.05) 1.49* (1.22) 1.56* (1.34) 1.27* (1.26) 
Diabetes Measures 
and Utilization  4 MEASURES 3 MEASURES 2 MEASURES 1 MEASURE 0 MEASURES 
HbA1c Measurement 100.0%* 95.2%* 79.0%* 29.0%* 0.0%* 
LDL Cholesterol 
Measurement 
100.0%* 94.7%* 76.7%* 25.3%* 0.0%* 
Eye Exams 100.0%* 44.3%* 19.5%* 24.6%* 0.0%* 
Attention for 
Nephropathy 
100.0% 65.8%* 24.8%* 21.0%* 0.0%* 
Diabetes Education 7.0%* 5.2%* 3.6%* 1.9%* 1.2%* 
Evaluation and 
Management Visit for 
Diabetes 
81.6%* 71.6%* 59.7%* 45.5%* 31.7%* 
Number of E&M 
Visits for Diabetes 
2.8 (2.6)* 2.3 (2.6)* 1.7 (2.3)* 1.1 (1.9)* *0.7 (1.5) 
*Differences between groups significant at p<0.05 
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Table 3.2: Results from Multivariate Logistic Regressions* Predicting the Likelihood  
of Hospitalization for Diabetes and All Ambulatory Care Sensitive Conditions (ACSC) 
in 2007 based on Number of Ambulatory Diabetes Care Processes in 2006 
 
 
Number of 
Ambulatory 
Diabetes Care 
Processes in 
2006 
Diabetes ACSC Hospitalizations in 
2007 
 
ACSC Hospitalizations in 2007 
 
Odds Ratio 95% CI of Odds Ratio Odds Ratio 
95% CI of Odds 
Ratio 
Zero vs. All 2.19** 1.78-2.69 1.62** 1.51-1.75 
One  vs. All 1.64** 1.37-1.97 1.50** 1.41-1.60 
Two vs. All 1.35** 1.16-1.58 1.24** 1.17-1.32 
Three vs. All 1.16 1.00-1.35 1.05 0.99-1.11 
 
  
One vs. Zero 0.75** 0.61-0.92 0.92** 0.86-0.99 
Two vs. Zero 0.61** 0.51-0.74 0.76** 0.71-0.82 
Three vs. Zero 0.55** 0.46-0.66 0.69** 0.64-0.74 
Four vs.  Zero 0.46** 0.37-0.56 0.61** 
 
0.57-0.66 
* Adjusted for beneficiary characteristics viz. age, sex, race, dual eligible status, rural-urban status, 
median zip code income, median zip code education, Type I diabetes, diabetes duration in years (as 
per CCW records), comorbidities using 70  hierarchical condition categories (HCCs) computed  
using the CMS HCC model on beneficiary’s claims for 2006, self-monitoring of blood glucose, and 
hospitalizations for diabetes ACSC or All ACSC hospitalizations in 2006.  
** Significant at p<0.05 
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Table 3.3: Results from Multivariate Logistic Regressions * Predicting the Likelihood  
of Hospitalization for Diabetes and All Ambulatory Care Sensitive Conditions (ACSC) 
in 2007 based on  Ambulatory Diabetes Care Processes within a Measure Set 
Subgroup in 2006 
* Adjusted for beneficiary characteristics viz. age, sex,  race, dual eligible status, disability, rural-
urban status, median zip code income, median zip code education, Type I diabetes, diabetes 
duration in years (as per CCW records),  comorbidities using 70  hierarchical condition categories 
(HCCs) computed  using the CMS HCC model on beneficiary’s claims for 2006, self-monitoring of 
blood glucose, and  hospitalizations for micro/macro vascular complications or ASC 
hospitalizations in 2006. ** Significant at p<0.05 
Measure Set Subgroup of 
Ambulatory Diabetes Care 
Processes in 2006 
Diabetes ACSC 
Hospitalizations in 2007 
 
All ACSC Hospitalizations in 
2007 
 
 
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of Odds 
Ratio 
One Measure (Reference: LDLC) 
HbA1c 0.96 0.60-1.51 0.88 0.75-1.03 
Eye Examination 1.19 0.78-1.83 1.03 0.89-1.20 
Nephropathy Testing 1.34 0.86-2.07 1.09 0.94-1.27 
Two Measures (Reference: LDLC+HbA1c) 
LDLC+Eye Examination 0.64 0.37-1.12 0.98 0.85-1.14 
LDLC + Nephropathy Testing 0.69 0.41-1.16 1.04 0.92-1.19 
HbA1c+ Eye Examination 0.99 0.73-1.34 1.04 0.92-1.18 
HbA1c+ Nephropathy Testing 1.24 0.93-1.66 1.14 1.00-1.28 
Eye Examination + Nephropathy 
Testing 1.44** 1.03-2.08 1.35** 1.15-1.58 
Three Measures (Reference: LDLC+HbA1c+ Eye Examination) 
LDLC+HBA1C+ Nephropathy 
Testing 0.72 0.39-1.35 0.94 0.79-1.11 
LDLC+ Eye Examination + 
Nephropathy Testing 1.08 0.88-1.31 1.02 0.95-1.09 
HbA1c+ Eye Examination + 
Nephropathy Testing 1.24 0.89-1.71 1.08 0.95-1.23 
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CHAPTER 4: COMPOSITE QUALITY OF AMBULATORY 
DIABETES CARE: COMPARING APPROACHES TO WEIGHTING 
MEASURES 
 
Objective:  Current approaches to composite quality measurement for diabetes care weight all 
measures equally, even when they are not equally important for either diabetes care or 
outcomes. The correct approach to weighting measures in a composite depends on whether 
the measures are viewed as effects of unobserved quality, or causes of quality- which might be 
unobserved or observed as outcomes. Accordingly we compare measure weights for four 
diabetes care processes using three alternate approaches for developing weighted composites: 
1) factor-based weighting 2) physician-based weighting and 3) outcomes-based weighting, to 
study whether equal weighting of these process measures is justified in practice.  
Methods: A retrospective cohort design following a 5 percent nationally representative sample 
of 194,345 fee-for-service Medicare beneficiaries with diabetes, aged 18-75 years in 2006, who 
were alive at the end of 2007. We used confirmatory factor analysis on two split-half samples 
to examine factor loadings of four diabetes care process measures and eight ambulatory care 
process measures on an underlying quality factor. We asked a technical expert panel of eight 
physician quality leaders to rate the four process measures based on the relative importance 
to quality. We employed multiple logistic regressions with propensity score inverse probability 
treatment weighing to compare the association of the four process measures on 
hospitalizations for ambulatory care sensitive conditions associated with diabetes and all 
ambulatory care sensitive conditions in the following year. 
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Results: HbA1c testing and LDLC testing loaded more strongly on the single underlying factor 
than eye exams and testing for nephropathy. The eight ambulatory care measures, related and 
unrelated to diabetes also loaded on the same single underlying factor. Physicians in the 
technical expert panel rated all four measures as equally important to quality. HbA1c testing 
and LCLC testing were associated with significantly lower risk of hospitalizations for diabetes 
ACSCs, while eye exams and testing for nephropathy were not. 
Conclusion: Current approaches to composite quality measurement weight all measures in the 
diabetes measure set equal. While physician quality leaders endorse this dogma, measures like 
HbA1c and LDLC measurement are more strongly related to quality of diabetes care than eye 
exams or testing for nephropathy.  
BACKGROUND 
Diabetes care has been a prominent focus of ambulatory care quality measurement 
and improvement initiatives over the last two decades, since the first national effort to 
develop a set of performance measures for the disease was convened in 1995 [36]. Apart 
from being incorporated as measures of plan quality in Healthcare Effectiveness Data and 
Information Set (HEDIS), payers and providers have more recently adopted diabetes quality 
measures for use at the physician or group practice level with payment programs such as 
Medicare’s Physician Quality Reporting System (PQRS) and Accountable Care Organization 
(ACO) demonstrations [3-5, 53]]. The move towards pay-for-performance and value-based 
purchasing has highlighted the need for summary measures for diseases/conditions 
spurring development of composite quality measurement.   
The National Quality Form defines a composite measure as a combination of two or 
more measures into a single measure, resulting in a single score[53].  Composites have the 
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potential of enhancing measurement, beyond the mere tracking of performance on separate 
measures, by determining whether critical aspects of care for a given condition have been 
achieved for an individual patient [54].  By providing an overall summary of quality of care, 
composites can allow for comparison of providers over multiple domains of care. 
Composites also have higher reliability than unaggregated measures, allowing for 
comparison of providers with smaller patient samples [23]. However, composites are 
harder to interpret and more difficult to validate than individual measures. There is also a 
lot of debate how to combine measures to create a composite7 [23]. In practice, different 
scoring methods used to create quality composites have yielded different provider rankings, 
making the comparison of quality between providers onerous [25] 
The rationale for weighting measures in a composite and how to weight them is also 
is also a subject of debate [23]. Unaggregated measures in the diabetes measure set are not 
equally important for diabetes care or outcomes - making the case for weighting them 
accordingly in the composite. The approach used to weight unaggregated measures should 
be based on the importance of these measures for either diabetes care or subsequent 
outcomes. Quality can be theoretically viewed as either the cause or effect of these 
                                                             
7
 Unaggregated measures can be combined to yield a composite, using linear scoring, multiplicative 
scoring, or opportunity scores. In linear scoring, the composite is a linear combination of the individual 
items that could be equally or diffentially weighted. In multiplicative or all-or-none scoring the composite 
is a product of the individual items that are always equally weighted. There are two types of opportunity 
scores- indicator averages and patient averages. Indicator averages are created by dividing the number of 
eligible patients who receive recommended care for each measure by the number of eligible patients. 
Patient averages are the care opportunities that were met for each patient, providing a measure of 
average quality of care provided to a sample of patients. (Reeves et al 2007) 
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unaggregated measures8 [23].  In the former case, factor analysis can be employed to weight 
how important the unaggregated measures are to the unobserved quality of ambulatory 
diabetes care construct. In the latter case, unaggregated measures can be weighted using 
expert judgment - based on how important they are to the unobserved quality of care of 
ambulatory diabetes care construct [26], or empirically- based on how these measures 
predict subsequent observed outcomes associated with ambulatory diabetes care, such as. 
avoidable hospitalizations[27, 41].  
  In this paper we compare three approaches to weighting measures for measuring 
composite quality of ambulatory diabetes care: (i) factor-based weighting (ii) physician-
based weighting and (iii) outcomes-based weighting. The unaggregated measures chosen 
for the composite are four claims-computable diabetes process measures for fee-for-
services Medicare beneficiaries, viz. annual hemoglobin A1c (HbA1c) testing, annual low 
density lipoprotein cholesterol (LDLC) testing, annual dilated eye exams and annual testing 
for nephropathy.  These process measures have long been part of the diabetes HEDIS 
measure set for Medicare Advantage plans- where they are weighted equally in the diabetes 
quality composite [24]. These measures are also part of the diabetes measure set to be used 
for Medicare’s physician value-based modifier payments [6].  We compare the weights 
assigned to these four process measures from three different approaches to weighting to 
ask whether equally weighting of these measures is warranted or not. . 
                                                             
8
 Since quality is an abstract concept- it is viewed as a latent variable. Observed unaggregated measures 
could either be viewed as effects of an underlying quality construct (reflective measurement model) or 
causes of the quality construct (formative measurement model). The approach employed to weight 
measures depends on whether the relationship of the observed measures with the quality construct is 
viewed as reflective or formative.  
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METHODS 
     DATA AND STUDY SAMPLE 
This study employed data from the 2006 and 2007 Chronic Condition Data 
Warehouse (CCW) 5 percent Medicare sample. Specifically, we used personal summary, 
inpatient, outpatient, carrier claims files for a 5 percent random sample of Medicare 
beneficiaries. We also used Small Area income and education data sets from the Census 
Bureau and Area Resource File. 
Our study sample consisted of Medicare fee-for service beneficiaries with diabetes, 
who were alive at the end of 2007. Beneficiaries were continuously enrolled in Part A 
(coverage for hospital care) and Part B (coverage for physician care), with no months of 
managed care enrollment for both years. We identified beneficiaries with diabetes using the 
chronic condition flag for the disease [55]. We applied additional restrictions so that our 
sample met the HEDIS denominator definitions for quality: we excluded beneficiaries older 
than 75 years in 2006, those with HIV, active cancer treatment, organ transplant and end-
stage-renal disease (see Appendix 1 for exclusions) [44]. The final cohort consisted of 
194,345 beneficiaries. 
     PROCESS MEASURES FOR QUALITY OF AMBULATORY DIABETES CARE 
From the beneficiaries’ claims for 2006 we identified whether beneficiaries had 
received the following diabetes process measures during the year:(i) HbA1c test (ii) LDLC 
test (iii) dilated eye exam9 (iv) testing for nephropathy10. The definitions of these measures 
and the codes used to identify them from claims are summarized in Appendix 2. 
                                                             
9
 The HEDIS measure set counts any E&M visit to an Ophthalmologist or Optometrist as an eye exam. We 
use a more conservative definition of the process measure to include only dilated retinal exams. 
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   FACTOR WEIGHTED COMPOSITE 
While employing factor analysis, we assume that observed process measures for 
diabetes are effects of an underlying factor- the quality of ambulatory diabetes care. Any 
observed correlation between the processes measures at the beneficiary level can be 
explained by this factor. Our objective was to find the single underlying latent factor 
(quality) and identify how strongly process measures loaded on the factor11 .  
The sample of beneficiaries in 2006 was randomly split into two half-samples. We 
performed confirmatory factor analyses (CFA) with both half-samples with the four 
diabetes process measures in the measurement model. We compared the loadings of 
process measures on the factors from the two analyses, examined the goodness of fit 
                                                                                                                                                                                     
10
 The HEDIS measure set defines attention for nephropathy as documentation of nephropathy or testing 
for nephropathy. We define the process measure to include only testing for nephropathy. 
11
 The underlying variable approach assumes that the dichotomous process measures xi   are in fact 
continuous variables x*i, which actually measure the underlying latent factor f, but we can only ‘partially 
observe’ x*i  though  xi    
The dichotomous variable xi,     xi = 0 if    −∞ <x*i  ≤  τi; and  xi =1 if   τi  <  x*i   
Where, τi  is the threshold value. 
According to the linear factor model, x*i   is: 
x*i  = μ + Λf + ε 
where, f is the common factors, assumed to be random such that E(f) = 0 and Var(f) = I ; ε is a random 
error, such that  E(ε) = 0 and Var(ε) = Ψ; Λ is the matrix of factor loadings that describe how the variables 
are related to the factor; and μ a set of scalars commonly set to 0 for computational ease. 
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statistics and weighted each process measure by its factor loading scaling the total to 412. 
We used the average weight from the two factor analyses to get the final factor weight for 
each process measure. To examine whether the underlying factor was associated with 
ambulatory diabetes care or any ambulatory care we repeated these steps for an expanded 
measure set of eight ambulatory care process measures, related and unrelated to diabetes: 
(i-iv) the four diabetes process measures, (v) annual ambulatory care visit for diabetes, (vi) 
participation in a diabetes program (diabetes self-management education or  medical 
nutrition therapy), (vii) influenza vaccination, and (viii) screening for breast or prostate 
cancer.  The definitions of these measures and the codes used to identify them from claims 
are also summarized in Appendix 2. 
  PHYSICIAN WEIGHTED COMPOSITE 
The physician weighted composite is based on the opinion of an expert physician 
panel regarding the relative importance of diabetes process measures in determining 
unobserved quality of ambulatory diabetes care.  The assumption implicit here is that 
physicians can judge how strongly diabetes process measures ‘cause’ the ambulatory 
diabetes care quality construct.  We obtained relative weights for the diabetes processes 
from a physician expert panel13 that was convened to evaluate and rate quality measures 
                                                             
12
 The weight assigned to process measure m is,  W m=[L m /   ∑    
 
    x 4; where    is the factor 
loading of the measure on the underlying factor. 
 
13
 This expert panel was convened as part of a CMS project Alternative Measures of Physician Resource 
Use (HHSM-500-2005-000271 Task Order 0004).  
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that were useful for measuring quality of care provided in an ambulatory care setting. The 
panel had eight physicians in leadership roles in physician practices. These physicians were 
actively involved in state or national professional association activities in quality 
assessment and performance measurement.  First, members of the panel were introduced 
to the quality measures to be rated and explained the rating process that was to follow, over 
an in-person meeting. The raters were then interviewed to confirm that they clearly 
understood the rating exercise- and the rating process was then carried out.  
The physicians in the expert panel were asked to rate the usefulness of the four 
diabetes process measures in measuring ambulatory care quality, along with the usefulness 
of 180 other quality measures used in CMS’s Physician Quality Reporting System [3]. 
Physicians were asked to rate the measures using a scale of 0-100, where 100 represented 
the highest utility for measuring quality of ambulatory care and zero meant that a particular 
measure should not receive any consideration. We obtained the average physician rating for 
each diabetes process measure, and weighted each measure as follows: 
W m=[ Avgm /   ∑          x 4 
 Where Avgm was the average rating given to the measure (out of 100) by the 
physician panel. To measure inter-rater reliability, we calculated intra-class coefficient 
using two-way analysis of variance with random effects for raters [56]. 
 OUTCOMES WEIGHTED COMPOSITE 
The outcomes weighted composite for ambulatory diabetes care is based on the 
assumption that diabetes process measures ‘cause’ subsequent ambulatory diabetes care 
outcomes- and that this association can be measured empirically. The weights for process 
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measures are determined by how they empirically predict avoidable hospitalization 
outcomes in the subsequent year.  
   Choice of Outcomes and Regression Analysis 
We chose two outcomes in the subsequent beneficiary year that were closely tied to 
quality of ambulatory care for diabetes: 
 (i) Hospitalizations for ambulatory care sensitive conditions associated with 
diabetes (diabetes ACSCs): These were hospitalizations for complications of diabetes, 
uncontrolled diabetes, hypoglycemia, and hypertension [41]. 
 (b) Hospitalization for all ambulatory care sensitive conditions (ACSCs): These are a 
larger set of hospitalizations , defined by the Agency for Healthcare Research and Quality, 
that can be avoided by better ambulatory care  (all ACSCs) [41].  
We identified hospitalizations for diabetes ACSCs and all ACSCs in 2007 (see 
Appendix 3 for a list of conditions and diagnosis codes for hospitalizations). We modeled 
the association between diabetes process measure in the prior year and hospitalization in 
the subsequent year, using models discussed below. We ran separate analyses for each of 
the four process measures (as they are moderately correlated with one another at the 
beneficiary level) and the two hospitalization types. In the models, we controlled for 
beneficiary’s (i) demographic characteristics:. age (<60 years, 60-64 years, 66-69 years, 
and 70-75 years) , sex, race (White, Black, Hispanic, Asian and Other) , dual eligible status, 
rural-urban status, median zip code income and median zip code education (ii) diabetes 
severity in 2006: Type I diabetes, insulin pump use (from part B and DME claims),  self-
monitoring of blood glucose (from durable medical equipment claims)  and years of 
diabetes duration from CCW records (iii) comorbidity in 2006: using 70  hierarchical 
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condition categories (HCCs) computed  using the CMS HCC model on beneficiary’s claims for 
2006 [57] (iv) outcomes in 2006:  we also controlled for whether the beneficiary was 
hospitalized for micro/macro vascular hospitalizations or ACSC hospitalizations in 2006.  
Controlling for observed confounding using Propensity Score Inverse 
Probability Treatment Weighting: 
Estimating the effect of process measures on predicting outcomes in the subsequent 
year, required us to control for observed confounding, using propensity score inverse 
probably treatment weighting [58]. We first employed multivariate logistic regression to 
obtain the probability of each beneficiary receiving the process measure. For beneficiaries 
who received the process measure, the inverse probability treatment weighting assigns a 
weight of 1/p , and for those who did not receive the process weight assigned is 1/ (1-p). 
We then estimated the probability of having a hospitalization outcome in the subsequent 
year based on receipt of the process measure by the beneficiary, beneficiary covariates and 
the beneficiary’s inverse probability propensity score treatment weight, using multivariate 
logistic regression. We carried out separate analyses for each process measure and 
outcome.  
We attempted to control for both observed and unobserved confounding using 
instrumental variables. However we did not find suitable instruments that were associated 
with the process measures and not otherwise associated with the hospitalization outcomes.  
An instrument that we considered to be predictive of beneficiaries getting diabetes process 
measures was percentage of Medicare beneficiaries in the county enrolled in Medicare 
Advantage plans. However this instrument has been shown to be related to ASCSs at the 
area level [59].  
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All standard errors were robust in multivariate analyses. P values were 2-sided with 
a level of significance of ≤.05. All analyses were performed using SAS 9.2 [49] and STATA 
12[50]. 
We weighted each process measure based on the percentage decrease in the relative 
risk14 [51] of outcome in the subsequent year it was associated with, scaling the composite 
to 415. Finally we compared the rank order of weights of diabetes process measures across 
all three quality composites.   
RESULTS 
The characteristics of our study sample are summarized in Table 1. Our of sample of 
diabetics was predominantly type II diabetics (81 percent), white (79 percent), female (54 
percent), and non-rural (82 percent).Congestive heart failure, arthritis and coronary artery 
disease were the common comorbidities in over 20 percent of the population.   The rate of 
annual HbA1c testing, LDLC testing, dilated eye exams and nephropathy testing in our 
beneficiary sample were 79 percent, 78 percent, 45 percent and 44 percent respectively.   
The rates of self-monitoring of blood glucose, influenza vaccination and cancer screening in 
the population were high as the rates for eye exams and nephropathy testing. While 96 
                                                             
14
 Given the low incidence of both the outcomes of interest in the subsequent year (<10 percent), we 
assume that the odds ratio approximate relative risk (Zhang & Yu 1998). 
15
 The weight assigned to process measure m is , W m=[( 1-RRm )/   ∑        
 
    x 4, where RRm is the 
relative risk for the measure in lowering the probability of avoidable hospitalizations in the subsequent 
year. 
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percent of the beneficiaries had an annual ambulatory care visit, only 65 percent of them 
had an ambulatory care visit for diabetes. Finally the rate of hospitalizations for diabetes 
ACSCs and all ACSCs were approximately 1.8 percent and 9 percent, respectively, for both 
years.   
FACTOR BASED WEIGHTING OF PROCESS MEASURES 
 All four ambulatory diabetes care process measures loaded strongly on a single 
underlying factor.  The result of the factor score weighting, presented in Table 2, 
summarizes the results from CFA using both half-samples. The underlying quality of 
ambulatory diabetes care construct captured 60 percent of the variation in the diabetes 
process measures. The single factor model fit the data very well, as evinced by the high 
comparative fit index (0.9>) and very low standardized root mean square residual (~0). 
HbA1c testing and LDLC testing loaded more strongly on the underlying quality factor (with 
weights of 1.4 out of 4), while dilated eye exams had the lowest loading on the factor (with a 
weight of 0.5 out of 4). The expanded set of eight ambulatory care process measures 
(related to & unrelated to diabetes) also loaded on strongly a single underlying factor. The 
underlying ambulatory care quality construct captured 65 percent of variation in the eight 
process measures. Fit statistics showed that the single factor solution fit the data very well.  
HbA1c and LDLC testing loaded more strongly on the underlying factor than E&M visit for 
diabetes. However preventive measures like influenza vaccination and cancer screening 
loaded more strongly on the factor than eye exams or testing for nephropathy. 
PHYSICIAN BASED WEIGHTING OF PROCESS MEASURES 
       Physician weighting for the diabetes process measures is shown in Table 3. Scores for 
the four process measures were quite similar, ranging from 84 to 89 (on a scale of 0 to 100). 
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There was marginally higher variation in the scores for eye exams and nephropathy testing, 
compared to HbA1c and LDLC testing.  The intra class coefficient with rater random effects 
was 0.49, indicating moderate inter-rater reliability between physician raters, when the 
raters were assumed to be selected from a larger sample of physicians. The intra class 
coefficient with rater fixed effects was 0.67, indicating that the physicians in the panel were 
not likely to score measures in a similar manner. Physician raters in the Technical Expert 
Panel weighted all the process measures as equally important for the quality of ambulatory 
diabetes care, when the measures were reweighted to a scale of 4. 
OUTCOMES-BASED WEIGHTING OF PROCESS MEASURES 
Results from the outcomes based weighting of the process measures using 
propensity score inverse probability treatment weighting are summarized in Table 4.  
Among the process measures, LDLC testing in the prior year was significantly associated 
with lowering the relative risk16 [51]of diabetes ACSCs by 27 percent, followed by HBA1c 
testing (25 percent). Eye exams and testing for nephropathy were not associated with 
lowering the likelihood of diabetes ACSCs in the subsequent year. All four process 
measures were independently associated with a 52 percent reduction in relative risk of 
diabetes ACSCs. We assigned outcomes based weights, on the basis of how much each 
process measure contributed to lowering the risk of hospitalization. Accordingly, LDLC 
testing was given a weight of 2.1 [ (27 percent/52 percent)x4], HBA1c testing received 
weight of 1.9 [ (25 percent/52 percent)x4]. Eye exams and testing for nephropathy were 
assigned weights of zero as they were not associated with significantly lowering the risk of 
                                                             
16
 Given the low incidence of both the outcomes of interest in the subsequent year (<10 percent), we 
assume that the odds ratio approximate relative risk (Zhang & Yu, 1998) 
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diabetes ACSCs. The association of LDLC testing in lowering the risk of all ACSCs was lower 
than that for diabetes ACSCs- at 23 percent, followed by HBA1C testing (13 percent), eye 
exams (9 percent) and testing for nephropathy (4 percent). Accordingly the four measures 
received weights of 1.9, 1.1, 0.7 and 0.3 respectively out of 4. Among the four measures, 
LDLC testing and HbA1c testing had the highest association, while eye exams and testing 
for nephropathy had the lowest association with risk reduction for either hospitalization in 
the subsequent year.  
We compared the relative ranking of the four process measures weights from the 
alternative weighting approaches in Table 5. The physician panel weighted all diabetes 
process measures as equally important. Factor-based weighting gave the highest weights to 
HbA1c testing and LDLC testing, followed by nephropathy testing and eye exams. Empirical 
weighting of the  diabetes care process measures based on their association with 
hospitalizations for diabetes ACSCs and all ACSCs in the subsequent year, assigned LDLC 
testing the highest weight, followed by HbA1c testing; while nephropathy testing and eye 
exams received the lowest weights.   
DISCUSSION 
Our paper challenges the current practice of weighting all diabetes process 
measures as equally important for composite quality of ambulatory diabetes care. 
Weighting approaches employed by CMS/HEDIS (linear scoring) or Minnesota Community 
Measurement (multiplicative scoring) weight all diabetes process measures equally- even 
when some measures are based on consensus rather than evidence. Our physician expert-
panel - consisting of physician leaders in quality measurement- endorsed this dogma, 
weighting all diabetes process measures as equally important.  
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Results from factor-based weighting showed that while treating Medicare 
beneficiaries with diabetes, physicians performed HbA1c testing and LDLC testing more 
than testing for nephropathy or eye exams (which are not usually not performed by 
primary care practitioners treating diabetes) The former two diabetes process measures 
loaded more strongly than the latter two, on an underlying common factor assumed to be 
quality of ambulatory diabetes care. However using an a larger set of ambulatory care 
measures- that were either related or unrelated to diabetes care, we found that process 
measures unrelated to diabetes care also loaded on the same underlying factor. Hence the 
underlying factor that these diabetes process measures loaded on- was more likely to 
measure propensity for ambulatory care processes- rather than quality of ambulatory 
diabetes care. 
Management of hyperglycemia and hyperlipidemia – measured by HbA1c and LDLC 
testing, respectively, were associated with lowering the risk of hospitalizations for diabetes 
ACSCs and ACSCs in the subsequent year. Eye exams and testing for nephropathy were not 
associated with reducing the risk of avoidable hospitalizations related to diabetes, but had a 
low association in lowering the risk of ACSC hospitalizations. This effect is probably due to 
the two measures being correlated with the underlying propensity for ambulatory care 
processes construct. These two process measures were also not deemed as important as 
HbA1c or LDLC testing by physicians treating Medicare beneficiaries. Eye exams and testing 
for nephropathy are consensus based measures in the HEDIS diabetes measure set. These 
two process measures are measures of care related to diabetes progression 
(retinopathy/nephropathy) rather than measures associated temporally with better 
hospitalization outcomes.  
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It could be argued that lower outcome-based weight for eye exams could be 
expected, given that eye exams are carried out by ophthalmologists who do not provide 
usual ambulatory care associated with diabetes. Moreover, beneficiaries are not expected to 
be hospitalized for diabetic retinopathy or its complications.  The latter is a limitation of 
outcomes based weighting, in that the relative importance of the measure depends on the 
outcome chosen. However both factor-based weighting and outcomes-based weighting gave 
similar results for the relative weights of process measures. Measures that physicians 
providing ambulatory diabetes care gave more importance to were also more strongly 
associated with lowering the risk of diabetes ACSC and all ACSC hospitalizations in the 
subsequent year. The greater importance to management of hyperglycemia and 
hyperlipidemia in ambulatory diabetes care is keeping with evidence from large 
epidemiological studies like UK Prospective Diabetes Study and randomized control trials 
like Action to Control Cardiovascular Risk in Diabetes [ACCORD] [60].  
Outcomes-based and factor- based approaches to creating composites are premised 
on alternative views of the ambulatory care quality construct. While both approaches 
incidentally yield identical results in our study, they have different implications for how 
physicians and policy makers approach the culture of ambulatory care quality.  If 
ambulatory care process measures are viewed as effects of the underlying quality construct, 
then quality improvement efforts should be focused on the underlying quality culture in 
ambulatory care practice. Focusing quality improvement efforts at the level of processes 
measures, which in this case are merely manifests of the underlying ambulatory care quality 
construct, would not truly improve the quality of care[28]. If on the other hand, ambulatory 
care process measures are viewed to cause quality (unobserved as a latent construct or 
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observed as outcomes) , then quality improvement efforts should be focused on improving 
process measures  at the patient level. Improving measures, in this case, would result in 
quality improvement [28]. 
We acknowledge various limitations of this study. Our study used diabetes process 
measures that could be directly obtained from Medicare claims to create the quality of care 
composite. Intermediate outcome measures like HbA1c control or LDLC control, and other 
intermediate process measures like use of drugs such as statins, glycemic agents, aspirin 
etc., were not available on the Medicare claims that we used. The effect of process measures 
on outcomes could be mediated through intermediate outcomes. The effect of process 
measures on outcomes could also be mediated through the underlying ambulatory care 
construct that the measured loaded on. Our study controlled mainly for observed 
confounding. We attempted to control for unobserved confounding (arising from omission 
of intermediate measures) using  IVA in our sensitivity analyses- but the instrument at hand 
(number of Medicare advantage enrollees/1000 Medicare beneficiaries in the County) was 
suspect as it has been shown to be related to ACSC hospitalizations at the area level [59]. 
Finally, while the opinion of the physician expert panel was consistent with the views of 
quality measurement movements in the country, their judgment on the importance of 
diabetes process measures could very well be different from physicians who provide care to 
patients with diabetes. We however believe the strengths of this study outweigh these few 
limitations. 
CONCLUSION 
Irrespective of how the quality construct is viewed, this paper shows that current 
practices of treating all process measures as equally important for the quality of ambulatory 
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diabetes care is potentially specious. Even though physician leaders advocate equal 
importance of all process measures- practicing physicians treat certain measures as more 
important than others while providing care to Medicare beneficiaries with diabetes. Some 
process measures were also found to be more strongly associated than others with better 
patient outcomes in the subsequent year. While equal weighting of measures in a composite 
is simple and easy to implement- it is definitely not warranted unless all measures in the 
composite are truly equal.  With the increased adoption of more evidence and consensus 
based quality measures, it is vital to ascertain the importance of measures by examining 
their association with patient outcomes even prior to their adoption. But the current state 
of quality measurement for Medicare beneficiaries is limited by the beneficiary level 
outcomes that are readily available. Further investment in outcomes research is needed to 
improve the practice of quality measurement- which risks being naïve in its current state. 
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Table 4.1: Study Sample Description 
 
    
Number of Beneficiaries: 194,345   
Variable 
Mean (SD) or 
Percent   
Diabetes Measures and Utilization 
 
  
HbA1c Measurement 79.04%   
LDL Cholesterol Measurement 77.90%   
Retinal Eye Exams 45.30%   
Testing for Nephropathy  44.18%  
Demographic Characteristics 
 
  
  
 
  
Age < 60 years 18.2%   
Age 60-64  Years 8.0%   
Age 65-69 years 34.1%   
Age 70-75 Years 39.7%   
Female 54.50%   
White 79.0%   
Black 14.9%   
Other 6.1%   
Rural 18.26%   
Dual Eligible 27.44%   
Median Zip Code Income (In $10,000) 4.12(1.51)   
Median Zip Code Education (In Years) 13.22(1.10)   
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Number of Beneficiaries: 194,345   
Variable 
Mean (SD) or 
Percent   
 
 
Diabetes 
Diabetes Type 1 18.56%   
Insulin Pump 4.9%  
Self- Monitoring of Blood Glucose 46.15%  
Diabetes Duration in  Years 3.9 (2.4)   
Comorbidities 
 
  
Atrial Fibrillation 6.34%   
Dementia 5.43%   
Coronary Artery Disease 20.92%   
Chronic Kidney Disease 15.08%   
Chronic Obstructive Pulmonary Disorder 12.63%   
Congestive Heart Failure 22.06%   
Glaucoma 10.80%   
Depression 15.08%   
Osteoporosis 8.38%   
Arthritis 22.11%   
Stroke 4.74%   
Diabetes Utilization 
 
  
Diabetes Program (MNT or DSME) 4.58%   
Influenza Vaccination 48.14%   
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Number of Beneficiaries: 194,345   
Variable 
Mean (SD) or 
Percent   
Cancer Screening (Mammogram for Women/PSA for Men) 45.15%   
Evaluation and Management  Visit  96.56%   
Number of E&M Visits 10.38(8.2)   
Evaluation and Management Visit for Diabetes 65.49%   
Number of E&M Visits for Diabetes 2.04 (2.49)  
 
 
Outcome in Subsequent Year   
Diabetes ACSCs 1.8%  
All ACSCs  9.2%  
Hospitalizations in Prior Year 
 
  
Diabetes ACSCs 1.9%   
All ACSCs 9.4%   
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Table 4.2: Results of Confirmatory Factor Analysis and Scaled Factor Score Weights for 
Ambulatory Diabetes Care Processes and All Ambulatory Care Processes 
  CFA (Half-Sample-1) N= 97,000 CFA (Half-Sample-2) N= 97,000 
 
Factor Loading 
(SE) 
WEIGHT 
(Out of 4) Factor Loading (SE) 
WEIGHT 
(Out of 4) 
Model 1: Ambulatory 
Diabetes Care Processes* 
HbA1C Testing 1.00(Restricted) 1.4 1.00(Restricted) 1.4 
LDL Cholesterol Testing 1.03(0.01) 1.4 1.03(0.01) 1.4 
Dilated Eye Exam 0.33 (0.01) 0.5 0.33 (0.01) 0.5 
Testing for Nephropathy 0.54(0.01) 0.7 0.53(0.01) 0.7 
Model 2: All Ambulatory 
Care Processes** 
HbA1C Testing 
1.00(Constrained
) 1.8 1.00(Constrained) 1.8 
LDL Cholesterol Testing 0.88(0.01) 1.5 0.87(0.01) 1.5 
Eye Exam 0.40 (0.01) 0.7 0.40 (0.01) 0.7 
Testing for Nephropathy 0.50 (0.01) 0.9 0.51 (0.01) 0.9 
 Evaluation and Management 
Visit for Diabetes 
Screening for Cancer 
Influenza Vaccination 
Diabetes Program (Nutrition 
Therapy or Self-Management 
Education) 
 
0.71 (0.01) 
0.55 (0.01) 
0.40 (0.01) 
0.09 (0.002) 
 
 
1.3 
1.0 
0.7 
0.1 
 
 
0.72 (0.01) 
0.55 (0.01) 
0.40 (0.01) 
0.10 (0.002) 
 
 
1.3 
1.0 
0.7 
0.1 
 
 
* Model goodness of fit: Root mean squared error of approximation: 0.026; Comparative fit index: 0.95; 
Coefficient of determination: 0.60 
** Model goodness of fit: Root mean squared error of approximation: 0.064; Comparative fit index: 0.85; 
Coefficient of determination: 0.65. 
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Table 4.3: Results of Physician Technical Expert Panel and Physician Weights for Quality 
of Ambulatory Diabetes Care 
 
 
Average Score out of 100 
(S.D) 
 
Inter Rater Reliability 
N=8 
Measures=4 
Physician 
Weight (Out 
of 4) 
 
HbA1C Testing 89 (6.9) 
Mean Square Rater :  323.98 
Mean Square Measure: 181.20 
Mean Square Error:  89.88 
 
Shrout-Fleiss Intra Class 
Correlation Coefficient (With 
Rater Random Effects) : 0.49 
 
Shrout-Fleiss Intra Class 
Correlation Coefficient (With 
Rater Fixed Effects): 0.68 
1.0 
LDL Cholesterol 
Testing 87 (7.8) 1.0 
Dilated Eye Exam   84 (8.2) 1.0 
Testing for 
Nephropathy 86 (7.8) 1.0 
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Table 4.4: Results of Outcomes Based Weighting using Multivariate Logistic Regression 
with Propensity Score Inverse Probability Treatment Weighting 
 
 
Hospitalization for Diabetes 
Ambulatory Care Sensitive Conditions 
in 2007 
 
Hospitalization for All Ambulatory Care 
Sensitive Conditions in 2007 
Multivariate Logistic Regression with Propensity Score Inverse Probability Treatment Weighting 
Diabetes 
Process 
Measure in 
2006 
Relative Risk (95% 
CI) 
Outcomes 
Based Weight 
(Out of 4) 
Relative Risk (95% 
CI) 
Outcomes Based 
Weight (Out of 4) 
HbA1C 
Testing 0.75 (0.63-0.89) ** 1.9 0.87 (0.84-0.90) ** 1.1 
LDLC Testing 0.72 (0.62-0.82) ** 2.1 0.77 (0.75-0.79) ** 1.9 
Eye Exam 0.91 (0.76-1.1)  0 0.91 (0.88-0.93) ** 0.7 
Nephropath
y Testing 0.93 (0.83-1.0)  0 0.96 (0.94-0.98) ** 0.3 
      ** Significant at p<0. 05. Notes: Multivariate model adjusted for beneficiary characteristics viz. age, 
sex, race, dual eligible status, rural-urban status, median zip code income, median zip code education, 
Type I diabetes, diabetes duration in years), comorbidities using 70 hierarchical condition categories 
(HCCs) computed using the CMS HCC model on beneficiary’s claims for 2006, self-monitoring of blood 
glucose, and hospitalizations for diabetes ACSC or All ACSC hospitalizations in 2006.  
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Table 4.5: Relative Ranking of Measures by Importance using Different Approaches to 
Weighting 
 
Diabetes 
Process 
Measure in 
2006 
Current 
Approaches
+
 
to Weighting 
Physician Based 
Weighting 
Factor Based 
Weighting 
Outcomes  Based Weighting 
Propensity Score IPTW* 
Diabetes ACSC 
Hospitalization 
 
All ACSC 
Hospitalization 
HbA1C 
Testing 1 1 1 2 2 
LDLC Testing 1 1 1 1 1 
Eye Exam 1 1 4 4 3 
Nephropathy 
Testing 1 1 3 4 4 
+ 
Current Approaches to weighting include HEDIS or Minnesota Community Measurement 
Notes: IPTW: Inverse Probability Treatment Weighting, Diabetes ACSC Hospitalization: Hospitalizations for 
ambulatory care sensitive conditions associated with diabetes; All ACSC hospitalization: Hospitalization for 
all ambulatory care sensitive conditions. 
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CHAPTER 5: “IS QUALITY REPORTING ASSOCIATED WITH 
MORE CONSCIENTIOUS AMBULATORY CARE?”  THE CASE OF 
MEDICARE’S PHYSICIAN QUALITY REPORTING SYSTEM FOR 
DIABETES  
 
 
Objective: To examine if reporting for diabetes measures in Medicare’s Physician Quality 
Reporting System (PQRS) was related to more conscientious ambulatory care, we studied 
whether PQRS reporting for diabetes care measures was associated with better 
pharmacotherapy processes and ambulatory care sensitive hospitalization outcomes, among 
three groups of Medicare diabetics with varying intensity of PQRS reporting. 
Data and Methods: A retrospective cohort design followed 4,720 diabetics with PQRS 
reporting for intermediate outcomes, 7,063 diabetics with PQRS reporting for process 
measures and 83,416 diabetics with no PQRS reporting from the first quarter 2009 until the 
end of the year. We employed ordered logistic regression to examine the association between 
type of reporting and number of diabetes care processes. We studied the association between 
type of reporting and subsequent use of angiotensin converting enzyme (ACE) / angiotensin 
receptor blocker (ARB) therapy, statin therapy and anti-platelet therapy by appropriate 
denominator diabetics employing multivariate logistic regression. We studied the association 
between reporting and avoidable hospitalizations & time to hospitalizations for ambulatory 
care sensitive conditions (ACSCs) related to diabetes and all ACSCs using multivariate logistic 
and cox regressions. We controlled for diabetes care processes to investigate whether the 
effect of reporting on subsequent processes/outcomes was mediated through diabetes care 
processes or through more attention to ambulatory care. 
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Results: Diabetics receiving PQRS reporting were much more likely to receive all 
recommended diabetes care processes than diabetics not receiving reporting (63 percent vs. 
43 percent). Reporting was associated with greater likelihood of ACE/ARB and statin therapy. 
Reporting was associated with lesser risk and rate of diabetes ACSCs and all ACSCs. However 
after controlling for number of diabetes care processes, there was no effect of reporting on 
either pharmacotherapy or hospitalization outcomes. 
Conclusion: Reporting was associated with a higher rate of receipt of recommended diabetes 
care processes. PQRS reporting was associated with better pharmacotherapy and fewer 
hospitalizations outcomes through these diabetes care processes, and not via more 
conscientious ambulatory care.  
 
BACKGROUND 
The Centers for Medicare and Medicaid Services (CMS) have expanded their 
provider quality reporting initiatives beyond hospitals, skilled nursing facilities and home 
health agencies, to physicians.  Medicare’s Physician Quality Reporting System (PQRS) 
moved the measurement of quality of care delivered by physicians to Medicare patients 
beyond a limited set of claims computable process measures, to a larger set of clinically rich 
process and intermediate outcome measures[61].Established under the Tax Relief and 
Health Care Act (2006)17, PQRS offered bonus payments to physicians who reported to CMS 
selected quality measures18 for their Medicare patients from 2007. The Patient Protection 
                                                             
17
 The Tax Relief and Health care Act established the Physician Quality Reporting Initiative, which 
rechristened as  PQRS from 2010 
18
 To be eligible for incentive payments, physicians must report to CMS at least three PQRS quality 
measures for at least eighty percent of their patients who are eligible for each measure 
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and Affordable Care Act (2010) not only extended bonus payments for reporting quality 
measures until 2014, but also introduced payment penalties from 2015 for physicians 
failing to satisfactorily report patient quality data on Medicare claims [3]. The ultimate goal 
of PQRS is to implement a value-based payment system that ties a proportion of physicians’ 
future payment to higher quality and lower resource use. Encouraging reporting by 
physicians was the first step in this direction. 
By requiring physicians to report at least 3 measures in a condition measure set (e.g. 
diabetes or heart failure) for at least 80 percent of eligible beneficiaries, PQRS reporting is 
expected to improve the receipt of recommended process measures by Medicare patients - 
who have been shown to often not receive recommended care.  The effect of reporting on 
ambulatory care outcomes remains to be established. Studies on hospital quality reporting 
have shown minimal or no impact of reporting on outcomes [62]. One could expect 
physician quality reporting to be different. In the case of diabetes, patients receiving 
recommended care processes viz. Hemoglobin A1c (HbA1c) testing, low density lipoprotein 
cholesterol (LDLC) testing, and blood pressure measurement, get it due to more 
conscientious ambulatory diabetes care. More conscientious ambulatory care could produce 
better hospitalization outcomes for diabetes, although many diabetic hospitalizations are 
the result of years of diabetes [4]. Moreover, if this conscientiousness extended to all 
primary care provided, it could result in fewer ACSCs.  This conceptual relationship is 
shown in Figure 1.  
In this model conscientious care (the attention to care associated with delivering 
effective primary care) is a variable that we cannot assess directly.  Conscientious 
ambulatory care consists of a set of clinical actions, observed and unobserved, provided 
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over time in an ambulatory care setting for effectively managing the patient’s chronic 
conditions[11].  It may operate at two levels: 1] diabetes specific care and 2] more general 
primary care. The first would affect diabetes outcomes and the second ACSCs in general. 
Receipt of recommended diabetes care processes, guideline recommended 
pharmacotherapy and avoidable hospitalizations for diabetes, are all linked to 
conscientious ambulatory diabetes care. Processes like guideline recommended 
pharmacotherapy and outcomes like avoidable hospitalizations for diabetes are also linked 
to receipt of diabetes care processes, albeit through different mechanisms. Hence, if 
diabetics receiving PQRS reporting are more likely to get recommended diabetes care 
processes, they would also more be likely to receive guideline recommended 
pharmacotherapy and have fewer hospitalizations for diabetes, through diabetes care 
processes. We could also expect PQRS reporting and conscientious ambulatory care to be 
associated with each other. The causal association could be in both directions. Commitment 
to providing better ambulatory care might motivate physician participation in PQRS 
reporting. Reporting outcomes for ambulatory care processes might also motivate 
physicians to pay more attention to other clinical actions in this setting.   If PQRS reporting 
remains associated with guideline recommended pharmacotherapy or hospitalization 
outcomes for diabetes even after controlling for care processes, then it is through its 
association with conscientious ambulatory care. If PQRS reporting and conscientious 
ambulatory care are not related, then there would be no association between reporting and 
guideline recommended pharmacotherapy/avoidable hospitalizations after controlling for 
recommended diabetes care processes.    
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Figure 1: Conceptual Relationship between PQRS Reporting, Conscientious 
Ambulatory Care, Recommended Diabetes Care Processes and Avoidable 
Hospitalization Outcomes & Guideline Recommended Pharmacotherapy Processes 
 
 
 
 
 
 
 
 
 
This paper examines whether PQRS reporting for diabetes is associated with (1) 
greater receipt of recommended diabetes care processes (2) higher likelihood of guideline 
recommended pharmacotherapy and (3) lower likelihood of avoidable hospitalizations. 
Thereafter, we investigate whether PQRS reporting is related to conscientious ambulatory 
care by studying the association of reporting with guideline recommended 
pharmacotherapy and avoidable hospitalizations, after controlling for diabetes care 
processes. We use a retrospective cohort study design and identify three groups of 
Medicare diabetics in 2009 who differ in their level of receiving PQRS reporting: (1) those 
who had intermediate outcomes reported for a core set of PQRS diabetes measures- HbA1c 
testing and/or LDLC testing and/or BP measurement (2) those who those who had diabetes 
PQRS measures reported for other processes- dilated eye exams and/or attention for 
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nephropathy (3) those who did not receive any PQRS reporting but received recommended 
diabetes care processes that identifiable  from administrative data. We first examine the 
probability of getting recommended diabetes process measures across three groups of 
diabetics. We then compare the likelihood of receipt of subsequent guideline recommended 
pharmacotherapy and likelihood of subsequent avoidable hospitalizations across these 
three patient groups. We finally investigate whether the association between reporting and 
these two sets of dependent variables is through receipt of diabetes process measures alone 
or also through more conscientious ambulatory care.   Variation in level of reporting as well 
as diabetes care processes across these three groups of Medicare diabetics allows us to 
study whether reporting is merely associated with receipt of more diabetes care processes 
or also with conscientious ambulatory care. 
We study the association between reporting for care processes and three 
subsequent guideline recommended pharmacotherapy measures. The American Diabetes 
Association recommends that diabetics with hypertension receive angiotensin converting 
enzyme (ACE) inhibitor or Angiotensin receptor blocker (ARB) therapy[11]. Clinical 
guidelines recommend statin therapy for diabetics over the age of 40 years and anti-platelet 
agents for diabetics with coronary artery disease (CAD)[11]. Prescription of anti-platelet 
therapy for diabetics with CAD is part of existing diabetes quality measure sets for health 
plans and accountable care organizations [5]. We expect that after controlling for case-mix 
and number of diabetes care process measures, the group of diabetics (who vary by level of 
reporting) who receive more conscientious ambulatory diabetes care would be more likely 
to  get guideline recommended pharmacotherapy. We also study the association between 
reporting for diabetes care processes and two subsequent avoidable hospitalization 
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measures- hospitalizations for ambulatory care sensitive conditions associated with 
diabetes (diabetes ACSCs) and hospitalizations for all ambulatory care sensitive conditions 
(ACSCs)[45, 46, 63]. We expect that after controlling for case-mix and number of diabetes 
care process measures, the group of diabetics (who vary by level of reporting) receiving 
more conscientious ambulatory diabetes care would have fewer hospitalizations for ACSCs 
and diabetes ACSCs.   
METHODS 
DATA 
 We obtained Medicare claims for 199,999 beneficiaries who were seen by a 
nationally representative sample of 3,400 PQRS reporting or non-reporting physicians19 in 
2009.  Beneficiaries were continuously enrolled in Medicare Parts A (coverage for hospital 
services), B (coverage for physician services), and D (coverage for prescription drugs). We 
obtained the 2009 beneficiary summary, MedPAR, Carrier, Outpatient, and Part D claims 
files for these beneficiaries.  
 
STUDY SAMPLE 
                                                             
19The physicians were identified by their tax identification numbers (TINs). PQRS reporting and non-
reporting TINs were matched by zip-code, specialty and beneficiary case-load. The beneficiaries had 
claims during 2009 with these TINs as well as other TINs (who could be PQRS reporting or non-
reporting) 
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 We identified beneficiaries with diabetes aged 18-75 years, who had an ambulatory 
care evaluation and management visit (E&M visit) within the first quarter of 2009 and were 
alive at the end of the year. The Chronic Condition data Warehouse (CCW) disease flag for 
diabetes was used to identify beneficiaries with the diabetes [48]. We excluded 
beneficiaries with HIV, organ transplants, active cancer treatment and end-stage-renal 
disease (Appendix 1) [44] . Our final study sample had a total of 95,199 beneficiaries 
classified into three groups based on the level of diabetes reporting that they received 
within the first quarter of 2009 (1) 4,720 beneficiaries with diabetes PQRS reporting for 
intermediate outcomes for three measures (HbA1c testing, LDL-C testing and blood 
pressure testing) within the first quarter of 2009 (PQRS intermediate outcomes group), (2) 
7,063 beneficiaries with diabetes PQRS reporting for process measures for two 
measures (testing for nephropathy and dilated eye exams) and (3) 83,416 beneficiaries 
with no diabetes PQRS reporting. Limiting our sample to beneficiaries who had E&M 
visits in the first quarter, allowed for equal follow-up time over the remainder of 2009 for 
the three beneficiary groups. We limited beneficiaries in the non-PQRS group to those who 
did not receive any PQRS measures during the year, for both diabetes and all other 
conditions. The procedure codes used to identify the diabetes intermediate outcome and 
process measures from Part B carrier claims are listed in Appendix 2 & Appendix 18. Since 
there are no procedure codes for blood pressure measurement, we used E&M visits for 
diabetes as a proxy for blood pressure measurement, as blood pressure measurement and 
treatment is an integral part of these visits. We flagged the date when PQRS and non-PQRS 
beneficiaries last received diabetes process measures within the first quarter of 2009- as 
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the treatment date. For beneficiaries who did not receive any diabetes process measure in 
the first quarter of 2009, the last date of the first quarter was flagged as the treatment date.  
DEPENDENT VARIABLES 
We examined the association between PQRS reporting and three sets of dependent 
variables (i) number of recommended diabetes care processes during the first quarter (ii) 
subsequent receipt of guideline recommended pharmacotherapy and (ii) subsequent 
avoidable hospitalizations. 
(i) Recommended diabetes care processes: We identified whether 
beneficiaries in the three groups had received the following diabetes process 
measures in the first quarter of 2009: (i) HbA1c testing, (ii) LDL-C testing 
(iii) blood pressure measurement (iv) testing for nephropathy (v) eye 
exams. The procedure codes used to identify the diabetes intermediate 
outcome and process measures from Part B carrier claims are listed in 
Appendix 2. Since there are no procedure codes for blood pressure 
measurement, we used non-hospital evaluation and management visits for 
diabetes as a proxy for blood pressure measurement. We classified 
recommended diabetes care processes into two sets (i) core diabetes 
process measures: HbA1c testing, LDLC testing, and blood pressure 
measurement (ii) all diabetes process measures: HbA1c testing, LDLC 
testing, blood pressure measurement, testing for nephropathy and eye 
exams. 
(ii) Guideline Recommended Pharmacotherapy:  We defined use of 
guideline recommended pharmacotherapy after receipt of diabetes 
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measures as utilization of (a) ACE/ARB by diabetics with hypertension, (b) 
statins by diabetics over 40 years of age, and (c) anti-platelet drugs by 
diabetics with CAD. Beneficiaries with hypertension were identified from 
claims using CCW definitions. Diabetics with CAD were identified from the 
CCW condition flags for acute myocardial infarction and ischemic heart 
disease. Medicare Part D claims were used to identify utilization of ACE/ARB 
therapy, statin therapy, and anti-platelet therapy by beneficiaries on or after 
the date they received the three diabetes measures. The national drug codes 
for the three drug therapies are listed in Appendix 19. Utilization of drug 
therapy by beneficiaries was coded as a dichotomous variable. 
(iii) Avoidable hospitalizations: We identified two sets of avoidable 
hospitalizations for beneficiaries from the primary diagnosis code on the 
hospitalization claims : (a) Hospitalization for Ambulatory Care Sensitive 
Conditions associated with Diabetes (Diabetes ACSCs): These were 
hospitalizations for  complications of diabetes, uncontrolled diabetes, 
hypoglycemia, and hypertension [41] (b) Hospitalization for all Ambulatory 
Care Sensitive conditions (all ACSCs): These are a larger set of 
hospitalizations , defined by the Agency for Healthcare Research and Quality, 
that can be avoided by better ambulatory care[41, 45, 46, 63].  If 
beneficiaries receiving diabetes PQRS reporting received better overall 
ambulatory care then they might be expected to have fewer ACSCs 
compared to beneficiaries receiving process measure alone. The diagnoses 
codes and exclusions for these two hospitalization outcomes are listed in 
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Appendix 3. We coded both hospitalization outcomes as dichotomous 
variables and also calculated time to either hospitalization from the date 
beneficiary received diabetes measures. 
STATISTICAL ANALYSES: 
We compared beneficiary demographic and clinical characteristics for the three 
groups of beneficiaries at baseline (i.e. until treatment date) using chi-square and two 
sample t-tests. We studied the association between type of PQRS reporting and two sets of 
recommended diabetes care processes, viz. core diabetes care processes and all diabetes 
care processes, using ordered multivariate logistic regression. We studied the association 
between type of reporting and subsequent use of guideline recommended 
pharmacotherapy employing multivariate logistic regressions. We also used multivariate 
logistic regressions to evaluate the association between type of reporting and subsequent 
ACSC and diabetes ACSC hospitalizations. Since the rate of hospitalization over time can 
differ from risk of hospitalization, we examined the association between reporting and 
subsequent hazard of diabetes ACSC and all ACSC hospitalizations using Cox proportional 
hazards models.  Time to event was modeled as beneficiary-month and beneficiaries were 
censored at the end of the year.   
In all multivariate analyses, we controlled for the following beneficiary covariates:          
(i) demographic characteristics: Age, sex, race (White, Black, Hispanic, Other) , dual 
eligible status, rural-urban status, median zip code income and median zip code education 
(ii) diabetes severity at baseline: Type I diabetes , diabetes duration in months as 
measured from CCW records, insulin use and oral-anti diabetic agent use (iii) 
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comorbidities at baseline : 70  hierarchical condition categories (HCCs) computed  using 
the CMS HCC model on beneficiary’s claims at baseline[57]. 
We ran three sets of models while examining the association between reporting and 
subsequent guideline recommended pharmacotherapy/ avoidable hospitalizations. We 
incrementally controlled for diabetes care processes in these models to study whether the 
effect of reporting on subsequent pharmacotherapy processes/ hospitalization outcomes 
was mediated through diabetes care processes or provision of more conscientious 
ambulatory care:  
Model 1: controlling for demographics characteristics, diabetes severity and comorbidities   
Model 2: controlling for covariates in Model 1 & core diabetes processes- HbA1c testing, 
LDLC testing, and BP measurement  
Model 3: controlling for covariates in model 2 and other diabetes processes- testing for 
nephropathy and eye exams. 
All standard errors were robust in multivariate analyses. P values were 2-sided with 
a level of significance of ≤.05. We used SAS version 9.1[49] and STATA 12 [50] for all 
analyses.  
RESULTS 
The characteristics of diabetics receiving PQRS reporting for intermediate 
outcomes, PQRS reporting for processes, and no diabetes PQRS reporting at baseline are 
summarized in Table 1. The three groups of beneficiaries were similar in their age, gender 
distribution, urbanity, area income, and area education. PQRS diabetics were more likely to 
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be white compared to non-PQRS diabetics. Among PQRS diabetics, those receiving reporting 
for diabetes intermediate outcomes were more likely to be white. PQRS diabetics were 
more likely to have Type 1 diabetes, diabetes of longer duration, and use insulin or oral anti 
diabetic agents compared to non-PQRS diabetics. Among PQRS diabetics, those receiving 
reporting for process measures were more likely to have Type 1 diabetes and diabetes of 
longer duration compared to those receiving reporting for intermediate outcomes.  While 
the distribution of comorbidities was mixed across the PQRS and non-PQRS diabetics, the 
HCC case mix score at baseline for the two groups were similar. The distribution of 
comorbidities and the case mix scores for the two groups of PQRS diabetics was also similar.   
Table 2 summarizes the rate of receipt of recommended diabetes care processes 
among PQRS and non-PQRS diabetics. 63 percent of PQRS diabetics received all three core 
diabetes care processes (HbA1c/LDLC/BP measurement) while only 43 percent of the non-
PQRS beneficiaries received this processes. Among PQRS diabetics, 74 percent of diabetics 
receiving reporting for the intermediate outcomes associated with core diabetes processes 
received all three care processes, while 56 percent of diabetics receiving reporting for 
either nephropathy/eye exams received all three core care processes. PQRS diabetics had 
higher rates of nephropathy testing and eye exams compared to non-PQRS diabetics. Among 
PQRS diabetics, those receiving reporting for intermediate outcomes had higher rates of 
nephropathy testing, while the latter group was more likely to receive eye exams.  
Results from the multivariate ordered logistic regression predicting the likelihoods 
of receiving an additional core diabetes care process (HbA1c/LDLC/BP measurement) and 
any additional diabetes care process (HbA1c/LDLC/BP measurement/Eye Exam/Testing 
for Nephropathy) across PQRS and non-PQRS diabetics summarized in Table 2.  Odds of 
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receiving an additional core diabetes process was 2.2 times higher for PQRS diabetics [95% 
confidence interval (CI) for odds ratio (OR): 2.1-2.3], 4.2 times higher for PQRS diabetics 
receiving reporting for intermediate outcomes [95% CI for OR: 3.9-4.5], and 1.5 times 
higher for those receiving reporting for processes [95% CI for OR: 1.4-1.6], compared to 
non-PQRS diabetics. The odds of receiving any additional diabetes care process was 2.8 
times higher for PQRS diabetics [95% CI for OR: 2.1-2.3], 2.9 times higher for PQRS 
diabetics receiving reporting for intermediate outcomes [95% CI for OR: 2.8-3.0], and 2.7 
times higher for those receiving reporting for processes [95% CI for OR: 2.6-2.7], compared 
to non-PQRS diabetics.   
Results from multivariate logistic regressions predicting the likelihood of receiving 
guideline recommended pharmacotherapy across PQRS and non-PQRS diabetic groups is 
summarized in Table 3. Controlling for demographic characteristics, severity of diabetes 
and comorbidities, denominator diabetics receiving PQRS reporting for intermediate 
outcomes and reporting for processes had a significantly higher likelihood of receiving 
ACE/ARB therapy [Adjusted OR: 1.38 & 1.33 respectively] and statin therapy [Adj. OR: 1.42 
& 1.5 respectively], compared to diabetics receiving only process measures. However after 
controlling for three core diabetes care processes, there was no difference in the likelihood 
of getting ACE/ARB therapy or statin therapy between denominator diabetics receiving 
PQRS reporting for intermediate outcomes and non-PQRS diabetics; while, diabetics 
receiving PQRS reporting for other processes had a significantly higher likelihood of 
ACE/ARB [Adj. OR: 1.21] and statin therapy [Adj. OR: 1.12] compared to non-PQRS 
diabetics. Even after controlling for the all  process measures, denominator diabetics 
receiving PQRS reporting for other process measures had a had a significantly higher 
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likelihood of ACE/ARB [Adj. OR: 1.19] and statin therapy [Adj. OR: 1.08] compared to non-
PQRS diabetics.   
There was no difference in the likelihood of anti-platelet therapy across 
denominator diabetics in the three groups after controlling for demographic characteristics, 
severity of diabetes and comorbidities. However after controlling for number of processes, 
denominator diabetics receiving only process measures had significantly higher likelihood 
of receiving anti-platelet therapy compared to those receiving PQRS reporting for 
intermediate outcomes [Adj. OR: 1.19 after controlling for all diabetes processes]. 
Results from multivariate logistic regressions predicting the likelihood of avoidable 
hospitalizations, and cox regressions predicting the hazard of avoidable hospitalizations 
across PQRS and non-PQRS diabetic groups is summarized in Table 4. For each outcome we 
ran three sets of models. In the first model, we examine the effect of each level of PQRS 
reporting on outcome by controlling only for beneficiary characteristics that affect type of 
reporting and outcomes. In the second model, we control for variables in the first model as 
well as three core diabetes processes performed by practitioners who primarily provide 
diabetes care (PCPs), viz. HbA1c, LDL-C and BP measurement. Controlling for these 
processes allows us to see whether reporting for measures likely to be performed by PCPs 
has an independent relationship with the outcomes.  In the third model, we control for 
variables in the second model as well as other diabetes processes, viz. eye exams and testing 
for nephropathy likely to be performed by practitioners other than PCPs, to see if reporting 
by practitioners other than PCPs and core processes by PCPs are related to better 
ambulatory care. Comparing the three models allows us to estimate whether type of 
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reporting remains associated with outcomes through its relationship with conscientious 
ambulatory care, or whether the association of reporting on outcomes is through diabetes 
processes alone.  If the latter, we would not observe reporting to be associated with 
outcomes after controlling for diabetes processes in the second and third models. 
There was no difference in either the likelihood or hazard of diabetes ACSC 
hospitalizations between diabetics receiving PQRS reporting for intermediate outcomes and 
non-PQRS diabetics who received diabetes process alone.  Diabetics receiving PQRS 
reporting for processes had  34% lower risk[51] of hospitalizations for diabetes ACSCs 
[95% CI for relative risk (RR): 0.54-0.80] and significantly lower time to diabetes ACSC 
hospitalization [hazard ratio (HR): 0.67) compared to non-PQRS beneficiaries, Even after 
controlling for all diabetes care processes, diabetics receiving PQRS reporting for processes 
had  significantly lower risk of diabetes ACSCs [RR(95% CI): 0.72 (0.59-0.89)] and 
significantly lower time to diabetes ACSCs [HR (95% CI): 0.74 (0.61-0.90)] compared to 
non-PQRS beneficiaries.  
Diabetics receiving PQRS reporting for intermediate outcomes had 13% lower risk 
[51]of hospitalizations for all ACSCS [95% CI for RR:  0.70-0.95] compared non-PQRS 
diabetics. This difference became smaller (12% lower risk) but remained significant [95% 
CI for RR: 0.81-0.96] even after controlling for all process measures. But the hazard of ACSC 
hospitalizations was no different among these PQRS diabetics and non-PQRS diabetics. 
Diabetics receiving PQRS reporting for processes had 21% lower risk of hospitalizations for 
all ACSCS [95% CI for RR: 0.73-0.85] and significantly lower time to all ACSCs [HR (95% CI): 
0.80 (0.74-0.87)] compared to non-PQRS beneficiaries. However after controlling for all 
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processes, there was no difference in either the likelihood or hazard of ACSC 
hospitalizations between diabetics receiving PQRS reporting for processes and those 
receiving process measures alone. 
DISCUSSION 
Medicare beneficiaries, who received reporting for quality measures through 
Medicare’s Physician Quality Reporting System, received guideline recommended care 
processes at a rate much greater than that observed for non-reporters.  Diabetics receiving 
PQRS reporting were more likely to receive all recommended core diabetes care processes, 
viz. HbA1c testing, LDL-C testing and BP measurement, than diabetics not receiving 
reporting (63 percent vs. 43 percent). Diabetics receiving reporting for intermediate 
outcomes associated with these processes (74 percent) as well as those receiving reporting 
for other processes. (56 percent) had higher rates care processes than non-PQRS diabetics. 
Diabetics receiving PQRS reporting had higher likelihood of receiving ACE/ARB and 
statin therapy compared to non-PQRS diabetics. However after controlling for diabetes care 
processes, PQRS reporting was not associated with better ACE/ARB or statin therapy in 
those receiving reporting for intermediate outcomes; but was in fact found to be associated 
with poorer rates of statin therapy compared to non-PQRS diabetics.   Hence the effect of 
PQRS reporting on receipt of recommended pharmacotherapy is through diabetes care 
processes. The effect of PQRS reporting was greater for diabetes ACSCs than all ACSCs.  
Diabetes ACSCs account for 24 percent of all ACSCs for diabetics, with CHF (23 percent), 
Asthma/COPD (22 percent) and pneumonia (14 percent) accounting for the other major 
ACSCs.  Complications of diabetes account for 80 percent of hospitalizations for diabetes 
ACSCs, with hypertension (10 percent), uncontrolled diabetes (8 percent) and 
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hypoglycemia (2 percent) accounting for other diabetes ACSCs  PQRS reporting for diabetes 
processes (likely to be performed by non-PCPs) was associated with lower risk and rate of 
diabetes ACSCs than PQRS reporting likely to be performed by PCPs. This association did 
not persist after controlling for diabetes care processes, suggesting that reporting was not 
related to conscientious ambulatory care. Reporting was related to lower risk of all ACSCs, 
but effect of reporting on all ACSCs did not persist when all diabetes care processes were 
controlled for- suggesting that the effect of reporting on this outcome was through diabetes 
care processes rather than conscientious ambulatory care. 
In summary our study showed that PQRS reporting for diabetics was associated 
with greater rates of recommended diabetes care processes. The effect of reporting on 
guideline recommended pharmacotherapy processes and avoidable hospitalization 
outcomes however were through these diabetes care processes, rather than conscientious 
ambulatory care. The finding that diabetics who received PQRS reporting for processes had 
better diabetes ACSC outcomes than those who received PQRS reporting for intermediate 
outcomes suggests that performance of care processes may be more related to 
conscientious ambulatory care, rather than PQRS reporting. The differing motivations for 
provider participation in PQRS reporting could account for this finding. Most providers 
participated in PQRS reporting in 2009 for incentive payments, even though the incentive 
payments were not very high. Others participated in PQRS reporting to gain experience in a 
system that would be eventually used for future value-based payments for physicians. 
Commitment to a culture of quality was not the biggest motivator for provider participation 
in this reporting program. 
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The findings from our study are different from others that have shown little or no 
effect of quality reporting on either quality measures or outcomes [64-68]. Our study shows 
that PQRS reporting was associated with  higher receipt of diabetes care processes, and  
was associated with more guideline recommended pharmacotherapy and fewer avoidable 
hospitalization outcomes- through these processes. Pay for performance has been shown to 
have a stronger effect on quality measures and outcomes than quality reporting alone[69]. 
The effect of PQRS reports on processes and outcomes should be expected to increase when 
performance on PQRS reports are tied to physician payment [70, 71]. 
A few limitations of this study need to be considered. We examined the association 
of reporting and outcomes at the patient level and not the physician level. The effect of 
reporting on processes and outcomes could vary by physicians who have differing 
motivations for participating in PQRS reporting.  We studied the effect of reporting in the 
third year of the PQRS program. The effect of reporting on outcomes could improve over the 
years with physicians gain more experience in responding to feedback from reporting. But 
it could also be argued that outcomes are not likely to improve if early adopters are 
physicians who are more motivated by quality. Secondly, due to constraints imposed by our 
data, we only examined the effect of reporting on outcomes in the short-run, i.e. within the 
year.  The effect of reporting on outcomes could be more pronounced in the long-run, 
especially given that reporting was found to be associated with higher guideline 
recommended medication use. We used E&M visit for diabetes as a proxy for blood pressure 
measurement process for diabetics who did not receive PQRS reporting for blood pressure. 
The true rate of blood pressure measurement may be higher for non-PQRS diabetics and 
diabetics with PQRS reporting for processes. This measurement error is in the direction of 
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our finding that reporting leads to better processes and outcomes, and against the direction 
of our finding that  the effect of reporting on outcomes is mainly through diabetes care 
processes. Our measure of anti-platelet therapy included aspirin and other anti-platelet 
agents. But given that aspirin can be procured over the counter- our measure of anti-
platelet therapy obtained from Medicare claims is lower than the true measure. Finally, 
diabetics in our sample had at least one E&M visit during the first quarter of 2009, and were 
hence more likely to be higher utilizers of care than the average Medicare diabetics.  
CONCLUSION 
Even as PQRS inches towards its goal of motivating Medicare physicians across the 
board to report quality measures through incentive payments or penalties, we find in our 
study that PQRS reporting was associated with greater receipt of care processes for 
Medicare beneficiaries. But reporting was not indicative of more conscientious ambulatory 
care and was associated with better recommended pharmacotherapy and fewer 
hospitalization outcomes only through care processes. Given that the ultimate goal of the 
PQRS program is to facilitate the creation of a system that rewards more conscientious 
ambulatory care by employing its wealth of quality measures – the value of this reporting 
program would be further realized in the near future.        
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Table 5.1: Characteristics of beneficiaries receiving Diabetes PQRS measures and No 
Diabetes PQRS measures in 2009 
 Total 
Beneficiary 
Sample=95,199 
Diabetics with 
PQRS Reporting 
Diabetics with 
PQRS  
Reporting for 
Intermediate 
Outcomes 
Diabetics with PQRS 
Reporting for Processes 
Diabetics with 
No PQRS 
Reporting 
  N=11,783 N=4,720 N=7,063 N=83,416 
DEMOGRAPHICS   
 
    
Age 66.1 (9.0)* 65.7(9.3)
 #
 66.4(8.5)
 #
 65.1(9.7)* 
Female 60.0% 59.3%
#
 61.9%
#
 60.9% 
White 80.9%* 84.8%
#
 78.3%
#
 76.2%* 
Black  12.4%* 10.9%
#
 13.5%
#
 14.6%* 
Hispanic 3.0%* 1.6%
#
 3.8%
#
 3.9%* 
Other 3.7%* 2.6%
#
 4.4%
#
 5.3%* 
Median Income $42,647(1,562)* $43,343(1,542)
#
 $42,182(1,574)
#
 
$41,396(1,603)
* 
Median 
Education in 
Years 
13.2(1.1)* 13.3(1.0)
 #
 13.1(1.2)
 #
 13.1(1.2)* 
Rural 6.2% 5.9% 6.5% 5.9% 
Diabetes         
Type I Diabetes  18.5%* 17.0%
#
 21.4%
#
 11.4%* 
Diabetes 
Duration in 
Months 
63.7(39.3)* 62.3(39.8)
 #
 64.7(39.7)
 #
 52.3(40.9)* 
Insulin at 
Baseline 
22.30%* 21.5% 22.9% 14.40%* 
Oral Anti 
Diabetics at 
Baseline 
31.8%* 32.0% 31.7% 24.8%* 
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 Total 
Beneficiary 
Sample=95,199 
Diabetics with 
PQRS Reporting 
Diabetics with 
PQRS  
Reporting for 
Intermediate 
Outcomes 
Diabetics with PQRS 
Reporting for Processes 
Diabetics with 
No PQRS 
Reporting 
  N=11,783 N=4,720 N=7,063 N=83,416 
COMORBIDITIES 
Hypertension 77.80%* 77.8% 77.9% 74.9%* 
Coronary Artery 
Disease  
51.7%* 50.7% 52.4% 47.0%* 
Atrial 
Fibrillation 
8.5% 8.9% 8.1% 8.5% 
Dementia 7.2%* 6.7% 7.4% 10.1%* 
Chronic Kidney 
Disease 
30.9%* 31.6% 30.5% 26.3%* 
COPD 17.2%*    18.4%
#
 16.5%
#
 21.6%* 
Congestive 
Heart Failure 
28.0%* 28.1% 28.0% 30.0%* 
Depression 24.3%* 26.3%
 #
 23.0%
 #
 28.4%* 
Stroke 6.5%* 6.3% 6.6% 7.8%* 
Cancer 6.6%* 7.1% 6.2% 7.2%* 
Baseline HCC 
SCORE 
0.74(0.67)* 0.75(0.67)
 
 0.73(0.67)
 
 0.79(0.77)* 
* Differences between  PQRS and Non-PQRS diabetics significant at P<0.05 
#
 Differences between 
diabetics receiving PQRS reporting for intermediate outcomes and PQRS reporting for processes 
significant at P<0.05. 
Notes: PQRS Reporting for Intermediate Outcomes: HbA1c testing, LDLC testing, BP measurement; PQRS 
Reporting for Processes: Testing for Nephropathy, Eye Exams; COPD: Chronic Obstructive Pulmonary 
Disease: HCC Score: Hierarchical Conditions Categories Case Mix Score. 
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Table 5.2: Rate of Diabetes Care Processes among PQRS and Non-PQRS Diabetics in 
2009 and Adjusted Odds ratio for getting Diabetes Care Processes  
 
 Diabetics with 
PQRS Reporting 
Diabetics with 
PQRS Reporting 
for Intermediate 
Outcomes 
Diabetics with 
PQRS  
Reporting for 
Processes 
Diabetics 
with No 
PQRS 
Reporting 
  N=11,783 N=4,720 N=7,063 N=83,416 
CORE DIABETES CARE 
PROCESSES 
(HbA1c/LDLC/BP 
Measurement) 
3 Measures 63%* 74%
#
 56%
#
 43%* 
2 Measures 15%* 13%
#
 17%
#
 21%* 
1 Measure 15%* 13%
#
 16%
#
 14%* 
None 7%* 0%
#
 11%
#
 22%* 
OTHER DIABETES CARE 
PROCESSES 
Testing for Nephropathy 65%* 67%
#
 63%
#
 57%* 
Eye Exam 79%* 66%
#
 87%
#
 54%* 
Adj. OR for Any Core 
Diabetes Process 2.22(2.13-2.31)* 4.20 (3.92-4.49)*
#
 1.52(1.45-1.60)*
#
 Reference 
Adj. OR for Any Diabetes 
Process  2.79(2.70-2.90)* 2.92 (2.77-3.01)*
#
 2.70 (2.60-2.73)*
#
 Reference 
* Differences between PQRS and Non-PQRS diabetics significant at P<0.05 # Differences between 
diabetics receiving PQRS reporting for intermediate outcomes and PQRS reporting for processes 
significant at P<0.05.Notes: PQRS Reporting for Intermediate Outcomes: HbA1c testing, LDLC testing, 
BP measurement; PQRS Reporting for Processes: Testing for Nephropathy, Eye Exams. 
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Table 5.3 Adjusted Odds Ratio for Subsequent Guideline Recommended 
Pharmacotherapy for PQRS Diabetics  
  Covariates Controlled For  
Diabetics with PQRS 
Reporting for 
Intermediate 
Outcomes 
Diabetics with PQRS  
Reporting for Processes 
GUIDELINE RECOMMENDED PHARMACOTHERAPY  Adjusted Odds Ratio (95% CI)  
ACE/ARB 
Therapy (with 
Hypertension) 
Demographics+Severity of 
Diabetes+Comorbidities 
  1.38(1.26-1.51)*
 
 1.33(1.23-1.43)*
 
 
  +HbA1c+LDLC+BP  1.07 (0.97-1.18) 1.21(1.17-1.30)* 
  +Eye+Nephro 1.07(0.97-1.17) 1.19(1.10-1.29)* 
Statin Therapy 
(Age>40 years) 
Demographics+Severity of 
Diabetes+Comorbidities  1.42(1.31-1.54)* 1.25(1.17-1.33)* 
  +HbA1c+LDLC+BP 1.06(0.98-1.15) 1.12(1.05-1.19)* 
  +Eye+Nephro 1.05(0.97-1.14) 1.08(1.01-1.15)* 
Anti-Platelet 
Therapy (with 
Coronary Artery 
Disease) 
Demographics+Severity of 
Diabetes+Comorbidities 
     0.94(0.83-1.07) 1.03(0.93-1.14) 
  +HbA1c+LDLC+BP   0.84(0.74-0.96)* 0.99(0.89-1.10) 
  +Eye+Nephro   0.84(0.74-0.96)* 1.03(0.93-1.14) 
* Differences between PQRS and Non-PQRS diabetics significant at P<0.05 Notes: PQRS Reporting for 
Intermediate Outcomes: HbA1c testing, LDLC testing, BP measurement; PQRS Reporting for Processes: 
Testing for Nephropathy, Eye Exams 
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Table 5.4 Adjusted Relative Risk and Adjusted Hazard Ratio for Diabetes ACSC 
Hospitalizations and All ACSC Hospitalizations for PQRS Diabetics  
* Differences between PQRS and Non-PQRS diabetics significant at P<0.05 Notes: PQRS Reporting for 
Intermediate Outcomes: HbA1c testing, LDLC testing, BP measurement; PQRS Reporting for Processes: 
Testing for Nephropathy, Eye Exams 
  
Covariates Controlled For 
Diabetics with PQRS 
Reporting for 
Intermediate 
Outcomes 
Diabetics with 
PQRS 
Reporting for 
Processes 
  
Adjusted Relative Risk or Hazard Ratio 
 (95% CI) 
LIKELIHOOD OF 
DIABETES ACSC 
HOSPITALIZATIONS 
Demographics+Severity of 
Diabetes+Comorbidities 
 
  
1.11 (0.91-1.35) 0.66 (0.54-0.80)*
 
 
+HbA1c+LDLC+BP Processes 0.94 (0.77-1.14) 0.62 (0.51-0.76)*
 
 
+Eye+Nephro Processes 0.96 (0.78-1.17) 0.72 (0.59-0.89)*
 
 
HAZARD  OF 
DIABETES ACSC 
HOSPITALIZATIONS 
Demographics+Severity of 
Diabetes+Comorbidities 
 
  
1.10  (0.91-1.32) 0.67 (0.55-0.81)* 
+HbA1c+LDLC+BP Processes 0.96 (0.79-1.16) 0.64 (0.52-0.77)* 
+Eye+Nephro Processes 0.98 (0.81-1.19)   0.74 (0.61-0.90)*
 
 
LIKELIHOOD OF ALL  
ACSC 
HOSPITALIZATIONS 
Demographics+Severity of 
Diabetes+Comorbidities 
    
0.87(0.70-0.95)* 0.79 (0.73-0.85)* 
+HbA1c+LDLC+BP Processes 0.87(0.80-0.95)* 0.79 (0.74-0.85)* 
      +Eye+Nephro Processes 0.88(0.81-0.96)* 0.93 (0.87-1.01) 
HAZARD  OF ALL 
ACSC 
HOSPITALIZATIONS 
Demographics+Severity of 
Diabetes+Comorbidities 
    
0.91(0.83-1.00)  0.80 (0.74-0.87)* 
+HbA1c+LDLC+BP Processes 0.93(0.84-1.02)   0.80 (0.74-0.87)* 
+Eye+Nephro Processes 0.94(0.85-1.04) 0.94 (0.86-1.02) 
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CHAPTER 6: CONCLUSIONS 
 
This study found two of the current practices in measurement of quality of diabetes 
care to be inapt for Medicare beneficiaries with diabetes. While our study focused on 
diabetes care, these findings apply to quality of care for other chronic conditions managed 
in ambulatory care settings as well. 
THE ALL-OR-NONE APPROACH: SIMPLE IS NOT BETTER 
The all-or-none approach to diabetes care quality measurement, currently 
employed in Medicare’s ACO demonstration, is unsuitable for measurement of quality of care 
for chronic conditions- where multiple care components vary in their relative importance. 
In Chapter 3, we found that this approach has poor predictive validity, discards meaningful 
& important quality information and has low discrimination for the Medicare population. 
Most Medicare beneficiaries, who are unlikely to get all recommended care measures, 
would be classified as failures in meeting the quality bar, using this approach. The approach 
also has poor reliability, lacking the sensitivity for distinguishing between physicians and 
plans. This approach may be more suited for evaluating multistep processes of care, e.g. 
diagnosis and treatment of pneumonia, where each step is vital for a successful outcome. 
But it is definitely not suited for measuring quality of diabetes care or other chronic 
conditions [4]. 
EQUAL WEIGHTING OF MEASURES: SOME MEASURES ARE MORE EQUAL  
Our findings in Chapter 4 challenge the approach intended to be used for quality 
measurement in Medicare’s Physician Value-Based Modifier. The proposed approach, equally 
weights all measures in the diabetes measure set even when they are not equally important 
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for quality of diabetes care. We found that while physician quality leaders endorsed this 
dogma, measures like HbA1c and LDL-C measurement were more strongly related to 
quality of diabetes care- than eye exams or testing for nephropathy.  
As acknowledged by the National Quality Forum, consensus drives every aspect of 
quality measurement work in practice today. Quality measures chosen for conditions are 
rarely exclusively based on evidence from RCTs. The temptation to ensure that measures in 
a disease measure set cover all important aspects of care for the disease – motivates the 
addition of guideline-based measures alongside evidence-based measures. Assigning 
measures in the composite equal weight ensues from the temptation to keep measurement 
simple. This not only dilutes the association of the measure set with the quality, but also 
propagates inefficiencies in the healthcare system when processes of care that truly do not 
add value to patients are performed by providers. Eye exams and testing for nephropathy 
are examples of such guideline-based measures. Monitoring progress of retinopathy and 
nephropathy annually is important in diabetics who have early stages of retinopathy and 
nephropathy respectively. Annual testing for retinopathy and nephropathy is not as 
important in other diabetics as annual HbA1c and LDL-C testing. Equally weighting all four 
measures would be justified only if the denominator population for eye exams and testing 
for nephropathy were limited to diabetics with some form of retinopathy or nephropathy. 
Our study found that ambulatory care process measures related and unrelated to 
diabetes were explained by a single underlying factor. Viewing measures as causes or 
effects of quality has different implications for how physicians and policy makers approach 
quality improvement [23].  If measures are believed to cause quality- which might be 
unobserved, or observed as outcomes, then quality improvement efforts should be focused 
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on improving measures to have its desired effect [23].  If measures are in fact effects of the 
underlying quality construct, then quality improvement efforts should be focused on 
improving the quality culture of ambulatory care practice. Focusing quality improvement 
efforts at the level of measures, in this case, would not result in any quality improvement 
[23]. 
 QUALITY REPORTING: IMPROVING RECOMMENDED CARE PROCESSES 
Medicare beneficiaries often do not receive recommended processes of care. In 
Chapter 5, we found that Medicare beneficiaries who received PQRS reporting received 
recommended care processes at a much higher rate than beneficiaries who received process 
measures alone. It would be fair to conclude that PQRS reporting has succeeded in 
improving recommended measure rates among Medicare beneficiaries. Diabetics who 
received PQRS reporting had higher rates of clinical action measures like receipt of 
guideline recommended pharmacotherapy processes. They also had better outcomes, in the 
form of fewer avoidable hospitalizations. But reporting was not indicative of more 
conscientious ambulatory care and was associated with better recommended 
pharmacotherapy and fewer hospitalization outcomes only through care processes. Given 
that the ultimate goal of the PQRS program is to facilitate the creation of a system that 
rewards more conscientious ambulatory care by employing its wealth of quality measures – 
the value of this reporting program should be further realized in the near future.        
FUTURE OF DIABETES QUALITY MEASUREMENT 
 Improving the future of diabetes quality measurement requires us to better link 
ambulatory diabetes care to consequences of care- viz. clinical actions and patient 
outcomes. In this dissertation we linked diabetes care to clinical actions such as receipt of 
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guideline recommended pharmacotherapy, as well as outcomes such as hospitalizations for 
diabetes ACSCs. Medicare’s physician value-based modifier payment system has already 
incorporated pharmacotherapy and hospitalization outcomes measures in their 
measurement of care quality. Evolving technology, including use of electronic health 
records should allow us to incorporate richer clinical action measures and patient reported 
health outcomes to diabetes performance measurement, than what is limitedly available 
now through claims and registries. 
 Finally, it is important to recognize that true quality of ambulatory care is unseen- 
we only observe some of its indicators. Essential components of quality such as provider 
communication and proactivity remain unmeasured. Quality is in a state of constant flux for 
a patient - patient preferences change along with their health status, from changing clinical 
care & its varying consequences.  The models of quality measurement that we use in our 
quest for quality improvement need to appreciate the nature of this variable, so that we can 
measure it better. The latent variable approach to measuring quality of care succeeds in this 
regard.  Future research in quality measurement to be to be undertaken include latent 
growth modeling to capture effects of care continuity and  care coordination on the quality 
construct, as well as  multiple-group factor analysis to study how latent quality differs by 
providers. 
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APPENDICES 
 
APPENDIX 1: CODES TO IDENTIFY BENEFICIARIES WITH HIV, ACTIVE CANCER TREATMENT, ORGAN 
TRANSPLANT AND END-STAGE RENAL DISEASE FOR EXCLUSION 
Condition Codes 
HIV ICD-9 diagnosis code: 042 
Active Cancer  Treatment ICD-9 diagnosis codes: 140-208, 230-23 
; ICD-9 procedure codes: 41.0, 41.91, 
92.2; CPT codes: 38230, 38240-38242, 
77261-77799, 79000-79999, 96400-
96549 
Organ Transplant ICD-9 procedure codes: 33.5, 33.6, 
37.5, 41.94, 46.97, 50.5, 52.8, 55.6;  
CPT codes: 32850-32856, 33930-33945, 
44132-44137, 44715-44721, 47133-
47147, 48160, 48550-48556, 50300-
50380; HCPCS codes: S2152, S2053-
S2055, S2060, S2061, S2065 
End-Stage Renal Disease ICD-9 diagnosis codes:585.5, 585.6, 
V42.0, V45.1, V56;   ICD-9 procedure 
codes: 38.95, 39.27, 39.42, 39.43, 
39.53, 39.93, 39.94, 39.95, 54.98; CPT 
codes: 36145, 36800-36821, 36831-
36833, 90919-90921, 90923-90925, 
90935, 90937, 90939, 90940, 90945, 
90947, 90989, 90993, 90997, 90999, 
99512 ; HCPCS codes: G0257, G0311-
G0319, G0321-G0323, G0325-G0327, 
G0392, G0393, S9339 
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APPENDIX 2: CODES TO IDENTIFY DIABETES CARE PROCESSES, AMBULATORY CARE PROCESSES 
AND SEVERITY OF DIABETES VARIABLES 
Measure/Variable Codes 
Diabetes Care Processes 
HbA1c Testing CPT codes: 83036, 83037, 3044F, 3045F, 3046F, and 3047F 
LDLC Testing CPT codes: 80061, 83700, 83701, 83704, 83715, 83716, 83721, 
3048F, 3049F, and 3050F 
Dilated Eye Exams CPT codes:  67028, 67030, 67031, 67036, 67038, 67039, 67040, 
67101, 67105, 67107, 67108, 67110, 67112, 67121, 67141, 
67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 
92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 
92230, 92235, 92240, 92250, ,92260, 2022F, 2024F, 2026F, and 
3072F 
Testing for Nephropathy CPT codes:  81000, 81001, 81002, 81003,  81005, 82042, 82043, 
82044, 84156, 3060F, 3062F and 3061F 
Evaluation & Management 
(E&M) Visit for Diabetes 
Berenson-Eggers type of service (BETOS) codes:  M1A  and M1B 
with ICD-9 diagnosis codes:249.00, 249.01, 249.10, 249.11, 
249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50, 249.51, 
249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90, 249.91, 
250.00, 250.01, 250.02, 250.03, 250.10, 250.11, 250.12, 250.13, 
250.20, 250.21, 250.22, 250.23, 250.30, 250.31, 250.32, 250.33, 
250.40, 250.41, 250.42, 250.43, 250.50, 250.51, 250.52, 250.53, 
250.60, 250.61, 250.62, 250.63, 250.70, 250.71, 250.72, 250.73, 
250.80, 250.81, 250.82, 250.83, 250.90, 250.91, 250.92, 250.93, 
357.2, 362.01, 362.02, and 366.41  
  
Diabetes Program CPT codes:  97802, 97803, 97804 , G0108, G0109, G0270, and 
G0271 
Ambulatory Care Processes 
Influenza Vaccination CPT codes:  90724, 90658, 90659, 90656 ,and  G0008 
Breast/Prostate Cancer 
Screening  
CPT codes: 77057, G0202, 84153, and G0103 or ICD-9 diagnosis 
codes: V7612, and V7644 
Severity of Diabetes 
Type 1 Diabetes ICD-9 diagnosis codes: 250.01, 250.03, 250.11, 250.13, 250.21, 
250.23, 250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61, 
250.63, 250.71, 250.73, 250.81, 250.83, 250.91, and 250.93 
Self-Monitoring of Blood 
Glucose 
CPT/HCPCS Code on Carrier/Durable Medical Equipment Claims: 
82962, A4253, A4256, A4258, A4259,E0607, E2100, E2101, 
Insulin Pump Use** CPT/HCPCS Code on Carrier/Durable Medical Equipment Claims: 
E0781, E0784, A4231, A4230, K0552, S5565, S5566, A4221, 
J1815, J1816, J1817, A4632, K0601, K0602, K0605, A4365, 
A5120, A4245, A4247, A6257, A6258, A4364, A4450, A9274   
** Medicare Part B covers insulin pumps, while Medicare Part D covers insulin taken in the injectable 
form.  
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APPENDIX 3: CODES TO IDENTIFY HOSPITALIZATIONS FOR AMBULATORY CARE SENSITIVE 
CONDITIONS (ACSCS) AND ACSCS ASSOCIATED WITH DIABETES 
 
ACSC Hospitalization  Codes 
Diabetes 
Complications** 
All discharges with principal ICD-9 diagnosis codes: Diabetes Short 
term Complications: 250.10, 250.11, 250.12,250.13, 250.20, 
250.21, 250.22,250.23, 250.30, 250.31, 250.32, and 250.33; or 
Diabetes Long term Complications: 250.40, 250.41, 250.42,250.43, 
250.50, 250.51, 250.52,250.53, 250.60, 250.61, 250.62,250.63, 
250.70, 250.17, 250.72,250.73, 250.80, 250.81, 250.82,250.83, 
250.90, 250.91, 250.92, and 250.93. 
Uncontrolled Diabetes** All discharges with principal ICD-9 diagnosis codes: 250.02 and 
250.03 
Hypoglycemia** All discharges with principal ICD-9 diagnosis codes: 251.2, and 
251.20 with accompanying secondary ICD-9 diagnosis codes: 
250.x0, 250.x1, 250.x2 and 250.x3. 
Hypertension** All discharges with principal ICD-9 diagnosis codes: 410.0, 401.9, 
402.00, 402.10, 402.90, 403.00, 403.10, 403.90, 404.00, 404.10, 
and 404.90. Exclude cases with a cardiac procedure code. Exclude 
cases with any diagnosis code for Stage I-IV kidney disease and 
accompanying procedure code for hemodialysis. 
Chronic Obstructive 
Pulmonary Disease 
All discharges with principal ICD-9 diagnosis codes: 466.0*, 490*, 
491.0, 491.1, 491.20, 491.21, 491.8, 491.9, 492.0, 492.7, 494, 
494.0, 494.1, and 496 *. Qualifies only if accompanied by 
secondary diagnosis of 491.xx, 492.x, 494.x, or 496. 
Congestive Heart Failure All discharges with principal ICD-9 diagnosis codes: 398.91, 428.0, 
428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 
428.33, 428.40, 428.41, 428.42, 428.43, and 428.9. Exclude cases 
with cardiac procedure code.  
Dehydration All discharges with principal ICD-9 diagnosis codes: 276.5, 276.50, 
276.51, and 276.52; OR All discharges with Secondary ICD-9 
diagnosis codes: 276.5, 276.50, 276.51, and 276.52 with 
accompanying Principal ICD-9 diagnosis codes: 276.0, 008.6x, 
008.8, 009.0, 009.1, 009.2, 009.3, 558.9, 584.5, 584.6, 584.7, 
584.8, 586, and 997.5. Exclude cases with any diagnosis code for 
chronic renal failure. 
Bacterial Pneumonia All discharges with principal ICD-9 diagnosis codes: 481, 482.2, 
482.30, 482.31, 482.32, 482.39, 482.41, 484.42, 482.9, 483.0, 
483.1, 483.8, 485, and 486. Exclude cases with any diagnosis code 
of sickle cell anemia or HB-S disease. Exclude cases with any 
diagnosis or procedure code for immunocompromised state. 
Urinary Tract Infection All discharges with principal ICD-9 diagnosis codes: 590.10, 
590.11, 590.2, 590.3, 590.80, 590.81, 590.9, 595.0, 595.9, and 
599.0. Exclude cases with any diagnosis of kidney/urinary tract 
disorder. Exclude cases with any diagnosis or procedure code for 
immunocompromised state. 
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ACSC Hospitalization  Codes 
Angina without 
Procedure 
All discharges with principal ICD-9 diagnosis codes: 411.1, 411.81, 
411.89, 413.0, 413.1 and 413.9. Exclude cases with a cardiac 
procedure code. 
Adult Asthma All discharges with principal ICD-9 diagnosis codes: 493.00, 
493.01, 493.02, 493.10, 493.11, 493.12, 493.20, 493.21, 493.22, 
493.81, 493.82, 493.90, 493.91 and 493.92. Exclude cases with any 
diagnosis code of cystic fibrosis and anomalies of the respiratory 
system. 
**ACSCs associated with Diabetes 
Conditions for ACSC 
Exclusions 
Codes 
Trauma ICD-9 diagnosis codes: 895.0, 895.1, 896.0, 896.1, 896.2, 896.3, 
897.0, 897.1, 897.2, 897.3, 897.4, 897.5, 897.6, and 897.7. 
Cardiac Procedures ICD-9 procedure codes: 005.1, 005.2, 0053, 005.4, 005.6, 005.7, 
006.6, 175.1, 175.2, 175.5, 350.0, 350.1, 350.2, 350.3, 350.4, 
350.5, 350.6, 350.7, 350.8, 350.9, 351.0, 351.1, 351.2, 351.3, 
351.4, 352.0, 352.1, 352.2, 352.3, 352.4, 352.5, 352.6,  352.7, 
352.8, 353.1, 353.2, 353.3, 353.4, 353.5,  353.9,  354.1, 354.2, 
355.0, 355.1, 355.2, 355.3, 355.4, 355.5, 356.0, 356.1, 356.2, 
356.3,  357.0, 357.1, 357.2, 357.3, 358.1,  358.2,  358.3, 358.4, 
359.1, 359.2, 359.3, 359.4, 359.5, 359.6, 359.8, 359.9, 360.1, 
360.2, 360.3, 360.4, 360.5, 360.6, 360.7, 360.9, 361.0, 361.1, 
361.2, 361.3, 361.4, 361.5, 361.6, 361.7,  361.9, 362, 363, 363.1, 
363.2, 363.3, 363.4, 363.9,  369.1, 369.9, 373.1,  373.2, 373.3, 
373.4,  373.5, 373.6, 374.1,  375 , 375.1, 375.2, 375.3, 375.4, 
375.5, 376.0, 376.1, 376.2, 376.3, 376.4, 376.5, 376.6, 377.0, 
377.1, 377.2, 377.3, 377.4, 377.5, 377.6, 377.7, 377.8, 377.9, 
378.0, 378.1, 378.2, 378.3, 378.5, 378.6, 378.7, 378.9, 379.4, 
379.5, 379.6, 379.7, 379.8, and  382.6  
Stage I-IV Kidney Disease 
with Hemodialysis  
ICD-9 diagnosis codes: 403.00, 403.10, 403.90, 404.00, 404.10, 
and 404.90 with accompanying ICD-9 procedure codes: 389.5, 
392.7, 392.9, 394.2, 399.3, and 399.4.  
Chronic Renal Failure ICD-9 diagnosis codes: 403.00, 403.01, 403.10, 403.11, 403.90, 
403.91, 404.00, 404.01, 404.02, 404.03, 404.10, 404.11, 404.12, 
404.13, 404.90, 404.91, 404.92, 404.93, 585,  585.5 , and 585.6 
Sickle Cell Anemia or HB-S  ICD-9 diagnosis codes: 282.41, 282.42, 282.60, 282.61, 282.62, 
282.63, 282.64, 282.68, and 282.69 
Immunocompromised 
States 
ICD-9 diagnosis codes: 042, 136.3, 199.2,238.73, 238.76, 238.77, 
238.79, 260 ,261, 262 , 279.00, 279.01 , 279.02, 279.03, 279.04, 
279.05, 279.06, 279.09, 279.10, 279.11, 279.12, 279.13 ,279.19 
,279.2, 279.3, 279.4, 279.41, 279.49, 279.50, 279.51, 279.52, 
279.53, 279.8, 279.9, 284.09, 284.1, 284.11, 284.12 , 284.19, 
288.0, 288.00, 288.01, 288.02,  288.03, 288.09, 288.1 , 288.2, 
288.4 , 288.50,  288.51, 288.59 , 28953, 289.83, 403.01, 403.11, 
403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 579.3, 
585 , 585.5 , 585.6, 996.8,  996.80, 996.81, 996.83, 996.84, 
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Conditions for ACSC 
Exclusions 
Codes 
996.85, 996.86, 996.87, 996.88, 996.89, V42.0, V42.1, V42.6, 
V42.7, V42.8, V42.81, V42.82, V42.83, V42.84, V42.89, V45.1 , 
V45.11, V56.0 , V56.1, and V56.2; OR ICD-9 procedure  codes: 
335, 335.0, 335.1,335.2, 336, 375, 375.1, 410, 410.0, 410.1, 
410.2, 410.3, 410.4, 410.5, 410.6, 410.7, 410.8, 410.9, 505.1, 
505.9, 528.0, 528.1, 528.2, 528.3, 528.5, 528.6, and 556.9. 
Kidney/Urinary Tract 
Disorder 
ICD-9 diagnosis codes:  590.00,  590.01, 593.70, 593.71,  593.72, 
593.73, 753.0 , 753.10, 753.11, 753.12, 753.13, 753.14, 753.15, 
753.16, 753.17, 753.19, 753.20, 753.21, 753.22,  753.23, 753.29, 
753.3 , 753.4, 753.5 ,753.6, 753.8 , and 753.9. 
Cystic Fibrosis and 
Anomalies of the 
Respiratory System  
ICD-9 diagnosis codes: 277.00, 277.01, 277.02, 277.03, 277.09, 
747.21, 748.3, 748.5, 748.60, 748.61, 748.69, 748.8, 748.9, 750.3, 
759.3, and 770.7  
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APPENDIX 4: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD  OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON DIABETES CARE PROCESSES IN 2006 : ZERO, ONE , TWO THREE VS. ALL 
 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  Odds Ratio 
95% CI of 
Odds Ratio 
Odds Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes         
Zero vs. All 2.19** 1.78-2.69 1.62** 1.51-1.75 
One  vs. All 1.64** 1.37-1.97 1.50** 1.41-1.60 
Two vs. All 1.35** 1.16-1.58 1.24** 1.17-1.32 
Three vs. All 1.16 1.00-1.35 1.05 0.99-1.11 
Diabetes ACSC/All ACSC in 2006 5.4** 3.65-7.99 2.89** 2.51-3.33 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.71 0.43-1.16 0.87 0.69-1.08 
65-69 years 0.64 0.26-1.55 0.78 0.56-1.07 
70-75 years 0.60 0.24-1.50 0.78 0.57-1.07 
Female vs. Male 0.74 0.53-1.03 1.19 1.07-1.35 
Race (Reference: White)         
Black 1.8** 1.14-2.70 1.04 0.89-1.22 
Other 0.74 0.35-1.57 0.84 0.65-1.08 
Median Zip code Income  1.00 0.99-1.00 0.99 0.99-1.00 
Median Zip code Education (years) 0.82 0.61-1.10 0.97  0.90-1.04 
Dual vs. Non Dual 1.41 0.93-2.14 1.21** 1.06-1.38 
Severity of Diabetes         
Type 1 vs. Type 2 1.66**  1.28-2.15 1.2** 1.09-1.32 
Insulin vs. No Insulin 1.41 0.66-2.99 1.28 0.89-1.83 
Self-Monitoring Blood Glucose 1.12 0.77- 1.61 0.89** 0.78-0.99 
Diabetes Duration in Years 1.17** 1.09- 1.25 1.06** 1.03-1.09 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.72** 1.61-4.62 1.19**  1.01-1.41 
HCC16:Diabetes with Neurologic/Other 
Manifestation 3.17** 1.99-5.06 1.31** 1.12-1.54 
HCC32:Pancreatic Disease 2.7** 1.46-4.99 1.23 0.91-1.65 
HCC54: Schizophrenia 0.51** 0.30-0.86 0.60** 0.47-0.77 
HCC55:Major Depressive, Bipolar, and 
Paranoid Disorders 0.87 0.56-1.34 1.04 0.85-1.26 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  Odds Ratio 
95% CI of 
Odds Ratio 
Odds Ratio 
95% CI of 
Odds Ratio 
HCC70:Muscular Dystrophy 0.08** 0.01-0.61 0.54 0.10-2.76 
HCC71: Polyneuropathy 1.1 0.86-1.39 1.02 0.88-1.19 
HCC77: Respirator Dependence 3.14**  1.29-7.61 0.73 0.51-1.38 
HCC80: Congestive Heart Failure 1.00 0.67-1.49 1.65** 1.46-1.89 
HCC81: Acute Myocardial Infarction 0.27** 0.16-0.48 1.12 0.85- 1.50 
HCC82: Unstable Angina and Ischemic 
Heart Disease 1.43 0.67- 3.08 1.30** 1.04-1.62 
HCC95: Cerebral Hemorrhage 3.66** 1.70-7.89 1.36 0.79-2.34 
HCC96: Ischemic or Unspecified Stroke 1.27 0.89-1.80 1.17 0.98-1.41 
HCC100: Hemiplegia/Hemiparesis 0.46** 0.26-0.82 1.01 0.76-1.35 
HCC104: Vascular Disease with 
Complications 0.54 0.68-1.27 1.00 0.80-1.25 
108: Chronic Obstructive Pulmonary 
Disease 0.83 0.49-1.40 2.05** 1.80-2.32 
HCC111: Aspiration and Specified 
Bacterial Pneumonias 0.35** 0.15-0.85 1.25 0.92-1.70 
HCC119: Proliferative Diabetic 
Retinopathy and Vitreous Hemorrhage 1.56**  1.12-2.18 1.30**  1.06-1.60 
HCC131: Renal Failure 1.45**  1.02-2.07 1.24**  1.08-1.43 
** OR significant at P<0.05 
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APPENDIX 5: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD  OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON DIABETES CARE PROCESSES IN 2006 –ONE, TWO, THREE, FOUR VS. ZERO 
 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes         
One vs. Zero 0.75** 0.61-0.92 0.92** 0.86-0.99 
Two vs. Zero 0.61** 0.51-0.74 0.76** 0.71-0.82 
Three vs. Zero 0.55** 0.46-0.66 0.69** 0.64-0.74 
Four vs.  Zero 0.46** 0.37-0.56 0.61** 0.57-0.66 
Diabetes ACSC/All ACSC in 2006 4.79** 4.04-5.67 2.50** 2.39-2.62 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.83** 0.70-0.99 0.98 0.91-1.04 
65-69 years 0.87 0.67-1.13 0.95 0.87-1.04 
70-75 years 0.79 0.61-1.02 1.01 0.92-1.10 
Female vs. Male 0.90** 0.82-0.99 1.12** 1.08-1.16 
Race (Reference: White)         
Black 1.61** 1.43-1.80 1.10** 1.05-1.15 
Other 0.98 0.80-1.21 0.91** 0.85-0.99 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.97 0.91-1.03 0.99 0.97-1.01 
Dual vs. Non Dual 1.36** 1.22-1.52 1.30** 1.25-1.36 
Severity of Diabetes         
Type 1 vs. Type 2 1.80** 1.61-2.01 1.25** 1.20-1.31 
Insulin vs. No Insulin 1.32** 1.04-1.68 1.12** 1.01-1.26 
Self-Monitoring Blood Glucose 1.14** 1.02-1.26 1.03 0.99-1.07 
Diabetes Duration in Years 1.10** 1.08-1.13 1.05** 1.05-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.93** 2.09-4.10 1.05 0.96-1.15 
HCC16:Diabetes with Neurologic/Other 
Manifestation 3.33** 2.39-4.64 1.13** 1.04-1.24 
HCC32:Pancreatic Disease 1.40** 1.10-1.78 1.20** 1.08-1.33 
HCC54: Schizophrenia 1.07 0.86-1.33 1.01 0.92-1.11 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.99 0.83-1.17 1.14** 1.07-1.22 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC70:Muscular Dystrophy 0.44 0.05-4.17 0.66 0.35-1.24 
HCC71: Polyneuropathy 1.13** 1.01-1.29 1.08** 1.03-1.14 
HCC77: Respirator Dependence 0.95 0.52-1.76 0.99 0.80-1.23 
HCC80: Congestive Heart Failure 1.19** 1.05-1.34 1.75** 1.68-1.83 
HCC81: Acute Myocardial Infarction 0.78 0.55-1.11 1.11 0.99-1.24 
HCC82: Unstable Angina and Ischemic Heart 
Disease 1.15 0.95-1.38 1.17** 1.10-1.25 
HCC95: Cerebral Hemorrhage 1.72** 1.06-2.80 1.05 0.86-1.29 
HCC96: Ischemic or Unspecified Stroke 1.55** 1.32-1.82 1.25** 1.17-1.33 
HCC100: Hemiplegia/Hemiparesis 0.68** 0.50-0.93 1.08 0.97-1.21 
HCC104: Vascular Disease with Complications 1.18 0.95-1.47 1.19** 1.09-1.29 
HCC108: Chronic Obstructive Pulmonary Disease 1.00 0.88-1.13 1.87** 1.79-1.94 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.77 0.50-1.17 1.08 0.94-1.23 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.62** 1.36-1.95 1.31** 1.20-1.43 
HCC131: Renal Failure 1.17** 1.02-1.34 1.33** 1.26-1.39 
** OR significant at P<0.05 
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APPENDIX 6: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD  OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON  AMBULATORY DIABETES CARE PROCESSES WITHIN A MEASURE SET SUBGROUP IN 
2006- ONE MEASURE 
 
  
Diabetes ACSC 
Hospitalizations in 
2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Diabetes Care Processes  (Reference: LDLC)         
HbA1c 0.96 0.60-1.51 0.88 0.75-1.03 
Eye Examination 1.19 0.78-1.83 1.03 0.89-1.20 
Nephropathy Testing 1.34 0.86-2.07 1.09 0.94-1.27 
          
Diabetes ACSC/All ACSC in 2006 6.14** 3.93-9.60 1.89** 1.62-2.21 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.92 0.58-1.48 1.33** 1.10-1.60 
65-69 years 1.20 0.57-2.51 1.37** 1.04-1.81 
70-75 years 0.81 0.38-1.70 1.34** 1.02-1.75 
Female vs. Male 1.17 0.87-1.55 0.88 0.79-0.98 
Race (Reference: White) 
 
      
Black 1.64** 1.22-2.21 1.16** 1.02-1.32 
Other 1.24 0.75-2.05 0.96 0.77-1.19 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.95 0.80-1.14 1.00 0.94-1.07 
Dual vs. Non Dual 1.36** 1.01-1.85 1.10 0.97-1.23 
Severity of Diabetes         
Type 1 vs. Type 2 2.18** 1.59-2.99 1.10 0.95-1.26 
Insulin vs. No Insulin 0.83 0.37-1.88 1.30 0.92-1.82 
Self-Monitoring Blood Glucose 1.23 0.91-1.65 1.05 0.94-1.17 
Diabetes Duration in Years 1.13** 1.07-1.20 1.06** 1.03-1.08 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.07** 1.01-4.29 1.39** 1.11-1.75 
HCC16:Diabetes with Neurologic/Other 
Manifestation 2.08** 1.03-4.20 1.32** 1.06-1.64 
HCC32:Pancreatic Disease 2.29** 1.38-3.80 1.20 0.91-1.60 
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Diabetes ACSC 
Hospitalizations in 
2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
HCC54: Schizophrenia 0.82 0.43-1.56 0.75 0.56-1.01 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.90 0.55-1.45 1.16 0.96-1.41 
HCC71: Polyneuropathy 1.71** 1.20-2.44 1.17** 1.01-1.38 
HCC77: Respirator Dependence 3.35** 1.06-10.56 0.78 0.44-1.38 
HCC80: Congestive Heart Failure 1.45** 1.01-2.07 1.69** 1.49-1.92 
HCC81: Acute Myocardial Infarction 0.40 0.13-1.27 1.15 0.85-1.57 
HCC82: Unstable Angina and Ischemic Heart Disease 0.79 0.42-1.50 1.5**7 1.29-1.91 
HCC95: Cerebral Hemorrhage 2.63 0.87-8.00 1.53 0.93-2.52 
HCC96: Ischemic or Unspecified Stroke 1.60** 1.01-2.53 1.34** 1.12-1.61 
HCC100: Hemiplegia/Hemiparesis 0.72 0.32-1.66 0.97 0.71-1.31 
HCC104: Vascular Disease with Complications 0.85 0.42-1.69 1.65** 1.33-2.05 
HCC108: Chronic Obstructive Pulmonary Disease 0.87 0.61-1.24 1.17** 1.03-1.33 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 1.24 0.49-3.11 0.89 0.60-1.31 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 2.63** 1.54-4.48 1.52** 1.13-2.04 
HCC131: Renal Failure 0.93 0.63-1.39 1.49** 1.30-1.72 
** OR significant at P<0.05 
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APPENDIX 7: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD  OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON  AMBULATORY DIABETES CARE PROCESSES WITHIN A MEASURE SET SUBGROUP IN 
2006- TWO MEASURES 
 
  
Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Diabetes Care Processes  (Reference: : LDLC+HbA1c)         
LDLC+Eye  Exam 0.64 0.37-1.12 0.98 0.85-1.14 
LDLC + Nephropathy Testing 0.69 0.41-1.16 1.04 0.92-1.19 
HbA1c+ Eye Exam 0.99 0.73-1.34 1.04 0.92-1.18 
HbA1c+ Nephropathy Testing 1.24 0.93-1.66 1.14 1.00-1.28 
Eye Exam + Nephropathy Testing 1.44** 1.03-2.08 1.35** 1.15-1.58 
Diabetes ACSC/All ACSC in 2006 3.94 2.79-5.55 1.79 1.62-1.99 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.81 0.58-1.12 1.03 0.90-1.18 
65-69 years 0.84 0.50-1.41 1.03 0.85-1.24 
70-75 years 0.75 0.45-1.24 1.00 0.83-1.20 
Female vs Male 0.85 0.69-1.03 0.93 0.86-1.00 
Race (Reference: White) 
 
      
Black 1.78 1.42-2.23 1.13 1.03-1.24 
Other 0.84 0.52-1.35 0.88 0.75-1.04 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.89 0.79-1.00 0.96 0.92-1.00 
Dual vs. Non Dual 1.26 1.01-1.57 1.13 1.04-1.22 
Severity of Diabetes         
Type 1 vs. Type 2 1.41 1.13-1.76 1.26 1.16-1.38 
Insulin vs. No Insulin 1.09 0.66-1.81 1.16 0.92-1.47 
Self-Monitoring Blood Glucose 1.24 1.01-1.51 1.09 1.01-1.17 
Diabetes Duration in Years 1.12 1.08-1.17 1.05 1.04-1.07 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory Manifestation 9.11 2.10-39.50 1.18 0.97-1.43 
HCC16:Diabetes with Neurologic/Other Manifestation 11.42 2.64-49.49 1.26 1.04-1.53 
HCC32:Pancreatic Disease 1.29 0.83-2.02 1.38 1.14-1.68 
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Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
HCC54: Schizophrenia 1.07 0.67-1.71 0.86 0.71-1.05 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 1.35 0.99-1.84 0.98 0.86-1.12 
HCC71: Polyneuropathy 1.19 0.93-1.51 1.05 0.95-1.17 
HCC77: Respirator Dependence 1.36 0.56-3.30 0.79 0.51-1.22 
HCC80: Congestive Heart Failure 1.22 0.96-1.54 1.48 1.36-1.62 
HCC81: Acute Myocardial Infarction 0.85 0.46-1.58 1.38 1.12-1.70 
HCC82: Unstable Angina and Ischemic Heart Disease 1.18 0.84-1.66 1.74 1.53-1.97 
HCC95: Cerebral Hemorrhage 1.44 0.55-3.74 1.20 0.80-1.80 
HCC96: Ischemic or Unspecified Stroke 1.45 1.06-1.98 1.46 1.29-1.65 
HCC100: Hemiplegia/Hemiparesis 0.60 0.34-1.05 0.84 0.68-1.05 
HCC104: Vascular Disease with Complications 1.16 0.77-1.76 1.75 1.51-2.04 
HCC108: Chronic Obstructive Pulmonary Disease 0.86 0.67-1.10 1.25 1.14-1.36 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.28 0.10-0.81 0.79 0.58-1.08 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 2.48 1.71-3.59 1.31 1.06-1.61 
HCC131: Renal Failure 1.35 1.05-1.73 1.58 1.45-1.73 
** OR significant at P<0.05 
 
 
 
 
 
 
 
 
 
 
114 
 
APPENDIX 8: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD  OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON  AMBULATORY DIABETES CARE PROCESSES WITHIN A MEASURE SET SUBGROUP IN 
2006- THREE MEASURES 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Diabetes Care Processes  (Reference: : LDLC+HbA1c+ 
Eye Exam) 
        
LDLC+HBA1C+ Nephropathy Testing 0.72 0.39-1.35 0.94 0.79-1.11 
LDLC+ Eye Exam+ Nephropathy Testing 1.08 0.88-1.31 1.02 0.95-1.09 
HbA1c+ Eye Exam + Nephropathy Testing 1.24 0.89-1.71 1.08 0.95-1.23 
          
Diabetes ACSC/All ACSC in 2006 5.05 3.76-6.80 1.75 1.59-1.92 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.74 0.55-1.01 1.00 0.88-1.13 
65-69 years 0.73 0.47-1.15 1.11 0.94-1.30 
70-75 years 0.73 0.47-1.13 1.04 0.88-1.22 
Female vs Male 0.92 0.78-1.09 0.93 0.88-0.99 
Race (Reference: White) 
 
      
Black 1.47 1.20-1.80 1.05 0.96-1.14 
Other 1.06 0.75-1.51 0.94 0.83-1.07 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.99 0.89-1.10 0.97 0.94-1.01 
Dual vs. Non Dual 1.38 1.14-1.67 1.12 1.04-1.20 
Severity of Diabetes         
Type 1 vs. Type 2 1.89 1.58-2.26 1.28 1.20-1.38 
Insulin vs. No Insulin 1.42 0.95-2.12 1.06 0.87-1.29 
Self-Monitoring Blood Glucose 1.04 0.87-1.23 1.10 1.03-1.17 
Diabetes Duration in Years 1.09 1.05-1.13 1.04 1.03-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory Manifestation 8.99 1.18-68.61 1.04 0.81-1.33 
HCC16:Diabetes with Neurologic/Other Manifestation 9.86 1.30-75.03 1.08 0.84-1.38 
HCC32:Pancreatic Disease 1.21 0.79-1.86 0.99 0.81-1.20 
HCC54: Schizophrenia 1.12 0.78-1.60 0.90 0.76-1.08 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.81 0.59-1.10 0.98 0.87-1.10 
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HCC71: Polyneuropathy 1.04 0.84-1.29 1.12 1.03-1.22 
HCC77: Respirator Dependence 0.19 0.03-1.34 0.73 0.43-1.25 
HCC80: Congestive Heart Failure 1.17 0.96-1.43 1.49 1.38-1.60 
HCC81: Acute Myocardial Infarction 0.87 0.47-1.61 1.57 1.30-1.90 
HCC82: Unstable Angina and Ischemic Heart Disease 1.23 0.90-1.67 1.65 1.47-1.85 
HCC95: Cerebral Hemorrhage 0.78 0.27-2.31 0.99 0.70-1.41 
HCC96: Ischemic or Unspecified Stroke 1.60 1.21-2.10 1.43 1.29-1.60 
HCC100: Hemiplegia/Hemiparesis 0.65 0.38-1.12 0.90 0.74-1.11 
HCC104: Vascular Disease with Complications 1.51 1.07-2.13 1.55 1.35-1.78 
HCC108: Chronic Obstructive Pulmonary Disease 1.13 0.92-1.39 1.15 1.07-1.24 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.94 0.46-1.94 0.98 0.74-1.31 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.10 0.79-1.53 1.32 1.16-1.50 
HCC131: Renal Failure 1.27 1.00-1.62 1.42 1.30-1.55 
** OR significant at P<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
APPENDIX 9: RESULTS OF EXPLORATORY FACTOR ANALYSIS WITH HALF-SAMPLE OF MEDICARE 
DIABETICS IN 2006 
 
1. With Four Diabetes Care Process Measures: Hba1c testing, LDLC testing, Eye exams 
and testing for Nephropathy 
 
 
 
 
 
 
 
 
    LR test:    1 factor vs. saturated:  chi2(2)  =  274.21 Prob>chi2 = 0.0000
    LR test: independent vs. saturated:  chi2(6)  = 4.7e+04 Prob>chi2 = 0.0000
                                                                              
        Factor1         0.91825            .            1.0000       1.0000
                                                                              
         Factor      Eigenvalue   Difference        Proportion   Cumulative
                                                                              
    Log likelihood = -137.1064                     (Akaike's) AIC   =  282.213
                                                   Schwarz's BIC    =  322.874
    Rotation: (unrotated)                          Number of params =        4
    Method: maximum likelihood                     Retained factors =        1
Factor analysis/correlation                        Number of obs    =   192000
                                           
          nephro     0.2868        0.9178  
             eye     0.1799        0.9676  
            ldlc     0.6278        0.6059  
           hba1c     0.6400        0.5904  
                                           
        Variable    Factor1     Uniqueness 
                                           
Factor loadings (pattern matrix) and unique variances
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2. With Eight Diabetes and Ambulatory Care Process Measures: Hba1c testing, LDLC 
testing, Eye exams, testing for Nephropathy, Evaluation & Management visit for 
Diabetes, Diabetes education, Cancer screening (breast or prostate) and Influenza 
Vaccination 
 
 
 
 
 
 
    LR test:   4 factors vs. saturated:  chi2(2)  =   28.05 Prob>chi2 = 0.0000
    LR test: independent vs. saturated:  chi2(28) = 1.0e+05 Prob>chi2 = 0.0000
                                                                              
        Factor4         0.06289            .            0.0277       1.0000
        Factor3         0.29123      0.22834            0.1280       0.9723
        Factor2         0.55875      0.26752            0.2457       0.8443
        Factor1         1.36149      0.80274            0.5986       0.5986
                                                                              
         Factor      Eigenvalue   Difference        Proportion   Cumulative
                                                                              
    Log likelihood = -14.02474                     (Akaike's) AIC   =  80.0495
                                                   Schwarz's BIC    =  344.346
    Rotation: (unrotated)                          Number of params =       26
    Method: maximum likelihood                     Retained factors =        4
Factor analysis/correlation                        Number of obs    =   192000
                                                                         
    emvisit_diab     0.3742    0.1473    0.4369    0.0725        0.6421  
             flu     0.1351    0.2660    0.0587   -0.1407        0.8877  
        diab_edu     0.0851    0.0958    0.0768    0.0707        0.9727  
          cancer     0.1809    0.4575   -0.1832    0.0077        0.7244  
          nephro     0.2035    0.2452   -0.0132    0.1023        0.8878  
             eye     0.1273    0.2957    0.1757   -0.1351        0.8472  
            ldlc     0.4350    0.3132   -0.1621    0.0634        0.6824  
           hba1c     0.9573   -0.0466   -0.0123   -0.0061        0.0812  
                                                                         
        Variable    Factor1   Factor2   Factor3   Factor4     Uniqueness 
                                                                         
Factor loadings (pattern matrix) and unique variances
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APPENDIX 10: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON HBA1C TESTING IN 2006 
 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
HbA1c 0.77 0.68-0.87 0.8 0.76-0.83 
  
    
Diabetes ACSC/All ACSC in 2006 4.90 4.19-5.75 2.54 2.43-2.65 
Demographics 
  
  Age (Reference: <60 years) 
    60-64  years 0.82 0.70-0.98 0.97 0.91-1.03 
65-69 years 0.86 0.66-1.12 0.95 0.86-1.04 
70-75 years 0.77 0.60-1.00 0.99 0.91-1.09 
Female vs Male 0.88 0.80-0.97 1.10 1.07-1.14 
Race (Reference: White) 
    Black 1.63 1.45-1.82 1.11 1.06-1.16 
Other 0.98 0.80-1.21 0.91 0.85-0.98 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.97 0.91-1.03 0.99 0.97-1.02 
Dual vs. Non Dual 1.36 1.22-1.52 1.30 1.25-1.35 
Severity of Diabetes 
    Type 1 vs. Type 2 1.78 1.60-1.98 1.25 1.20-1.30 
Insulin vs. No Insulin 1.31 1.04-1.65 1.12 1.01-1.25 
Self-Monitoring Blood Glucose 1.11 1.00-1.23 1.03 0.99-1.06 
Diabetes Duration in Years 1.11 1.08-1.13 1.05 1.05-1.06 
Selected HCCs 
    HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.71 1.93-3.82 1.05 0.96-1.15 
HCC16:Diabetes with Neurologic/Other 
Manifestation 3.04 2.17-4.26 1.12 1.03-1.23 
HCC32:Pancreatic Disease 1.39 1.09-1.77 1.19 1.08-1.31 
HCC54: Schizophrenia 1.05 0.84-1.30 1.00 0.91-1.09 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.97 0.82-1.16 1.13 1.06-1.20 
HCC71: Polyneuropathy 1.12 0.99-1.27 1.07 1.02-1.13 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC77: Respirator Dependence 0.97 0.53-1.76 1.00 0.82-1.22 
HCC80: Congestive Heart Failure 1.19 1.06-1.34 1.76 1.69-1.83 
HCC81: Acute Myocardial Infarction 0.79 0.57-1.10 1.11 0.99-1.23 
HCC82: Unstable Angina and Ischemic Heart Disease 1.14 0.95-1.37 1.16 1.09-1.24 
HCC95: Cerebral Hemorrhage 1.70 1.07-2.72 1.05 0.87-1.26 
HCC96: Ischemic or Unspecified Stroke 1.55 1.32-1.81 1.24 1.17-1.32 
HCC100: Hemiplegia/Hemiparesis 0.69 0.51-0.93 1.09 0.98-1.21 
HCC104: Vascular Disease with Complications 1.19 0.97-1.46 1.19 1.10-1.28 
HCC108: Chronic Obstructive Pulmonary Disease 1.00 0.88-1.13 1.86 1.79-1.93 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.78 0.52-1.17 1.08 0.95-1.22 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.51 1.27-1.79 1.25 1.15-1.36 
HCC131: Renal Failure 1.24 1.10-1.41 1.39 1.33-1.46 
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APPENDIX 11: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON LDLC TESTING IN 2006 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
LDLC 0.67 0.61-0.75 0.73 0.70-0.76 
          
Diabetes ACSC/All ACSC in 2006 4.77 4.07-5.60 2.50 2.39-2.61 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.83 0.70-0.98 0.97 0.91-1.04 
65-69 years 0.87 0.67-1.12 0.95 0.86-1.04 
70-75 years 0.78 0.61-1.01 1.00 0.91-1.09 
Female vs Male 0.88 0.80-0.97 1.11 1.07-1.14 
Race (Reference: White) 
 
      
Black 1.62 1.44-1.81 1.10 1.05-1.15 
Other 0.99 0.80-1.21 0.91 0.85-0.98 
Median Zip code Income  0.96 0.90-1.02 1.00 1.00-1.00 
Median Zip code Education (years) 1.00 1.00-1.00 0.99 0.97-1.01 
Dual vs. Non Dual 1.35 1.21-1.50 1.30 1.25-1.35 
Severity of Diabetes         
Type 1 vs. Type 2 1.77 1.59-1.97 1.24 1.19-1.29 
Insulin vs. No Insulin 1.32 1.05-1.66 1.13 1.01-1.26 
Self-Monitoring Blood Glucose 1.11 1.01-1.23 1.02 0.98-1.06 
Diabetes Duration in Years 1.10 1.08-1.13 1.05 1.04-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.61 1.87-3.64 1.00 0.92-1.09 
HCC16:Diabetes with Neurologic/Other 
Manifestation 2.90 2.09-4.03 1.06 0.97-1.15 
HCC32:Pancreatic Disease 1.39 1.09-1.77 1.20 1.09-1.32 
HCC54: Schizophrenia 1.05 0.85-1.31 1.00 0.92-1.09 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 1.05 0.85-1.31 1.13 1.06-1.20 
HCC71: Polyneuropathy 1.13 0.99-1.27 1.08 1.03-1.13 
HCC77: Respirator Dependence 0.96 0.53-1.73 0.99 0.81-1.20 
HCC80: Congestive Heart Failure 1.19 1.06-1.34 1.76 1.69-1.83 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC81: Acute Myocardial Infarction 0.81 0.58-1.13 1.13 1.01-1.26 
HCC82: Unstable Angina and Ischemic Heart Disease 1.16 0.96-1.39 1.19 1.11-1.27 
HCC95: Cerebral Hemorrhage 1.71 1.07-2.72 1.06 0.88-1.28 
HCC96: Ischemic or Unspecified Stroke 1.55 1.32-1.81 1.24 1.17-1.32 
HCC100: Hemiplegia/Hemiparesis 0.68 0.51-0.92 1.08 0.97-1.20 
HCC104: Vascular Disease with Complications 1.19 0.97-1.46 1.19 1.10-1.29 
HCC108: Chronic Obstructive Pulmonary Disease 1.00 0.89-1.13 1.87 1.80-1.94 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.76 0.50-1.14 1.06 0.94-1.20 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.50 1.27-1.78 1.25 1.15-1.36 
HCC131: Renal Failure 1.24 1.09-1.41 1.39 1.33-1.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
APPENDIX 12: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON EYE EXAM IN 2006 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
Dilated Eye Exam 0.79 0.71-0.88 0.87 0.84-0.90 
          
Diabetes ACSC/All ACSC in 2006 4.90 4.18-5.74 2.56 2.45-2.67 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.83 0.70-0.98 0.97 0.91-1.04 
65-69 years 0.86 0.66-1.12 0.95 0.86-1.04 
70-75 years 0.78 0.61-1.01 1.00 0.92-1.10 
Female vs Male 0.89 0.80-0.98 1.11 1.07-1.15 
Race (Reference: White) 
 
      
Black 1.64 1.46-1.84 1.12 1.07-1.17 
Other 0.99 0.81-1.22 0.92 0.85-0.99 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.97 0.91-1.03 0.99 0.97-1.01 
Dual vs. Non Dual 1.35 1.21-1.51 1.30 1.25-1.35 
Severity of Diabetes         
Type 1 vs. Type 2 1.78 1.60-1.98 1.25 1.20-1.30 
Insulin vs. No Insulin 1.30 1.03-1.64 1.12 1.01-1.25 
Self-Monitoring Blood Glucose 1.09 0.98-1.21 1.01 0.97-1.04 
Diabetes Duration in Years 1.10 1.08-1.13 1.05 1.04-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.36 1.69-3.29 0.93 0.85-1.01 
HCC16:Diabetes with Neurologic/Other 
Manifestation 2.65 1.91-3.68 0.99 0.91-1.08 
HCC32:Pancreatic Disease 1.39 1.09-1.77 1.19 1.08-1.32 
HCC54: Schizophrenia 1.05 0.84-1.30 1.00 0.92-1.10 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 1.05 0.84-1.30 1.13 1.07-1.21 
HCC71: Polyneuropathy 1.12 0.99-1.27 1.07 1.02-1.13 
HCC77: Respirator Dependence 0.97 0.54-1.77 1.00 0.82-1.22 
HCC80: Congestive Heart Failure 1.19 1.06-1.34 1.76 1.69-1.83 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC81: Acute Myocardial Infarction 0.79 0.56-1.10 1.11 0.99-1.23 
HCC82: Unstable Angina and Ischemic Heart Disease 1.14 0.95-1.37 1.16 1.09-1.24 
HCC95: Cerebral Hemorrhage 1.70 1.06-2.72 1.05 0.87-1.27 
HCC96: Ischemic or Unspecified Stroke 1.55 1.32-1.81 1.24 1.17-1.32 
HCC100: Hemiplegia/Hemiparesis 0.68 0.51-0.92 1.09 0.98-1.21 
HCC104: Vascular Disease with Complications 1.19 0.97-1.46 1.19 1.10-1.29 
HCC108: Chronic Obstructive Pulmonary Disease 1.00 0.89-1.13 1.86 1.79-1.94 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.78 0.52-1.18 1.08 0.96-1.23 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.66 1.39-1.98 1.32 1.22-1.44 
HCC131: Renal Failure 1.24 1.09-1.40 1.38 1.32-1.45 
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APPENDIX 12: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON NEPHROPATHY TESTING IN 2006 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
Nephropathy Testing 0.85 0.77-0.95 0.94 0.91-0.97 
          
Diabetes ACSC/All ACSC in 2006 4.95 4.22-5.80 2.57 2.46-2.68 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.82 0.69-0.97 0.96 0.90-1.03 
65-69 years 0.85 0.66-1.10 0.94 0.86-1.03 
70-75 years 0.77 0.60-0.99 0.99 0.91-1.08 
Female vs Male 0.88 0.80-0.97 1.10 1.06-1.14 
Race (Reference: White) 
 
  |   
Black 1.64 1.47-1.84 1.12 1.07-1.17 
Other 0.99 0.81-1.22 0.92 0.85-0.99 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.97 0.91-1.02 0.99 0.97-1.01 
Dual vs. Non Dual 1.36 1.22-1.52 1.30 1.25-1.36 
Severity of Diabetes         
Type 1 vs. Type 2 1.77 1.59-1.97 1.24 1.19-1.29 
Insulin vs. No Insulin 1.30 1.03-1.64 1.12 1.00-1.25 
Self-Monitoring Blood Glucose 1.09 0.98-1.20 1.00 0.97-1.04 
Diabetes Duration in Years 1.10 1.08-1.13 1.05 1.04-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 2.32 1.66-3.24 0.91 0.84-1.00 
HCC16:Diabetes with Neurologic/Other 
Manifestation 2.68 1.93-3.72 0.99 0.91-1.07 
HCC32:Pancreatic Disease 1.17 0.89-1.52 1.20 1.08-1.32 
HCC54: Schizophrenia 1.05 0.85-1.30 1.00 0.92-1.09 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.98 0.82-1.16 1.13 1.07-1.21 
HCC71: Polyneuropathy 1.12 0.99-1.27 1.07 1.02-1.13 
HCC77: Respirator Dependence 0.97 0.54-1.77 1.01 0.83-1.23 
HCC80: Congestive Heart Failure 1.19 1.06-1.34 1.76 1.69-1.83 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC81: Acute Myocardial Infarction 0.79 0.57-1.11 1.11 1.00-1.24 
HCC82: Unstable Angina and Ischemic Heart Disease 1.14 0.95-1.37 1.17 1.09-1.24 
HCC95: Cerebral Hemorrhage 1.72 1.07-2.74 1.05 0.87-1.27 
HCC96: Ischemic or Unspecified Stroke 1.55 1.32-1.81 1.24 1.17-1.32 
HCC100: Hemiplegia/Hemiparesis 0.69 0.51-0.93 1.09 0.98-1.21 
HCC104: Vascular Disease with Complications 1.19 0.97-1.46 1.19 1.10-1.29 
HCC108: Chronic Obstructive Pulmonary Disease 1.00 0.89-1.13 1.87 1.80-1.94 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.78 0.52-1.17 1.08 0.95-1.22 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.50 1.27-1.78 1.25 1.15-1.36 
HCC131: Renal Failure 1.16 1.02-1.32 1.35 1.29-1.42 
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APPENDIX 14: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON HBA1C TESTING IN 2006 WITH PROPENSITY SCORE INVERSE PROBABILITY 
TREATMENT WEIGHTING 
  
Diabetes ACSC 
Hospitalizations in 2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
HbA1c 0.75 0.63-0.90 0.86 0.80-0.91 
          
Diabetes ACSC/All ACSC in 2006 5.84 4.25-8.03 2.51 2.27-2.77 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.82 0.60-1.12 0.96 0.83-1.11 
65-69 years 1.04 0.64-1.69 0.97 0.81-1.18 
70-75 years 0.83 0.51-1.36 0.96 0.80-1.16 
Female vs. Male 0.98 0.82-1.18 1.10 1.03-1.18 
Race (Reference: White) 
 
      
Black 1.46 1.15-1.85 1.20 1.08-1.33 
Other 0.80 0.53-1.20 0.97 0.84-1.13 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 1.04 0.88-1.22 0.97 0.92-1.02 
Dual vs. Non Dual 1.54 1.17-2.04 1.23 1.12-1.34 
Severity of Diabetes         
Type 1 vs. Type 2 1.83 1.42-2.37 1.25 1.13-1.38 
Insulin vs. No Insulin 1.11 0.62-1.97 0.99 0.78-1.26 
Self-Monitoring Blood Glucose 1.01 0.82-1.24 1.06 0.99-1.15 
Diabetes Duration in Years 1.08 1.03-1.14 1.05 1.03-1.07 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory Manifestation 3.07 1.67-5.65 0.88 0.74-1.05 
HCC16:Diabetes with Neurologic/Other Manifestation 3.33 1.84-6.01 1.15 0.95-1.38 
HCC32:Pancreatic Disease 1.10 0.73-1.66 1.00 0.83-1.19 
HCC54: Schizophrenia 1.04 0.66-1.63 0.96 0.81-1.13 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.91 0.66-1.27 1.05 0.94-1.19 
HCC71: Polyneuropathy 1.27 0.98-1.65 1.06 0.94-1.20 
HCC77: Respirator Dependence 0.83 0.36-1.93 1.03 0.73-1.46 
HCC80: Congestive Heart Failure 1.26 0.93-1.72 1.87 1.70-2.06 
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Diabetes ACSC 
Hospitalizations in 2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC81: Acute Myocardial Infarction 1.04 0.55-1.95 1.13 0.92-1.38 
HCC82: Unstable Angina and Ischemic Heart Disease 1.30 0.92-1.84 1.31 1.14-1.50 
HCC95: Cerebral Hemorrhage 1.18 0.54-2.57 0.95 0.70-1.28 
HCC96: Ischemic or Unspecified Stroke 1.18 0.90-1.54 1.16 1.00-1.34 
HCC100: Hemiplegia/Hemiparesis 0.70 0.41-1.19 1.05 0.79-1.41 
HCC104: Vascular Disease with Complications 1.19 0.79-1.81 1.17 0.98-1.41 
HCC108: Chronic Obstructive Pulmonary Disease 0.23 0.02-2.50 1.93 1.78-2.11 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.84 0.47-1.47 0.93 0.75-1.14 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.67 1.21-2.31 1.16 0.97-1.37 
HCC131: Renal Failure 1.30 0.98-1.73 1.50 1.33-1.68 
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APPENDIX 15: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON LDLC TESTING IN 2006 WITH PROPENSITY SCORE INVERSE PROBABILITY 
TREATMENT WEIGHTING 
  
Diabetes ACSC 
Hospitalizations in 
2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Diabetes Care Processes           
LCLC 0.72 0.63-0.82 0.77 0.74-0.81 
          
Diabetes ACSC/All ACSC in 2006 4.77 3.72-6.11 2.52 2.35-2.70 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.88 0.69-1.11 1.02 0.93-1.13 
65-69 years 1.10 0.75-1.61 1.04 0.91-1.20 
70-75 years 1.01 0.69-1.47 1.07 0.93-1.23 
Female vs Male 0.86 0.74-1.01 1.09 1.03-1.15 
Race (Reference: White) 
 
      
Black 1.51 1.28-1.79 1.07 1.01-1.15 
Other 1.16 0.87-1.57 0.94 0.84-1.05 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.93 0.84-1.03 0.97 0.94-1.00 
Dual vs. Non Dual 1.43 1.19-1.70 1.34 1.26-1.43 
Severity of Diabetes         
Type 1 vs. Type 2 1.85 1.55-2.20 1.24 1.16-1.33 
Insulin vs. No Insulin 1.10 0.81-1.51 1.17 0.91-1.50 
Self-Monitoring Blood Glucose 1.05 0.90-1.23 1.00 0.95-1.06 
Diabetes Duration in Years 1.10 1.07-1.14 1.04 1.03-1.05 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory 
Manifestation 3.39 2.30-4.98 1.00 0.89-1.12 
HCC16:Diabetes with Neurologic/Other 
Manifestation 3.66 2.52-5.31 1.13 1.01-1.26 
HCC32:Pancreatic Disease 1.32 0.99-1.77 1.15 1.00-1.32 
HCC54: Schizophrenia 0.96 0.74-1.24 0.99 0.83-1.18 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 1.01 0.78-1.30 1.08 0.98-1.18 
HCC71: Polyneuropathy 1.06 0.86-1.29 0.99 0.91-1.08 
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Diabetes ACSC 
Hospitalizations in 
2007 
ACSC Hospitalizations 
in 2007 
  
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Odds 
Ratio 
95% CI of 
Odds Ratio 
HCC77: Respirator Dependence 0.97 0.47-1.99 1.01 0.77-1.34 
HCC80: Congestive Heart Failure 1.13 0.90-1.43 1.80 1.68-1.93 
HCC81: Acute Myocardial Infarction 0.70 0.46-1.05 1.05 0.87-1.27 
HCC82: Unstable Angina and Ischemic Heart Disease 1.47 1.05-2.08 1.13 1.01-1.27 
HCC95: Cerebral Hemorrhage 1.71 0.90-3.24 1.04 0.82-1.32 
HCC96: Ischemic or Unspecified Stroke 1.76 1.34-2.33 1.27 1.14-1.41 
HCC100: Hemiplegia/Hemiparesis 0.56 0.39-0.80 1.08 0.93-1.26 
HCC104: Vascular Disease with Complications 0.98 0.72-1.33 1.15 1.02-1.29 
HCC108: Chronic Obstructive Pulmonary Disease 1.01 0.82-1.23 1.90 1.78-2.02 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.70 0.40-1.21 0.93 0.76-1.13 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.52 1.18-1.96 1.38 1.19-1.60 
HCC131: Renal Failure 1.20 0.96-1.50 1.30 1.20-1.40 
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APPENDIX 16: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON EYE EXAM IN 2006 WITH PROPENSITY SCORE INVERSE PROBABILITY 
TREATMENT WEIGHTING 
  
Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Diabetes Care Processes           
Dilated Eye Exam 0.91 0.7-1.09 0.9 0.84-0.97 
          
Diabetes ACSC/All ACSC in 2006 4.59 3.64-5.79 2.43 2.18-2.70 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.77 0.54-1.09 0.87 0.76-1.01 
65-69 years 0.82 0.53-1.26 0.91 0.77-1.09 
70-75 years 0.68 0.44-1.04 0.88 0.74-1.05 
Female vs Male 1.00 0.81-1.23 1.13 1.06-1.21 
Race (Reference: White) 
 
      
Black 1.57 1.32-1.87 0.99 0.90-1.11 
Other 1.62 0.63-4.20 0.95 0.78-1.15 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 1.03 0.91-1.16 0.98 0.94-1.02 
Dual vs. Non Dual 1.13 0.84-1.53 1.32 1.20-1.45 
Severity of Diabetes         
Type 1 vs. Type 2 1.63 1.37-1.93 1.23 1.13-1.33 
Insulin vs. No Insulin 0.82 0.47-1.45 1.16 0.65-2.07 
Self-Monitoring Blood Glucose 1.20 0.96-1.50 0.95 0.88-1.04 
Diabetes Duration in Years 1.11 1.07-1.14 1.05 1.03-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory Manifestation 3.47 2.35-5.11 0.95 0.84-1.09 
HCC16:Diabetes with Neurologic/Other Manifestation 3.32 2.26-4.86 0.95 0.84-1.07 
HCC32:Pancreatic Disease 1.37 1.03-1.82 1.09 0.94-1.25 
HCC54: Schizophrenia 1.01 0.73-1.39 1.00 0.85-1.18 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.83 0.61-1.12 1.02 0.87-1.19 
HCC71: Polyneuropathy 1.43 0.95-2.16 1.13 1.01-1.26 
HCC77: Respirator Dependence 1.08 0.53-2.19 1.00 0.74-1.36 
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Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
HCC80: Congestive Heart Failure 1.13 0.96-1.34 1.98 1.78-2.19 
HCC81: Acute Myocardial Infarction 0.78 0.52-1.16 1.12 0.97-1.29 
HCC82: Unstable Angina and Ischemic Heart Disease 1.20 0.95-1.51 1.26 1.10-1.45 
HCC95: Cerebral Hemorrhage 1.52 0.74-3.15 1.03 0.79-1.35 
HCC96: Ischemic or Unspecified Stroke 1.61 1.32-1.95 1.30 1.19-1.42 
HCC100: Hemiplegia/Hemiparesis 0.77 0.52-1.15 1.08 0.94-1.25 
HCC104: Vascular Disease with Complications 1.18 0.87-1.60 1.13 0.99-1.28 
HCC108: Chronic Obstructive Pulmonary Disease 0.98 0.84-1.13 1.89 1.76-2.04 
HCC111: Aspiration and Specified Bacterial 
Pneumonias 0.60 0.35-1.03 1.13 0.91-1.40 
HCC119: Proliferative Diabetic Retinopathy and 
Vitreous Hemorrhage 1.13 0.76-1.67 0.80 0.58-1.12 
HCC131: Renal Failure 1.22 1.02-1.45 1.41 1.30-1.53 
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APPENDIX 17: MULTIVARIATE LOGISTIC REGRESSION PREDICTING THE LIKELIHOOD OF 
HOSPITALIZATION FOR DIABETES AND ALL AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) IN 
2007 BASED ON NEPHROPATHY TESTING IN 2006 WITH PROPENSITY SCORE INVERSE 
PROBABILITY TREATMENT WEIGHTING 
  
Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
Diabetes Care Processes           
Nephropathy Testing 0.94 0.84-1.05 0.96 0.92-1.00 
          
Diabetes ACSC/All ACSC in 2006 4.87 3.98-5.97 2.54 2.40-2.70 
Demographics         
Age (Reference: <60 years)         
60-64  years 0.80 0.66-0.97 0.98 0.90-1.07 
65-69 years 0.95 0.70-1.28 1.00 0.89-1.12 
70-75 years 0.78 0.58-1.05 1.03 0.92-1.15 
Female vs. Male 0.90 0.80-1.01 1.10 1.06-1.15 
Race (Reference: White) 
 
      
Black 1.64 1.42-1.88 1.10 1.04-1.16 
Other 1.02 0.80-1.31 0.92 0.85-1.01 
Median Zip code Income  1.00 1.00-1.00 1.00 1.00-1.00 
Median Zip code Education (years) 0.95 0.89-1.03 0.99 0.96-1.01 
Dual vs. Non Dual 1.32 1.15-1.51 1.28 1.22-1.35 
Severity of Diabetes         
Type 1 vs. Type 2 1.81 1.59-2.06 1.26 1.19-1.32 
Insulin vs. No Insulin 1.20 0.91-1.58 1.05 0.91-1.21 
Self-Monitoring Blood Glucose 1.11 0.98-1.26 1.02 0.97-1.06 
Diabetes Duration in Years 1.11 1.08-1.14 1.05 1.04-1.06 
Selected HCCs         
HCC15:Diabetes with Renal/Circulatory Manifestation 2.69 1.85-3.93 0.93 0.83-1.04 
HCC16:Diabetes with Neurologic/Other Manifestation 3.31 2.28-4.79 1.00 0.90-1.12 
HCC32:Pancreatic Disease 1.38 1.05-1.83 1.23 1.09-1.39 
HCC54: Schizophrenia 1.00 0.77-1.31 1.00 0.90-1.11 
HCC55:Major Depressive, Bipolar, and Paranoid 
Disorders 0.99 0.80-1.23 1.16 1.07-1.25 
HCC71: Polyneuropathy 1.09 0.94-1.26 1.05 0.99-1.12 
HCC77: Respirator Dependence 0.98 0.49-1.94 0.88 0.67-1.17 
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Diabetes ACSC 
Hospitalizations in 
2007 
ACSC 
Hospitalizations in 
2007 
  
Odds 
Ratio 
95% CI of 
Odds Ratio 
Odds 
Ratio 
95% CI of 
Odds 
Ratio 
HCC80: Congestive Heart Failure 1.20 1.03-1.41 1.77 1.68-1.86 
HCC81: Acute Myocardial Infarction 0.93 0.57-1.53 1.18 1.01-1.37 
HCC82: Unstable Angina and Ischemic Heart Disease 1.05 0.84-1.32 1.12 1.03-1.21 
HCC95: Cerebral Hemorrhage 1.45 0.80-2.65 1.10 0.86-1.41 
HCC96: Ischemic or Unspecified Stroke 1.45 1.16-1.81 1.28 1.18-1.39 
HCC100: Hemiplegia/Hemiparesis 0.79 0.48-1.28 1.10 0.94-1.28 
HCC104: Vascular Disease with Complications 1.38 1.06-1.80 1.19 1.07-1.31 
HCC108: Chronic Obstructive Pulmonary Disease 0.94 0.81-1.09 1.86 1.77-1.95 
HCC111: Aspiration and Specified Bacterial Pneumonias 0.90 0.56-1.46 1.06 0.89-1.26 
HCC119: Proliferative Diabetic Retinopathy and Vitreous 
Hemorrhage 1.52 1.23-1.88 1.25 1.12-1.39 
HCC131: Renal Failure 1.30 1.09-1.56 1.33 1.25-1.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
APPENDIX 18: CODES TO IDENTIFY PQRS REPORTING FOR DIABETES CARE PROCESSES FROM 
MEDICARE CLAIMS 
Measure/Variable Codes 
Diabetes Care Processes 
HbA1c Testing CPT codes 3044F, 3045F,  and 3046F,  
LDLC Testing CPT codes: 3048F, 3049F, and 3050F 
Blood Pressure 
Measurement 
CPT codes: 3074F, 3075F, 3077F, 3078F, 3079F, 3080F, 
Dilated Eye Exams CPT codes: 2022F, 2024F, 2026F, and 3072F 
Testing for Nephropathy CPT codes:  3060F, 3061F , 3062F and 3066F 
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APPENDIX 19: NATIONAL DRUG CODES TO IDENTIFY PHARMACOTHERAPY FOR DIABETICS FROM 
MEDICARE PART D CLAIMS 
 
Pharmacotherapy National Drug Codes 
Insulin Source: HEDIS 2011 NDC List. Table CDC-A/Table DCDC-A.xls. Available at: 
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS
2011/HEDIS2011NDCLicense/HEDIS2011FinalNDCLists.aspx 
 
Oral Anti-Diabetic 
Agents 
Source: HEDIS 2011 NDC List. Table CDC-A/Table DCDC-A.xls. Available at: 
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS
2011/HEDIS2011NDCLicense/HEDIS2011FinalNDCLists.aspx 
 
ACE 
Inhibitors/ARBs 
Source: HEDIS 2011 NDC List. Table CDC-L/ Table DCDC-P.xls.Available at: 
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS
2011/HEDIS2011NDCLicense/HEDIS2011FinalNDCLists.aspx 
 
Oral Anti-Platelet 
Therapy  
 
Source: HEDIS 2011 NDC List. Table IVD-E.xls. Available at: 
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS
2011/HEDIS2011NDCLicense/HEDIS2011FinalNDCLists.aspx 
 
Statin Therapy 68645026254, 68462019890, 68462019805, 68462019790, 
68462019705, 68462019690, 68462019605, 68462019590, 
68462019505, 68382007316, 68382007305, 68382007216, 
68382007205, 68382007116, 68382007105, 68382007016, 
68382007005, 68382006916, 68382006914, 68382006910, 
68382006906, 68382006905, 68382006840, 68382006816, 
68382006814, 68382006810, 68382006806, 68382006805, 
68382006724, 68382006716, 68382006714, 68382006710, 
68382006706, 68382006705, 68382006624, 68382006616, 
68382006614, 68382006610, 68382006606, 68382006605, 
68382006516, 68382006514, 68382006510, 68382006506, 
68382006505, 68258915401, 68258912801, 68258900101, 
68258601303, 68258600903, 68258600209, 68258600203, 
68258600109, 68258600103, 68258600009, 68258600003, 
68258105701, 68258104001, 68180048809, 68180048802, 
68180048709, 68180048702, 68180048609, 68180048602, 
68180048509, 68180048502, 68180048209, 68180048206, 
68180048103, 68180048102, 68180048101, 68180048003, 
68180048002, 68180048001, 68180047903, 68180047902, 
68180047901, 68180047803, 68180047802, 68180047801, 
68180046907, 68180046905, 68180046903, 68180046901, 
68180046807, 68180046805, 68180046803, 68180046801, 
68180046707, 68180046703, 68180046701, 68115083690, 
68115083630, 68115080090, 68115077790, 68115077730, 
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68115075930, 68115072030, 68115067230, 68115066890, 
68115066830, 68115066815, 68115066490, 68115065860, 
68115065800, 68115049460, 68115049430, 68115021960, 
68115021930, 68115021830, 68084018811, 68084018801, 
68084018711, 68084018701, 68084018611, 68084018601, 
68084016511, 68084016501, 68084016411, 68084016401, 
68084016311, 68084016301, 68084016211, 68084016201, 
68084016111, 68084016101, 68084013311, 68084013301, 
68084013211, 68084013201, 68084013111, 68084013101, 
68071078430, 68071043330, 68071039930, 68071031030, 
68071026330, 68071015430, 67544125760, 67544125745, 
67544125645, 67544125630, 67544125615, 67544125560, 
67544125545, 67544125530, 67544125515, 67544125445, 
67544125415, 67544107830, 67544103299, 67544103282, 
67544103245, 67544103215, 67544103099, 67544102999, 
67544100353, 67544100345, 67544100315, 67544100160, 
67544100130, 67544085760, 67544085745, 67544085715, 
67544085645, 67544085615, 67544085560, 67544085545, 
67544085530, 67544085515, 67544085460, 67544085445, 
67544024730, 67544024560, 67544024530, 67544022580, 
67544022560, 67544022553, 67544022545, 67544022530, 
67544022515, 67544010680, 67544010660, 67544010653, 
67544010645, 67544010630, 67544010615, 67544008245, 
67544008215, 67544008160, 67544008145, 67544008130, 
67544008115, 67544006060, 67544006045, 67544006030, 
67544006015, 67544005153, 67544005145, 67544005116, 
67544005115, 67544005060, 67544005053, 67544005045, 
67544005030, 67544005015, 66582031574, 66582031566, 
66582031554, 66582031552, 66582031531, 66582031501, 
66582031386, 66582031374, 66582031354, 66582031352, 
66582031331, 66582031301, 66582031287, 66582031282, 
66582031254, 66582031231, 66582031228, 66582031201, 
66582031182, 66582031154, 66582031131, 66582031128, 
66582031101, 66336098690, 66336098630, 66336095490, 
66336095430, 66336095390, 66336095330, 66336081390, 
66336081330, 66336068590, 66336068530, 66336067430, 
66336060205, 66336041230, 66336041205, 66336031060, 
66336031030, 66336031005, 66267056190, 66267056160, 
66267056130, 66116027730, 66116027630, 66116023830, 
66105098803, 66105050610, 66105050609, 66105050606, 
66105050603, 66105050601, 66105014710, 66105014709, 
66105014706, 66105014703, 66105014701, 66105012215, 
66105012209, 66105012206, 66105012203, 66105012201, 
66105012115, 66105012109, 66105012106, 66105012103, 
66105012101, 66105012015, 66105012009, 66105012006, 
66105012003, 66105012001, 65862005499, 65862005490, 
65862005439, 65862005430, 65862005399, 65862005390, 
65862005330, 65862005322, 65862005299, 65862005290, 
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65862005230, 65862005226, 65862005199, 65862005190, 
65862005130, 65862005126, 65862005099, 65862005090, 
65862005030, 65243036745, 65243036709, 65243036545, 
65243036145, 65243036045, 65243035245, 65243035209, 
65243035203, 65243035045, 65243034945, 65243034915, 
65243034845, 65243034815, 65243012745, 65243008245, 
65243008215, 65243006545, 65243006515, 63874059090, 
63874059030, 63874059015, 63874059010, 63874059001, 
63874058990, 63874058930, 63874058910, 63874058901, 
63874031990, 63874031930, 63874031915, 63874031910, 
63739043810, 63739043710, 63739043610, 63739043510, 
63739042210, 63739042110, 63739042010, 63739041910, 
63739028210, 63739028203, 63739028115, 63739028110, 
63739028103, 63739028015, 63739028010, 63629358302, 
63629358301, 63629356301, 63629340804, 63629340803, 
63629340802, 63629340801, 63629339304, 63629339303, 
63629339302, 63629339301, 63629339201, 63629338505, 
63629338504, 63629338503, 63629338502, 63629338501, 
63629338104, 63629338103, 63629338102, 63629338101, 
63629336604, 63629336603, 63629336602, 63629336601, 
63629178402, 63629178401, 63629160602, 63629160601, 
63629146403, 63629146402, 63629146401, 63629144701, 
63304079390, 63304079350, 63304079330, 63304079310, 
63304079290, 63304079230, 63304079210, 63304079190, 
63304079130, 63304079110, 63304079090, 63304079030, 
63304079010, 63304078990, 63304078930, 63304078910, 
63304059890, 63304059805, 63304059790, 63304059690, 
63304059590, 62037079360, 62037079301, 62037079260, 
62037079201, 62037079160, 62037079101, 62022078130, 
62022078030, 62022077030, 62022076030, 62022063030, 
62022062930, 62022062830, 62022062730, 61442014360, 
61442014310, 61442014305, 61442014301, 61442014260, 
61442014210, 61442014205, 61442014201, 61442014160, 
61442014110, 61442014101, 60598000990, 60598000890, 
60598000790, 60598000690, 60505132309, 60505132305, 
60505017900, 60505017800, 60505017700, 60505017009, 
60505017008, 60505017007, 60505016909, 60505016907, 
60505016809, 60505016805, 60429025090, 60429025060, 
60429025010, 60429024960, 60429024910, 60429024860, 
60429024810, 59630063030, 59630062930, 59630062830, 
58864083430, 58864078130, 58864078060, 58864078030, 
58864076030, 58864074330, 58864074315, 58864073930, 
58864068530, 58864068230, 58864065330, 58864062330, 
58864062315, 58864060830, 58016097990, 58016097960, 
58016097930, 58016097920, 58016097902, 58016097900, 
58016092290, 58016092260, 58016092230, 58016092202, 
58016092200, 58016090090, 58016090060, 58016090030, 
58016090002, 58016090000, 58016054600, 58016042590, 
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58016042560, 58016042530, 58016042500, 58016038590, 
58016038560, 58016038530, 58016038500, 58016036590, 
58016036560, 58016036530, 58016036500, 58016036490, 
58016036460, 58016036430, 58016036400, 58016007190, 
58016007160, 58016007130, 58016007100, 58016005290, 
58016005260, 58016005230, 58016005200, 58016005190, 
58016005160, 58016005130, 58016005100, 58016003790, 
58016003760, 58016003730, 58016003700, 58016001390, 
58016001360, 58016001330, 58016001300, 58016001290, 
58016001260, 58016001230, 58016001200, 58016000890, 
58016000860, 58016000830, 58016000800, 58016000790, 
58016000760, 58016000730, 58016000700, 58016000690, 
58016000660, 58016000630, 58016000600, 57866861501, 
57866798601, 57866798301, 57866798201, 57866660101, 
57866650001, 57866640001, 57866393201, 55887097430, 
55887092990, 55887085890, 55887085860, 55887085830, 
55887085810, 55887062490, 55887062482, 55887062460, 
55887062440, 55887062430, 55887062420, 55887036990, 
55887036960, 55887036930, 55887035090, 55887035060, 
55887035030, 55887020390, 55887020330, 55887019290, 
55289098021, 55289093530, 55289093230, 55289088130, 
55289087430, 55289087330, 55289087130, 55289087030, 
55289086130, 55289080030, 55289074060, 55289069230, 
55289069214, 55289054830, 55289052030, 55289047630, 
55289040030, 55289039590, 55289039530, 55289033890, 
55289033830, 55289033814, 55289029390, 55289029330, 
55289029314, 55289028030, 55289010430, 55111075090, 
55111075030, 55111075010, 55111074990, 55111074930, 
55111074910, 55111074090, 55111074030, 55111074010, 
55111073590, 55111073530, 55111073510, 55111072690, 
55111072630, 55111072610, 55111027490, 55111027405, 
55111026890, 55111026830, 55111026805, 55111023190, 
55111023105, 55111023090, 55111023005, 55111022990, 
55111022905, 55111020090, 55111020030, 55111020010, 
55111020005, 55111019990, 55111019930, 55111019910, 
55111019905, 55111019890, 55111019830, 55111019805, 
55111019790, 55111019730, 55111019705, 55045365508, 
55045301508, 55045301408, 54868616900, 54868606600, 
54868590701, 54868590700, 54868590401, 54868590400, 
54868588601, 54868588600, 54868569900, 54868567200, 
54868565301, 54868565300, 54868563001, 54868563000, 
54868562904, 54868562903, 54868562902, 54868562901, 
54868562900, 54868562802, 54868562801, 54868562800, 
54868562701, 54868562700, 54868557901, 54868557900, 
54868557802, 54868557801, 54868557800, 54868557701, 
54868557700, 54868557601, 54868557600, 54868556700, 
54868552301, 54868552300, 54868551300, 54868542000, 
54868535800, 54868534101, 54868534100, 54868525901, 
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54868525900, 54868525000, 54868520901, 54868520900, 
54868520001, 54868520000, 54868518901, 54868518900, 
54868518702, 54868518701, 54868518700, 54868517900, 
54868508700, 54868508503, 54868508502, 54868508501, 
54868508500, 54868499901, 54868499900, 54868496303, 
54868496302, 54868496301, 54868496300, 54868493402, 
54868493401, 54868493400, 54868480702, 54868480701, 
54868480700, 54868477403, 54868477402, 54868477401, 
54868477400, 54868463400, 54868460100, 54868459302, 
54868459301, 54868459300, 54868458503, 54868458502, 
54868458501, 54868458500, 54868422903, 54868422902, 
54868422901, 54868422900, 54868422401, 54868422400, 
54868418101, 54868418100, 54868415702, 54868415701, 
54868415700, 54868394604, 54868394603, 54868394602, 
54868394601, 54868394600, 54868393404, 54868393403, 
54868393402, 54868393401, 54868393400, 54868332900, 
54868328701, 54868328700, 54868327002, 54868327001, 
54868327000, 54868310401, 54868310400, 54868263901, 
54868263900, 54868228802, 54868228801, 54868228800, 
54868228702, 54868228701, 54868196800, 54868189001, 
54868189000, 54868120701, 54868120700, 54868108701, 
54868108700, 54868068604, 54868068603, 54868068602, 
54868068601, 54569611301, 54569611300, 54569609900, 
54569595100, 54569588100, 54569583404, 54569583403, 
54569583402, 54569583401, 54569583400, 54569583303, 
54569583302, 54569583301, 54569583300, 54569579401, 
54569579400, 54569579301, 54569579300, 54569576800, 
54569576600, 54569574600, 54569570400, 54569567200, 
54569564800, 54569564000, 54569560001, 54569560000, 
54569549800, 54569538200, 54569534702, 54569534700, 
54569534602, 54569534600, 54569534501, 54569534500, 
54569476101, 54569476100, 54569461000, 54569458701, 
54569458700, 54569458400, 54569446701, 54569446700, 
54569446602, 54569446601, 54569446600, 54569440400, 
54569440300, 54569434601, 54569418001, 54569407100, 
54569382101, 54569382100, 54569325601, 54569325600, 
54569061302, 54569061300, 54458098709, 54458098610, 
54458098510, 54458098507, 54458098410, 54458098310, 
54458098210, 54458093810, 54458093710, 54458093610, 
54458093410, 54458093310, 54458093210, 54458092804, 
54458092610, 54458092510, 53489060910, 53489060906, 
53489060901, 53489060810, 53489060806, 53489060801, 
53489060706, 53489060701, 53002156903, 53002156900, 
53002152803, 53002152800, 53002152703, 53002152700, 
53002138503, 53002138500, 53002117703, 53002117700, 
53002057030, 53002057000, 52959098930, 52959098830, 
52959097430, 52959097400, 52959094430, 52959076090, 
52959075990, 52959072030, 52959011230, 52959004630, 
140 
 
51079097656, 51079097620, 51079097601, 51079097556, 
51079097520, 51079097501, 51079097420, 51079097401, 
51079078220, 51079078201, 51079045820, 51079045801, 
51079045620, 51079045601, 51079045520, 51079045501, 
51079045420, 51079045401, 50111076417, 50111076403, 
50111076217, 50111076203, 50111076117, 49999099290, 
49999099230, 49999098930, 49999095830, 49999095730, 
49999090330, 49999090315, 49999090090, 49999088990, 
49999088960, 49999088930, 49999088290, 49999088230, 
49999087390, 49999087330, 49999048830, 49999047160, 
49999047130, 49999047100, 49999047090, 49999047060, 
49999047030, 49999046890, 49999046830, 49999046790, 
49999046730, 49999039290, 49999039230, 49999030630, 
49999029330, 49884075610, 49884075602, 49884075601, 
49884075510, 49884075502, 49884075501, 49884075410, 
49884075402, 49884075401, 49884018010, 49884018009, 
49884017910, 49884017909, 49884017610, 49884017609, 
'4746308233,0 '4746308223,0 '4746308213,0 47463077690, 
47463077630, 47463077590, 47463077530, 47463077490, 
47463077430, 47463059830, 47463059730, 47463059630, 
47463039530, 47463039490, 47463039430, 47463009730, 
47463009630, 47463009530, 47463003430, 47463003390, 
47463003330, 47463003230, 47463003130, 45802092465, 
45802087993, 45802087975, 45802087965, 45802087901, 
45802038493, 45802038475, 45802038465, 45802038401, 
45802029275, 45802029265, 45802009375, 45802009365, 
45802009301, 43683015230, 43353071860, 43353071845, 
43353068545, 43353066660, 43353066645, 43353066630, 
43353066560, 43353066545, 43353066530, 43353066515, 
43353066460, 43353066445, 43353066430, 43353066415, 
43353062560, 43353062545, 43353062530, 43353062515, 
43353049645, 43353039460, 43353039445, 43353039430, 
43353039415, 43353029045, 43353029015, 43353028945, 
43353028915, 43353022960, 43353022945, 43353022860, 
43353022845, 43353022830, 43353022815, 43353022745, 
43353022715, 43353003182, 43353003160, 43353003145, 
43353003115, 43063019530, 43063014330, 43063008090, 
43063008030, 43063000801, 42291037790, 42291037710, 
42291037690, 42291037590, 35356060430, 35356060030, 
35356051930, 35356041330, 35356012530, 33358022630, 
33358022560, 33358022500, 33358022430, 33358022330, 
33358021090, 33358021060, 33358021030, 33358021001, 
33261054860, 33261054830, 33261054290, 33261054260, 
33261054230, 33261054202, 33261054190, 33261054160, 
33261054130, 33261054102, 24658021490, 24658021445, 
24658021430, 24658021410, 24658021390, '2465802134,5 
24658021330, 24658021310, 24658021290, 24658021245, 
24658021230, 24658021210, 24658021190, 24658021145, 
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24658021130, 24658021110, 24658021090, 24658021045, 
24658021030, 24658021010, 23490992601, 23490935709, 
23490935706, 23490935703, 23490935609, 23490935606, 
23490935603, 23490935509, 23490935506, 23490935503, 
23490935409, 23490935406, 23490935403, 23490935309, 
23490935306, 23490935303, 23490935209, 23490935206, 
23490935203, 23490935109, 23490935106, 23490935103, 
23490935009, 23490935006, 23490935003, 23490584002, 
23490584001, 23490583901, 23490583900, 23490583809, 
23490583806, 23490583802, 23490016703, 23490013203, 
'2169508273,0 21695075990, 21695074290, 21695074230, 
21695074190, 21695074130, 21695074090, 21695074030, 
21695073990, 21695073930, 21695073890, 21695065930, 
21695053690, 21695053630, 21695053590, 21695053530, 
21695053430, 21695033930, 21695032530, 21695028890, 
21695028790, 21695025590, 21695018090, 21695018030, 
21695017990, 21695017930, 21695017830, 16729000717, 
16729000715, 16729000710, 16729000617, 16729000615, 
16729000610, 16729000517, 16729000515, 16729000510, 
16729000417, 16729000415, 16729000410, 16714068503, 
16714068502, 16714068501, 16714068403, 16714068402, 
16714068401, 16714068303, 16714068302, 16714068301, 
16714068203, 16714068202, 16714068201, 16714068102, 
16714068101, 16590094130, 16590054790, 16590054772, 
16590054760, 16590054730, 16590054690, 16590054630, 
16590044630, 16590043130, 16252052990, 16252052890, 
16252052850, 16252052790, 16252052750, 16252052690, 
16252050990, 16252050950, 16252050930, 16252050890, 
16252050850, 16252050830, 16252050790, 16252050750, 
16252050730, 16252050690, 16252050650, 16252050630, 
16252050590, 16252050550, 16252050530, 13411016215, 
13411016209, 13411016206, 13411016203, 13411016201, 
13411016115, 13411016109, 13411016106, 13411016103, 
13411016101, 13411013315, 13411013309, 13411013306, 
13411013303, 13411013301, 13411013215, 13411013209, 
13411013206, 13411013203, 13411013201, 13411011909, 
13411011906, 13411011903, 13411011902, 13411011901, 
13411011809, 13411011806, 13411011803, 13411011802, 
13411011801, 13411011515, 13411011509, 13411011506, 
13411011503, 13411011501, 13411011415, 13411011409, 
13411011406, 13411011403, 13411011401, 13411011315, 
13411011309, 13411011306, 13411011303, 13411011301, 
13411011110, 13411011106, 13411011103, 13411011102, 
13411011101, 12280039930, 12280039830, 12280039730, 
12280038630, 12280038590, 12280038530, 12280035190, 
12280035130, 12280033590, 12280033530, 12280033515, 
12280018190, 12280018130, 12280016490, 12280016415, 
12280015030, 12280010860, 12280003890, 10135051290, 
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10135051230, 10135051205, 10135051190, 10135051130, 
10135051105, 10135051090, 10135051030, 10135051005, 
10135050990, 10135050930, 10135050905, 10135050890, 
10135050830, 10135050805, 10135050090, 10135049990, 
10135049890, 00904611561, 00904611461, 00904611361, 
00904589361, 00904589261, 00904589161, 00904580261, 
00904580161, 00904580061, 00904558352, 00904558252, 
00904558152, 00781523492, 00781523410, 00781523292, 
00781523210, 00781523192, 00781523110, 00781507492, 
00781507431, 00781507392, 00781507331, 00781507292, 
00781507231, 00781507192, 00781507131, 00781507092, 
00781507031, 00781132360, 00781132305, 00781121360, 
00781121310, 00781121060, 00781121010, 00591001919, 
00591001905, 00591001619, 00591001610, 00591001419, 
00591001410, 00591001319, 00591001310, 00440832490, 
00440832430, 00440832390, 00440832330, 00440832290, 
00440832230, 00440832190, 00440832130, 00440832090, 
00440832030, 00440815890, 00440815860, 00440815830, 
00440815790, 00440815760, 00440815730, 00440815690, 
00440815660, 00440815630, 00440815590, 00440815560, 
00440815530, 00440769460, 00440769430, 00440769360, 
00440769330, 00440769260, 00440769230, 00406206990, 
00406206960, 00406206910, 00406206905, 00406206903, 
00406206890, 00406206860, 00406206810, 00406206805, 
00406206803, 00406206790, 00406206760, 00406206710, 
00406206705, 00406206703, 00406206690, 00406206660, 
00406206610, 00406206605, 00406206603, 00406206590, 
00406206560, 00406206510, 00406206505, 00406206503, 
00378828077, 00378828005, 00378824077, 00378824010, 
00378822077, 00378822010, 00378821077, 00378821010, 
00378654091, 00378654005, 00378652091, 00378652005, 
00378651091, 00378055777, 00378055477, 00378055377, 
00378055277, 00310075590, 00310075430, 00310075290, 
00310075239, 00310075190, 00310075139, 00247127630, 
00247115360, 00247115330, 00247115260, 00247115230, 
00247114060, 00247114030, 00247113960, 00247113930, 
00247113060, 00247113030, 00247112960, 00247112930, 
00228263550, 00228263506, 00228263450, 00228263406, 
00228263350, 00228263306, 00185007460, 00185007410, 
00185007401, 00185007260, 00185007210, 00185007201, 
00185007060, 00185007010, 00185007005, 00185007001, 
00093727098, 00093727010, 00093720298, 00093720210, 
00093720198, 00093720110, 00093715698, 00093715656, 
00093715610, 00093715598, 00093715593, 00093715556, 
00093715519, 00093715510, 00093715498, 00093715493, 
00093715456, 00093715419, 00093715410, 00093715398, 
00093715393, 00093715356, 00093715319, 00093715310, 
00093715298, 00093715293, 00093715256, 00093715219, 
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00093092893, 00093092819, 00093092810, 00093092806, 
00093092693, 00093092619, 00093092610, 00093092606, 
00093077198, 00093077110, 00093057693, 00093057619, 
00093057610, 00093057606, 00078035415, 00078035405, 
00078023415, 00078023405, 00078017615, 00078017605, 
00074345990, 00074345790, 00074345590, 00074331690, 
00074331590, 00074331290, 00074307290, 00074301090, 
00074300790, 00074300590, 00071015892, 00071015888, 
00071015873, 00071015823, 00071015788, 00071015773, 
00071015740, 00071015723, 00071015694, 00071015640, 
00071015623, 00071015540, 00071015534, 00071015523, 
00069298030, 00069297030, 00069296030, 00069227030, 
00069226030, 00069225030, 00069219030, 00069218030, 
00069217030, 00069216030, 00069215030, 00006074982, 
00006074961, 00006074954, 00006074931, 00006074928, 
00006074087, 00006074082, 00006074061, 00006074054, 
00006074031, 00006074028, 00006073587, 00006073582, 
00006073561, 00006073554, 00006073531, 00006073528, 
00006073294, 00006073287, 00006073282, 00006073261, 
00006073194, 00006073187, 00006073182, 00006073161, 
00006073128, 00006073061, 00006072682, 00006072661, 
00006072654, 00006072631, 00006072628, 00006054382, 
00006054361, 00006054354, 00006054331, 00006054328, 
00003519533, 00003519510, 00003519433, 00003519410, 
00003518411, 00003518311, 00003517875, 00003517806, 
00003517805, 00003517411, 00003517311, 00003516911, 
00003516811, 00003515405, 00002477290, 00002477190, and 
00002477090 
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APPENDIX 20: ADJUSTED KAPLAN MEIER CURVES FOR DIABETES ACSC AND ALL ACSC 
HOSPITALIZATIONS IN 2009 
Model 1: Adjusted for Beneficiary Demographic Characteristics, Severity of Diabetes and 
Comorbidities 
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Model 1: Adjusted Kaplan Meier Curves for Diabetes ACSC Hospitalizations
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Model 1: Adjusted Kaplan-Meier Curves for ACSC Hospitalizations
